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1.0 Abstract 
Hereditary sensory autonomic neuropathy IV (HSAN IV) is an autosomal recessive 
disorder characterised by inability to feel pain and anhidrosis and is a consequence 
of defective NGF/TrkA signalling and growth of sensory and sympathetic neurons. 
Glucocortiocoid-induced tumour necrosis factors receptor (GITR), a transmembrane 
protein, activated by its specific ligand, GITRL, is well known for its role in the 
regulation of innate and acquired immune system responses. Recently, GITR was 
found to be required for NGF-dependant and extracellular signal-related kinase 1/2 
(ERK1/2)-induced neurite growth and target innervation in the developing 
sympathetic nervous system (SNS). Given this novel role of GITR, it is possible that 
strategies targeting GITR have potential therapeutic benefit in promoting neurite 
growth in autonomic neuropathies such as HSAN IV. Using P1 mouse SCG neurons 
as a model, in addition to various SCG cell treatments, knock down models and 
transfection methods, we investigated whether GITR increases the sensitivity of 
sympathetic neurons to NGF; the region of GITR required for the enhancement of 
NGF-promoted growth, the signalling pathways downstream of GITR and how 
extensively GITR is involved in regulating peripheral innervation of the SNS. 
Results indicate that the region responsible for the growth promoting effects of GITR 
lies in its juxtamembrane intracellular region (here termed the growth promoting 
domain (GPD)) of GITR. The GPD of GITR activates ERK1/2 and inhibits nuclear 
factor kappa B (NF-B) in an inverse fashion to provide an optimal cellular growth 
environment for P1 SCG neurons. While deleting the GPD of GITR had no effect on 
TrkA expression, constitutive phosphorylation of specific sites in the GPD reduced 
TrkA expression indicating a possible role for GITR in increasing the sensitivity of 
SCG neurons to NGF by the regulation of these sites, TrkA expression and 
subsequent NGF/TrkA binding. GITR appears to be heterogeneously required for 
NGF-promoted target innervation of SCG neurons in some organs, implying 
additional factors are involved in extensive NGF-target innervation of the SNS. In 
conclusion, this study answers basic biological questions regarding the molecular 
mechanism behind the role of GITR in the development of the SNS, and provides a 
basis for future research if GITR modulation is to be developed as a strategy for 
promoting axonal growth. 
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2.0 Abbreviations 
 
ACh  Acetylcholine 
ACTH  Adrenocorticotropic hormone 
AM  Adrenal medulla 
ANOVA Analysis of variance 
ANS  Autonomic nervous system 
APC  Antigen presenting cells 
AR  Adrenergic receptors 
BAFF  B cell activation factor 
BAX  Bcl-2-associated X protein 
BDNF  Brain-derived neurotrophic factor 
BMP  Bone morphogenetic protein 
C  Cervical 
CCA  Common carotid artery 
CIPA  Congenitol insensitivity to pain with anhidrosis 
CN  Cranial nerve 
CNS  Central nervous system 
CNTF  Ciliary neurotrophic factor 
CPT  Choline-phosphate cytidylyltransferase 
CREB  Cyclic AMP responsive element-binding protein 
CRH  Corticotrophin-releasing hormone 
DC  Dendritic cells 
DMEM Dulbecco’s modified eagle media 
DRG  Dorsal root ganglia 
DUSP  Dual specificity phosphatases 
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E  Embryonic 
ECN  External carotid nerve 
EGF  Epidermal growth factor 
Elk-1  Ets-like gene 1 
ERK  Extracellular signal-related kinase 
FAP  Familial amyloid polyneuropathy 
GDNF  Glial cell-derived neurotrophic factor 
GIT  Gastrointestinal tract 
GITR  Glucocorticoid-induced tumour necrosis factor receptor 
GITRL GITR Ligand 
GRB2  Growth factor receptor bound 2 
GDP  Guanosine diphosphate 
GSK3b Glycogen synthase kinases 3 beta 
GTP  Guanosine triphosphate 
H  Hour 
HBSS  Hank’s balanced salt solution 
HEK 293 Human embryonic kidney cell line 293 
HGF  Hepatocyte growth factor 
HPA  Hypothalamic pituitary axis 
HRP  Horseradish peroxidase 
HSAN  Hereditary sensory autonomic neuropathies 
ICA  Internal carotid artery 
ICD  Intracellular domain 
ICN  Internal carotid nerve 
IFN-  Interferon-gamma 
IKK  I kappa B kinase  
9 
 
IL-1  Interleukin-1 
IMG  Inferior mesenteric ganglia 
JNK  c-Jun N-terminal kinase 
KO  Knock out 
KSR  Kinase suppressor of Ras 
L  Lumbar 
MAP1B Microtubule-associated protein 1B 
MAPK Mitogen-activated protein kinase  
Min  Minute 
MP1  MEK partner 1 
NCC  Neural crest cell 
NE  Norepinephrine 
NFAT  Nuclear factor of activated T-cells 
NF-B  Nuclear factor kappa B 
NGF  Nerve growth factor 
NIK  NF-B inducing kinase 
NKCs  Natural Killer cells 
NPY  Neuropeptide Y 
NRIF  Neurotrophin receptor interacting factor 
NRP-1  Neuropilin-1 
NT-3  Neurotrophin-3 
P  Postnatal 
P75NTR p75 Neurotrophic factor receptor 
PI3K  Phosphatidyl inositol-3 
PC  Phosphatidylcholine 
PKA  Protein kinase A 
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PNS  Peripheral nervous system 
RHD  Rel homology domain 
RPE cells Retinal pigment epithelial cells 
RPS3   Ribosomal protein S3 
RSK  Ribosomal protein S6 kinase 
SC  Sympathetic chain 
SCG  Superior cervical ganglia 
SEM  Standard error of mean 
Sema3A Semamorphin-3A 
SDF1  Stomal-cell derived factor 1 
SG  Stellate ganglia 
Shc  Src homology 2 domain containing 
SMG  Submandibular gland/Superior mesenteric ganglia 
SNS  Sympathetic nervous system 
SOS  Son of sevenless 
SRF  Serum response factor 
SYK  Spleen tyrosine kinase 
T  Thoracic 
TAD  Transcriptional activating domain 
TCR  T-cell antigen receptor 
TH  Tyrosine hydroxylase 
TNF  Tumour necrosis factor 
TNFR1 TNF receptor 1 
TNFRSF Tumour necrosis factor receptor superfamily 
TRADD TNFR1-assocated death domain protein 
TRAF  TNF-receptor associated factor 
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Treg cells Regulatory T cells 
TrkA  Tyrosine kinase A receptor 
VCAM-1 Vascular adhesion molecule-1 
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3.0 Introduction  
3.1 The autonomic nervous system 
The autonomic nervous system (ANS) plays a pivotal role in a wide range of 
physiological functions including homeostasis, and dysfunction of the ANS leads to 
a variety of diseases (Moberg, 2000). The term 'autonomic' nervous system was 
coined by Langley in his 1898 paper in the Journal of Physiology when he stated: "I 
propose the term 'autonomic nervous system' for the sympathetic system and the 
allied nervous system of the cranial and sacral nerves and for the local nervous 
system of the gut" (Langley, 1898).  
 The ANS is a subdivision of the nervous system which can be grossly 
divided into two main divisions; the central nervous system (CNS) consisting of the 
brain and spinal cord and the peripheral nervous system (PNS). The PNS is made up 
of both sensory and motor systems, which carry information in both afferent and 
efferent projections to and from the CNS respectively. The motor division of the 
PNS is composed of the ANS and somatic nervous system. Collectively, the ANS 
consists of parasympathetic and sympathetic nervous systems of which afferent 
nerves convey impulses from sensory organs, muscles, the circulatory system and all 
organs of the body to the controlling centre of the hypothalamus in the brain and 
elicits autonomic reflex responses through efferent autonomic nerves. Autonomic 
efferent nerves subsequently elicit appropriate reactions of the heart, the vascular 
system, and organs of the body to variations in environment (eg. temperature), 
posture, food intake, stressful experiences and other changes to which an individual 
is exposed. Together, the parasympathetic and sympathetic nervous systems provide 
automatic regulation of smooth muscle, cardiac muscle and glands and is associated 
with the control of involuntary action (Figure 3.1) (Martini, 2004). The 
hypothalamus receives visceral sensory information (eg. blood pressure); spinal cord 
information (eg. body temperature); visual (eg. light/dark) and complex sensory 
information (eg. emotion and smell) via the nucleus of the solitary tract; brainstem 
reticular formation; retina; limbic and olfactory system respectively and 
subsequently controls digestion; body temperature, circadian rhythm, reproduction 
and feeding. The hypothalamus has two major outputs; endocrine signals to or 
through the pituitary gland and neural signals to the ANS. Ouput to the ANS 
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involves lateral hypothalamic projection to the lateral medulla (where the 
parasympathetic vagal nuclei and sympathetic cells that descend to the spinal cord 
lie), through which, the hypothalamus controls the ANS (Martini, 2004). 
 
The parasympathetic or cranio-sacral division of the ANS consists of preganglionic 
fibres which originate in the brainstem and sacral segments of the spinal cord and 
synapse in ganglia close to or within the target organs. The parasympathetic system 
is responsible for a state known as ‘rest and digest’ as parasympathetic activation 
acts to reduce metabolic rate, decrease heart and blood pressure, increase salivary 
and digestive gland secretions, increase motility and blood flow in the 
gastrointestinal tract (GIT), and stimulate urination and defecation (Martini, 2004). 
 
Figure 3.1: The nervous system 
The nervous system is composed of two main divisions, the CNS and the PNS. The PNS is separated 
into sensory and motor divisions and the motor into the ANS and Somatic Nervous System. The ANS 
is composed of the parasympathetic and sympathetic nervous systems.  
 
3.2 The sympathetic nervous system 
The sympathetic nervous system (SNS) or the thoracolumbar division of the ANS 
consists of preganglionic fibres which emerge from the thoracic and superior lumbar 
segments of the spinal cord and synapse in ganglia near the spinal cord. The SNS 
14 
 
produces what is known as the ‘fight or flight’ response, which may involve 
heightened mental alertness, increased metabolic activity, increased heart rate and 
blood pressure, increased blood flow to skeletal muscle, increased respiratory rate, 
dilation of respiratory passageways, activation of sweat glands and temporary 
suspension of digestive and urinary functions (Martini, 2004). 
 
3.2.1 The organisation of the SNS 
The basic anatomical arrangement of the SNS consists of preganglionic neurons, 
prevertebral sympathetic ganglia, paravertebral sympathetic ganglia, the adrenal 
medulla and postganglionic neurons. Preganglionic neuron’s cells bodies lie in the 
the intermediolateral (IML) column of the gray matter of spinal cord segements T1 – 
L3 (T=Thoracic, L=Lumbar levels) and extend fibres to sympathetic ganglia where 
preganglionic and postganglionic neurons synapse. Unpaired prevertebral ganglia are 
located anterior to the vertebral column and include the celiac (CG), superior and 
inferior mesenteric (SMG and IMG) ganglia. Paired paravertebral ganglia are located 
parallel to the vertebral column and include the superior cervical (SCG), stellate 
(SG), thoracic, lumbar, saccral and coccygeal ganglia. The adrenal medulla (AM) is 
a modified ganglia located in the centre of the adrenal gland. Postganglionic neurons 
emerge from ganglia and innervate peripheral target organs (Glebova and Ginty, 
2005) (Figure 3.2). 
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Figure 3.2: Schematic representation of the SNS anatomy in the mouse 
Preganglionic sympathetic neurons (green) with cells bodies located in the IML column at thoracic 
and lumbar spinal cord segments synapse on postganglionic neurons (blue) in sympathetic ganglia. 
Paravertebral ganglia include the SCG, SG and sympathetic chain (SC) ganglia. Prevertebral ganglia 
include the CG, SMG and the IMG. Selected targets innervated by postganglionic neurons are shown. 
The AM receives preganglionic sympathetic innervation (Glebova and Ginty 2005). 
 
3.2.2 Activation of the SNS 
The SNS is activated in response to a stimulus, such as in ‘fight or flight’ situations 
(Goldstein, 1987) resulting in subsequent release of neurotransmitters from 
postganglionic neurons which then activate receptors on peripheral target tissue 
(Figure 3.3). Neurotransmitters are specialized chemical substances that send 
messages from one nerve ending across synapses to other nerves. Examples of 
neurotransmitters include acetylcholine (ACh); epinephrine (adrenaline); 
norepinephrine (noradrenaline) (NE) and dopamine. Preganglionic sympathetic 
neurons release ACh, while most postganglionic sympathetic neurons release NE 
and therefore neurons are termed cholinergic and adrenergic neurons respectively 
(Esler, et al., 1985).  Postganglionic sympathetic neurons subsequently activate 
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adrenergic receptors (ARs), including α1, α2, α3, β1 or β2 receptors on the 
peripheral target tissue (Martini, 2004). 
 
 
Figure 3.3: Activation and neurotransmitter release from sympathetic neurons 
Preganglionic sympathetic neurons (green) synapse with the postganglionic neurons (blue) at para and 
prevertebral ganglia (yellow). Preganglionic neurons release neurotransmitter ACh from vesicles 
(white) of presynaptic terminal (green) at synapse with postsynaptic cell (blue) receptors of 
postganglionic neurons. Postganglionic neurons release NE from axon terminals to activate adrenergic 
receptors in peripheral targets cells.  
 
3.3  Sympathetic innervation of the lymphatic system 
The SNS is responsible for the innervation to all the organs of the lymphatic system 
including the thymus, spleen, lymph nodes and bone marrow (Figure 3.4) (Felten, et 
al., 1985; Meltzer, et al., 1997; Panuncio, et al., 1999). The lymphatic system works 
together with the integumentary, cardiovascular, respiratory, digestive and nervous 
systems to create a physiological immune system. The immune system enables the 
body to fight against infection and disease by two responses, the innate and adaptive 
immune responses (Martini, 2004).  
The innate immune response functions in an antigen non-specific manner, by 
a variety of cells including monocytes, macrophages, dendritic cells (DCs), natural 
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killer cells (NKCs), basophils, eosinophils and granulocytes. The innate immune 
response is usually the body’s first line of defence (Martini, 2004).  
 The adaptive immune response functions in an antigen-specific manner and 
does so by T and B lymphocyte cells. There are three types of lymphocyte cells; T 
(thymus dependant), B (bone marrow-derived and responsible for antibody-mediated 
immunity or humoral immunity) and NKCs. T cells can be divided into Cytotoxic or 
effector T cells (attack foreign bodies, involved in cell-mediated immunity or 
cellular immunity), Helper T cells (stimulate T and B cells) and Supressor T cells 
(inhibit T and B cells) and are also known as T regulatory cells (Treg). Following 
antigen presentation by antigen presenting cells (APCs) and costimulatory signals 
(eg. through CD28 receptor), effector T cells are triggered. The expansion of 
activated T cells is controlled by Treg cells including CD4+CD25+, CD8+CD25+, 
CD8+CD28- or CD4-CD8-CD3+ T-cells. There is interplay amongst effector T-
cells, Treg cells and APCs and this determines the outcome of an immune response 
(Beissert, et al., 2006; Sakaguchi, et al., 1995). B cells can differentiate into plasma 
cells, responsible for the production and secretion of antibodies. NKCs are large 
granular lymphocytes which attack foreign cells, virus-infected cells and cancer 
cells. Through the adaptive immune response, the body develops a memory for a 
faster response following re-exposure (Martini, 2004).  
 The sympathetic input to the thymus originates from sympathetic chain 
ganglia extending from the SCG caudal to the T3 sympathetic ganglion (Nance, et 
al., 1987). Prevertebral sympathetic ganglia associated with the celiac-mesenteric 
plexus in addition to sympathetic postganglionic neurons that arise from the 
sympathetic chain ganglia of T1-T12 region of the thoracic spinal cord provide a 
major sympathetic input to the spleen (Cano, et al., 2001; Nance and Burns, 1989). 
There is less known regarding the specific origin of sympathetic innervation of 
lymph nodes however the origin is thought to reflect the specific regions of the body 
where the lymph nodes reside  (Nance and Sanders, 2007). Similar to that of lymph 
nodes, neuroanatomical studies examining the origin of innervation of bone marrow 
is limited. This said femoral bone marrow innervation has been linked to 
thoracolumbar paravertebral sympathetic ganglia that receive input from T8-L1 
spinal sympathetic preganglionic neurons (Denes, et al., 2005). 
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3.3.1 Sympathetic regulation of the immune system 
The brain receives input from sensory neurons (e.g. dorsal root ganglia (DRG)) or 
immune stimuli (e.g. cytokines) (Besedovsky and del Rey, 1992; Besedovsky and del 
Rey, 1996; Nance and Sanders, 2007). Signals are transported to the brain via blood 
(Banks and Kastin, 1991) or cytokine receptors on the vagus nerve (Watkins, et al., 
1995). In the case of an adaptive immune response, the brain communicates with the 
periphery by two pathways. The first pathway is via hypothalmic pituitary adrenal 
axis (HPA) and the second is via the SNS. The HPA regulation of immune function  
involves the release of corticotrophin releasing hormone (CRH) from the 
hypothalamus which stimulates the release of adrenocorticotropic hormone (ACTH) 
from the pituitary gland and subsequent release of corticosteroids from the adrenal 
cortex (Webster, et al., 2002). The SNS extends fibres to innervate organs of the 
immune system (Meltzer, et al., 1997; Panuncio, et al., 1999) by a vascular route 
(Bellinger, et al., 2001). The activation of the SNS stimulates the release of NE 
(Esler, et al., 1985) in addition to neuropeptide Y (NPY) (Ruohonen, et al., 2009) 
and opioids (Hall, et al., 1998; Straub, 2004) from sympathetic neurons. NE is 
released over the length of the sympathetic fibres (Madden, et al., 1995; Shimizu, et 
al., 1994) and binds to target immune cells, B and T lymphocytes, at their adrenergic 
receptor 2AR (Kohm and Sanders, 2001). Stimulation of the 2AR on an immune 
cell induces an increase in the intracellular level of cAMP, which activates protein 
kinase A (PKA) signalling cascade to regulate a variety of immune processes. 
Responses include leukocyte activation, cytokine production, and cell trafficking 
(Cole, et al., 1999; Cole, et al., 1998; Kammer, 1988; Madden, et al., 1995; Ottaway 
and Husband, 1994; Sanders and Straub, 2002). 
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Figure 3.4: Sympathetic innervation of immune organs 
All immune organs receive substantial sympathetic innervation from sympathetic postganglionic 
neurons. Input to the brain comes from sensory neurons (e.g. DRG) or immune stimuli (e.g. 
cytokines). The primary pathway for the neural regulation of immune function is provided by the SNS 
and its main neurotransmitter, NE. Activation of the SNS primarily inhibits the activity of cells 
associated with the innate immune system, while it either enhances or inhibits the activity of cells 
associated with the adaptive immune system. Via AR’s, which are primarily of the β2AR subtype, NE 
is able to regulate the level of immune cell activity by initiating a change in the level of cellular 
activity, which often involves a change in the level of gene expression for cytokines and antibodies. 
Adapted from Nance and Sanders, 2007. 
  
3.4 The development of the SNS 
The correct development of sympathetic neurons is essential in order to establish an 
optimal functioning SNS. The SNS undergoes development between the gestation 
periods of E12-15 in rats (E=Embryonic day of gestation) (Rubin 1985a; Rubin 
1985b; Rubin 1985). Sympathetic precursor cells first appear in the cervical region 
on E12 as a column along the dorsal aorta at all cervical levels (Rubin 1985a). Cells 
accumulate adjacent to cervical segments 1-5 (C1-5) forming a primitive SCG 
between days E12-14 (Rubin 1985a). Cells are scarce at more caudal cervical levels, 
forming a narrow region which is later filled with axons and form the cervical 
sympathetic trunk (Rubin 1985a). Enhanced proliferation occurs at the lowest 
cervical and upper thoracic levels that results in an accumulation of cells that form 
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the SCG and SG (Rubin 1985a). With accumulation of cells and growth of the 
embryo, the cervical sympathetic trunk elongates (Rubin 1985a). By E14, the SCG 
extends from C1-5, however, by E16, the SCG extends from C1-3 indicating these 
cells aggregate as opposed to disperse along the length of the cervical sympathetic 
trunk (Rubin 1985a). Some cells of the SCG extend processes by E12. These cells 
extend long fibres that follow a linear course and resemble postganglionic axons, 
with most axons extending rostrally, and run along branches of the carotid artery and 
establish the internal and external carotid nerves. Postganglionic axons then grow 
toward peripheral regions along their arterial branches and subsequently along 
cranial nerves. For example, the postganglionic axon destined for the lacrimal gland 
emerges from the SCG along the internal carotid nerve, transfers to the facial nerve 
and follows a facial nerve branch to the orbit and innervates the lacrimal gland by 
E15 (Rubin 1985a). By E14, postganglionic cells possess a number of dendritic 
processes in addition to their axons. Dendrites can be differentiated from axons on 
E14 as they appear narrower, closer to the cell body, follow irregular trajectories and 
branch frequently (Rubin 1985a). Synaptic formations occur on soma and dendrites 
of ganglionic cells by E14 (Rubin 1985c). There is subsequently an increase in the 
number of dendritic synapses by E15 and this number soon exceeds that of somatic 
contacts. At birth, most synaptic contacts are dendritic as opposed to somatic (85%) 
(Rubin, 1985b; Rubin, 1985c). 
 
3.4.1 Stages of development of the SNS 
The development of sympathetic neurons involves cell migration, ganglia formation, 
differentiation into sympathetic neurons, axonal extension and target innervation 
(Glebova and Ginty, 2005). Sympathetic neurons, like parasympathetic, arise from 
neural crest cells (NCCs), an embryonic progenitor cell population. NCCs arise from 
neural folds of the neural tube and migrate ventromedially through the rostral half of 
each somite. Once they pass through the somites, NCCs migrate further ventrally 
toward the dorsal aorta and form ganglia (Erickson, et al., 1989; Rickmann, et al., 
1985). The dorsal aorta releases molecules such as BMP-4 and BMP-7, which 
induce the NCCs to differentiate into sympathetic neurons (Reissmann, et al., 1996) 
(Schneider, et al., 1999); Anderson, et al., 1997) and these neurons then project 
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axons to peripheral targets (Rubin, 1985a). The extension and growth of axons to 
and within their targets during development of the SNS is controlled by a variety of 
attractive and repulsive cues or signals. 
 
3.4.2 Signalling throughout stages of SNS development 
NCCs migrate from the dorsal aspect of the neural tube initially following a 
ventromedial pathway via the rostral half of each somite and give rise to sympathetic 
ganglia in chicken embryos (Erickson, et al., 1989; Rickmann, et al., 1985). Cells 
migrate via the rostral half of somites due to repulsive signals from the caudal half. 
The caudal half of each somite express both Semaphorin-3A (Sema3A) and Ephrin-
B1 in mice, rat and chick (Adams, et al., 1996; Eickholt, et al., 1999; Giger, et al., 
1996; Koblar, et al., 2000; Krull, et al., 1997; Wang and Anderson, 1997). Both 
Sema3A and Ephrin-B1 molecules are inhibitory to migrating NCCs which express 
their respective receptors neuropilin-1 and EphB3 in mouse and chicken embryos 
(Kawakami, et al., 1996; Kawasaki, et al., 2002; Krull, et al., 1997). In addition, the 
caudal half of each somite expresse F-spondin and chondroitin sulphate 
proteoglycans, which were also inhibitory to migrating NCCs in avian embryos 
(Debby-Brafman, et al., 1999; Krull, 2001). The migration of NCCs further ventrally 
toward the dorsal aorta involves Neuregulin signalling. Neuregulins are a family of 
four structurally related proteins, part of the epidermal growth factor (EGF) family 
of proteins whose effects are mediated by members of ErbB family of tyrosine 
kinases (trks) (Falls, 2003). NCCs express ErbB2 and ErbB3, and neuregulin-1 is 
expressed by newly formed somites, the mesenchyme surrounding the dorsal aorta 
and the dorsal neural tube in mice (Britsch, et al., 1998). The bone morphogenetic 
protein (BMP) family member ligands, BMP4 and BMP7, are produced by the 
dorsal aorta and are required for the expression of Neuregulin 1, in addition to the 
expression of stromal cell–derived factor–1 (SDF1, a chemokine, also called 
CXCL12), which in turn mediates progenitor cell migration (Kim, et al., 2003b; Rio, 
et al., 1997). 
 The SCG is formed from the first cells that migrate ventrally. These cells 
coalesce into a column between C1–C7. Many of these cells then migrate rostrally, 
separate from the SG and form the SCG between C1-C4 in mice and rats (Nishino, et 
al., 1999; Rubin, 1985a). The rostral migration of SCG precursors involves artemin, 
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a member of the glial derived neurotrophic factor (GDNF) family, which acts at its 
receptor complex, Ret and GDNF family receptor a3 (GFRa3), in mice (Durbec, et 
al., 1996; Enomoto, et al., 2001; Honma, et al., 2002; Nishino, et al., 1999). Artemin 
is expressed by blood vessels and is chemoattractive to developing sympathetic 
neurons in mice (Honma, et al., 2002). Artemin may play a role in the rostral or 
caudal migration of cells that lead to the segmentation of columns of cells into 
ganglia throughout the sympathetic chain. 
 BMP-4 and BMP-7 are expressed in the dorsal aorta of mammalian and avian 
species at critical times during sympathetic neuron differentiation (Reissmann, et al., 
1996). These dorsal aorta-derived BMPs act on NCCs, that aggregate to form ganglia 
primordia, adjacent to the dorsal aorta, and induce the differentiation of these cells 
into sympathetic neurons in the chick embryo (Schneider, et al., 1999). BMPs elicit 
the expression of a network of transcription factors that, in turn, control autonomic 
neuron differentiation (Goridis and Rohrer, 2002). This network includes Mash1 and 
the paired transcription factors Phox2a and Phox2b. Phox2 proteins bind to the 
promoter of the subtype-specific noradrenergic marker genes for tyrosine 
hydroxylase (TH) (Goridis and Rohrer, 2002). Additional transcription factors 
involved in the specification of the noradrenergic phenotype of sympathetic neurons 
include HAND2 (previously known as dhand), cash1 and GATA-3 (Anderson, et al., 
1997). Sympathetic ganglion neuron differentiation depends upon both canonical and 
non-canonical pathways of BMP-mediated signalling. Canonical BMP signalling 
regulates the transcription of HAND2 and Phox2a, while non-canonical involves the 
activation of PKA (Liu, et al., 2005).   
 
Postganglionic sympathetic neurons begin to extend axons during the 
formation of ganglia at E12 (Rubin, 1985a). Hepatocyte growth factor (HGF), also 
known as scatter factor, as it was originally identified as a molecule that could 
trigger motility in a variety of epithelial cell types (Birchmeier and Gherardi, 1998), 
is produced by sympathetic neurons, and functions to enhance sympathetic neuronal 
survival, differentiation and proximal axonal growth (Maina, et al., 1998). HGF 
cooperates with NGF in postnatal neurons to promote arborisation of sympathetic 
neurons (Yang, et al., 1998) via both phosphoinositide-3 kinase (PI-3 kinase) and 
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mitogen activated protein kinase (MAP kinase)-dependent mechanisms (Thompson, 
et al., 2004).   
 Axon extension uses a vasculature route, in that axons travel to their targets 
by hitching a ride on arteries. Artemin (already discussed) is expressed in smooth 
muscles of blood vessels, and its receptor components Ret and GFR3A, mediate this 
projection of axons along arterial vasculature in mice (Baloh, et al., 1998; Enomoto, 
et al., 2001). Although known to be required for migration,  axonal projections of 
sympathetic neuroblasts and proximal extension of postganglionic sympathetic 
axons, in artemin -/- mice studies, sympathetic innervation of peripheral targets still 
exist (Enomoto, et al., 2001; Honma, et al., 2002). This suggests there is another 
factor at play in the role of proximal axon extension of sympathetic neurons.  
 Neurotrophin 3 (NT-3), a member of the neurotrophin family, is expressed by 
blood vessels and can induce proximal sympathetic axon extension along arterial 
vasculature on route to innervate peripheral targets of mice (ElShamy, et al., 1996; 
Kuruvilla, et al., 2004). In NT-3 -/ - mice, sympathetic axons fail to enter the pineal 
gland and the external ear and infusion of exogenous NT-3 into the external ear 
restored the sympathetic innervation in mutant mice (ElShamy, et al., 1996). But 
similar to that of artemin -/- studies, in NT-3 -/- mice, most targets received at least 
some peripheral target innervation (ElShamy, et al., 1996). This suggests that there 
are other molecules that contribute to axon extension along blood vessels during 
development. A number of molecules have been implicated in distal extension and 
target innervation of developing sympathetic neurons, including GDNF (Yan, et al., 
2003), vascular cell adhesion molecule-1 (VCAM-1), and a4-integrins (Wingerd, et 
al., 2002). Recently, Wnt5a derived from sympathetic neurons was found to be 
required for in vivo distal axon extension, arborisation and target innervation in mice 
via Ror tyrosine kinase receptors (Ryu, et al., 2013). While SEMA3A signalling 
through receptor neuropilin-1 (NRP1) was found to regulate target innervation of 
developing sympathetic neurons (of the heart and aorta) in mice (Maden, et al., 
2012). In distal axons of primary sympathetic neurons CTβ2 (isoforms of CTP: 
phosphocholine cytidylyltransferase (CT)), a major contributor to 
phosphatidylcholine (PC) synthesis, promoted axon branching (Strakova, et al., 
2011). However, the most well studied mediator of distal axon extension is nerve 
growth factor (NGF) (Levi-Montalcini, 1987).  
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3.5 NGF 
NGF is the founding member of the neurotrophin family which is a family of 
structurally related, secreted proteins that are essential for the development and 
functioning of the nervous system (Lewin and Barde, 1996). The neurotrophin 
family consists of a number of closely related factors including brain-derived 
neurotrophic factor (BDNF) (Leibrock, et al., 1989); NT-3 (already described) 
(Maisonpierre, et al., 1990); neurotrophin 4/5 (NT-4/5) (Berkemeier, et al., 1991; 
Hallbook, et al., 1991) and the prototype NGF (Levi-Montalcini, 1987).  
NGF is required for the survival of sympathetic neurons in vivo (Angeletti 
and Levi-Montalcini, 1971; Crowley, et al., 1994; Levi-Montalcini and Booker, 
1960) and in vitro (Deshmukh and Johnson, 1997; Greene, 1977; Martin, et al., 
1988). In addition, in vitro experiments demonstrate the axonal growth promoting 
effects on NGF in sympathetic neurons (Atwal, et al., 2000; Campenot, 1994; 
Campenot, et al., 1994; Cohen, et al., 1954; Deckwerth, et al., 1996; Mains and 
Patterson, 1973). As NGF is crucial for the survival of developing sensory and 
sympathetic neurons, this poses an obvious difficulty for the investigation of the role 
of NGF directly in promoting axonal growth of these neurons in vivo. This difficulty 
was overcome by Patel et al 2000, who studied DRG cells of NGF -/- Bax -/- and 
Bax -/- TrkA -/- mice (Patel, et al., 2000). Bax is a pro-apoptotic member of the Bcl-
2 family required for programmed cell death in a number of tissues (Korsmeyer, 
1999). The loss of DRG neurons in NGF -/- mice was prevented in NGF -/- Bax -/- 
mice. This method allowed for the study of NGF function in axonal growth 
independent of its function in survival. Using this method, Glebova and Ginty 2004, 
found that NGF is heterogeneously required for axonal growth and peripheral 
innervation of sympathetic targets of both paravertebral and prevertebral sympathetic 
ganglia in vivo. In addition, this study also highlights that target organs vary in their 
individual NGF requirements for sympathetic innervation. In NGF -/- Bax -/- mice, 
there is an absence of sympathetic innervation in the submaxillary salivary gland, the 
parotid gland and the iris, all targets of the SCG. Sympathetic innervation of the 
heart and lungs, targets of the SG is drastically decreased in the absence of NGF. 
However, the sympathetic innervation of the trachea, a target primarily of the SCG 
and secondarily of the SG, is only slightly reduced in the absence of NGF when 
compared to controls. The spleen, stomach and kidney receive sympathetic 
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innervation from the CG and thoracic chain ganglia; the innervation of these targets 
is reduced in NGF -/- mice but to a lesser extent than that of the targets of the SCG. 
A reduction in sympathetic innervation in the absence of NGF is also evident in the 
Gastro-intestinal tract (GIT), ureters, bladder and gonads, also targets of CG, in 
addition to SMG and IMG, thoracic and lumbsaccral ganglia (Glebova and Ginty, 
2004). This study confirms that, in addition to its role in neuronal survival, NGF 
plays a key role in axonal growth of sympathetic axons and consequently in the 
establishment of normal patterns of innervation in particular peripheral targets in 
vivo. However, the partial innervation of many organs in the absence of NGF 
confirmed that successful sympathetic axonal growth into peripheral targets is likely 
to depend on a range of factors with overlapping roles.   
 
3.5.1 Discovery of NGF 
NGF was discovered in the 1950s by Rita Levi-Montalcini and Victor Hamburger 
through a series of experiments on chicken embryos through the grafting of mouse 
sarcoma into the body wall of a 3 day old chicken embryo which was fixed 3-5 days 
later. Both sensory and sympathetic fibres entered the neoplastic tissue, building a 
high density network of fibres that branched between tumour cells. Sensory and 
sympathetic ganglia were significantly larger in chicken embryos grafted with 
sarcoma tissue compared to controls. They hypothesised that the neoplastic cells 
released a soluble diffusible agent that altered the differentiation and growth of 
developing neurons. This agent was termed a tumour nerve promoting factor, a 
factor that is now well known as NGF (Levi-Montalcini, 1987). NGF was purified 
from snake venom and injected into 6-8 day old chicken embryos resulting in 
overgrowth of sensory and sympathetic ganglia, and profuse branching into viscera 
and veins. This effect was inhibited with the application of NGF antiserum. An in 
vitro bioassay indicated that the submandibular gland is a source of NGF. Following 
injection of antiserum of submandibular-sourced NGF, mouse paravertebral and 
prevertebral ganglia disappeared (Levi-Montalcini, 1987; Levi-Montalcini and 
Hamburger, 1951). From these early experiments, it became clear that NGF is 
important for the regulation of survival of the developing sensory and sympathetic 
neurons.  
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3.5.2 Mechanism of action of NGF 
NGF is produced in the peripheral targets of NGF-dependant neurons, such as the 
heart, submandibular gland and the iris in rats (Heumann, et al., 1984; Korsching 
and Thoenen, 1985). Recently, mouse heart vascular smooth muscle cells were 
shown to secrete NGF, attracting axons toward their final cardiac target (Nam, et al., 
2013).  
 NGF production begins with the arrival of the earliest axons (Davies, et al., 
1987) and its production in target organs determines the density of innervation by the 
SNS (Korsching and Thoenen, 1983). Early studies examining the role of NGF lead 
to the development of the neurotrophic hypothesis (Levi-Montalcini, 1987; Levi-
Montalcini and Hamburger, 1951) which states that neurons compete for limiting 
amounts of target-derived survival factors and those that obtain sufficient amounts 
gain a competitive advantage over others and survive, whereas those that fail to 
compete die (Oppenheim, 1989). Therefore neurons innervate their peripheral targets 
initially in excess numbers and those in excess are eliminated by cell death following 
innervation of the target tissue.  
 NGF mediates its actions by binding two receptors, tyrosine kinase A (TrkA) 
and p75 neurotrophic factor receptor (p75NTR), both transmembrane glycoproteins, 
of which TrkA is a high affinity receptor and p75NTR, a low affinity receptor for 
NGF (Davies, et al., 1993; Kaplan and Miller, 1997). Deppmann et al put forward a 
model for neuronal competition during development. NGF is required for the 
expression and upregulation of TrkA in SCG neurons as deprivation of NGF in these 
neurons resulted in a reduction in TrkA upregulation and subsequent TrkA 
signalling. NGF also upregulated fellow members of the neurotrophin family, BDNF 
and NT-4 which promoted SCG neuronal cell death by binding p75NTR at 
subsaturating levels of NGF. However cell death was suppressed by concentrations 
of NGF that activate TrkA therefore neurons with enhanced NGF-survival signalling 
could facilitate the removal of other neurons through p75NTR-dependent pro-
apoptotic signalling (Deppmann, et al., 2008). 
 
3.5.3 TrkA 
TrkA is a member of the Trk gene family, which includes TrkB, the receptor for 
BDNF and NT-4, and TrkC, the receptor for NT-3. NT-3 also activates TrkA but 
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only does so at much higher concentrations than NGF (Kaplan and Miller, 1997). 
TrkA is known as the high affinity receptor for NGF (Mahadeo, et al., 1994). NGF is 
released from peripheral targets and acts directly on distal extending axons to 
promote local growth (Campenot, 1994; Kuruvilla, et al., 2004). Following 
NGF/TrkA binding at distal axons, NGF/TrkA is internalised by a process known as 
endocytosis which may be clathrin (a protein involved in the formation of vesicles) 
dependent or clathrin-independent (Doherty and McMahon, 2009). One type of 
clathrin-independent mechanism is macropinocytosis, which involves the formation 
of plasma membrane protrusions that eventually fuse together and engulf large 
volumes of membrane and extracellular fluid. Pincher, an NGF-upregulated GTPase, 
is involved in clathrin-independent internalization (Shao, et al., 2002). The 
internalised vesicle becomes a signalling endosome and is eventually degraded. A 
signalling endosome refers to an endosome containing active ligand-receptor 
complexes that associate with and activate components of downstream growth and 
survival signalling pathways as they traffic within axons and cell bodies (Harrington 
and Ginty, 2013). Members of the RAB family of GTPases are involved in the 
transformation of vesicle to a signalling endosome (Zerial and McBride, 2001). The 
signalling endosome is transported in a retrograde fashion which involves the 
directed, coordinated movement of proteins or vesicles from distal axons 
(Harrington and Ginty, 2013) towards the neuronal soma and dendrites (Sharma, et 
al., 2010).  At the cell soma the signalling endosome mediates a number of processes 
including neuronal survival, growth, gene expression, and synaptogenic signalling 
events (Harrington and Ginty, 2013; Pazyra-Murphy, et al., 2009; Sharma, et al., 
2010). A transcriptional response is required for axonal growth over long periods of 
time (Bodmer, et al., 2011). Transcription factors involved in axonal growth include 
cyclic AMP responsive element-binding protein (CREB) (Lonze, et al., 2002; 
Wickramasinghe, et al., 2008), serum response factor (SRF) (Wickramasinghe, et al., 
2008 ) and nuclear factor of activated T-cells (NFAT) (Graef, et al., 2003). 
TrkA activates PI3-kinase–Akt and extracellular related kinase (ERK) 
pathways and their downstream effectors including PI3K stimulation of Akt and 
ERK stimulation of MAP kinase cascades (Huang and Reichardt, 2003); Kaplan and 
Miller, 2000; Sofroniew, et al., 2001). TrkA activates these pathways via Ras (see 
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below) in rat sympathetic neurons as shown by the inhibition of survival in these 
neurons with a neutralising antibody to p21Ras (Nobes and Tolkovsky, 1995).  
 
3.5.4 ERK1/2 signalling 
TrkA activation has been shown to promote axonal growth via the ERK1/2 pathway. 
ERK1/2 is one of the many MAP kinase (MAPK) family signalling cascades. These 
cascades are regulated by phosphorylation (covalent binding of phosphate groups to 
an amino acid residue in a process catalysed by enzymes called kinases (Johnson 
and Lapadat, 2002). The MAPK family consists of a number of kinases which share 
similar homology, the founding member of which is ERK, a 42kDa proteins that 
phosphorylates at tyrosine residues (Boulton, et al., 1991). The MAPK family 
includes five branches: ERK1/2; c Jun N-terminal (JNK) 1, 2, 3; p38; ERK 3, 4, 5 
and ERK 6, 7, 8 (Bogoyevitch and Court, 2004). Different MAPK branches respond 
to different stimuli for example ERK responds to trophic factors and p38 responds to 
UV radiation (Chang and Karin, 2001). The common feature amongst all branches is 
three serially linked kinases in each pathway, MAPKKK, MAPKK, MAPK (where 
K=kinase), which can be described as the general pathway.  
ERK1/2 activation has been shown to regulate cell proliferation, 
differentiation, motility, survival and growth in a number of tissues (Meloche and 
Pouyssegur, 2007; Pearson, et al., 2001; Roux and Blenis, 2004). In the PNS, 
ERK1/2 signalling is required for axonal growth and target innervation of NGF-
dependant sympathetic neurons (O'Keeffe, et al., 2008). Growth factors activate 
ERK1/2 by binding to their relevant tyrosine kinase receptors (Blume-Jensen and 
Hunter, 2001). The tyrosine kinase cytoplasmic domain of these receptors contains 
regions that are subject to phosphorylation and autophosphorylation which act as 
recognition and recruitment sites for signalling proteins such as growth factor 
receptor bound 2 (GRB2), an adapter protein that binds trks directly or via another 
adapter protein, Src homology 2 domain containing transforming protein (Shc) 
(Pelicci, et al., 1992; Rojas, et al., 1996). GRB2 associates with nucleotide exchange 
factor Son of sevenless (SOS), which through guanine exchange, enhances GDP 
release and GTP binding to membrane bound product of proto-oncogene c-Rat 
sarcoma viral oncogene homolog (Ras), converting Ras GTPase into an active form 
(Li, et al., 1993). Ras then interacts with a number of downstream effectors. In the 
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ERK1/2 cascade, Ras acts as an adapter to activate Raf murine sarcoma viral 
oncogene homolog (Raf) kinases, the first of the central 3 tier core signalling module 
of all MAPKs (MAPKKK, MAPKK (MKK/MEK) and MAPK), where Raf = 
MAP3K (Jelinek, et al., 1996). There are three Raf proteins, Raf-1, A-Raf and B-Raf 
(Rapp, et al., 1983). Raf can be phosphorylated by v-Akt murine thymoma viral 
oncogene homolog (Akt), p21-activated protein kinase (PAK) and Sarcoma viral 
oncogene (Src). The phosphorylation of Raf activates MEK1/2 (MAPKK) (Zheng 
and Guan, 1993) which activates ERK1/2 (MAPK) by phosphorylation which occurs 
at two ERK sites, i.e. dual phosphorylation is required for significant ERK activation 
(Ferrell and Bhatt, 1997). MAPK signal transduction is regulated by dual specificity 
phosphatases (DUSPs) which dephosphorylate both sites. DUSPs are also known as 
MAPK phosphatases (MKPs) (Caunt, 2012). ERK signal transduction is assisted by 
scaffold proteins which increase specificity and efficiency of ERK signalling and 
regulate ERK signalling and include kinase suppressor of Ras (KSR), MEK partner 1 
(MP1) and similar expression to FGF genes (Sef) (Omerovic and Prior, 2009). 
Activated ERK regulates growth factor responses in the cytosol and translocates to 
the nucleus where it phosphorylates a number of transcription factors that regulate 
gene expression. Cytosol targets include members of the ERK pathway acting in a 
negative feedback loop such as SOS (Dong, et al., 1996) as well as ribosomal protein 
S6 kinases (RSK) which translocates to the nucleus and phosphorylates factors such 
as CREB (Xing, et al., 1996). Additional nuclear targets include ternary complex 
factors (TCFs) such as Ets-like gene 1 (Elk-1) (Marais, et al., 1993) and proto 
oncogene v-myc myelocytomatosis viral oncogene homolog (c-myc) (Sears, et al., 
2000).  
 Several neurotrophic factor-regulated transcription factors — including 
CREB, SRF and NFAT, mentioned earlier, have been implicated in promoting 
axonal outgrowth in vivo (Graef, et al., 2003; Lonze, et al., 2002; Wickramasinghe, 
et al., 2008). Embryonic mice deficient in calcineurin-NFAT signalling display 
dramatic defects in sensory axonal outgrowth, however little or no defects in 
neuronal differentiation or survival were found (Graef, et al., 2003). CREB is 
required for survival and axon extension of sensory and sympathetic neurons 
demonstrated by impaired axonal growth and projections in cultured neurons from 
CREB null mice (Lonze, et al., 2002). SRF-mediated NGF signalling is required for 
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axonal growth, branching, and target innervation by embryonic DRG sensory 
neurons via MEK/ERK signalling shown by murine gene deletion studies of SRF. 
This resulted in defects in extension and arborization of peripheral axonal 
projections in the target field in vivo which was similar to the target innervation 
defects observed in mice lacking NGF (Wickramasinghe, et al., 2008). 
 
Figure 3.5: The MAPK signalling pathway 
Ligand (eg. NGF) binds to its receptor (eg. TrkA) on the cell membrane which binds to docking 
proteins such as GRB2. GRB2 binds and activates SOS and subsequently Ras and MAP3K (eg. Raf) 
followed by MAP2Ks (MEK1/2) and lastly MAPKs (ERK1/2) resulting in transcription of target 
genes and changes in gene expression. 
 
 
3.5.5 ERK1/2 signalling in sympathetic axonal growth and target innervation 
MAPK was found to mediate neurite growth-enhancing actions of NGF in neonatal 
sympathetic neurons, as seen by pharmacological inhibition of MEK1 and MEK2 
which blocked NGF-induced phosphorylation of ERK1/2 and resulted in a 
significant reduction of axonal growth in neonatal sympathetic neurons (Thompson, 
et al., 2004). Further support for MAPK in axonal growth comes from Goold et al 
which found that NGF/TrkA signalling via MAPK activated serine/threonine kinase 
glycogen synthase kinase 3beta (GSK3) which phosphorylated microtubule-
associated protein 1B (MAP1B) which regulated microtubule dynamics in growing 
axons and induced axonal growth (Goold and Gordon-Weeks, 2005). To assess the 
importance of MAPK activation in NGF-promoted axonal growth in neonatal 
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sympathetic neurons, O’Keeffe et al. studied the effect of U0126, a selective 
pharmacological blocker of MEK 1 and 2, the kinases that phosphorylate ERK1/2. 
This compound caused a substantial decrease in the size and complexity of the 
neurite arbors of neonatal mouse sympathetic neurons grown with NGF. NGF 
activation of MAPK signalling in the growth promotion of developing sympathetic 
neurons is facilitated by a member of the tumour necrosis factor (TNF) receptor 
superfamily (TNFRSF), namely glucocorticoid-induced tumour necrosis factor 
receptor (GITR). O’Keeffe et al showed that ERK1/2 activation was reduced in 
neonatal sympathetic neurons from GITR -/- mice (O'Keeffe, et al., 2008). More 
recently, Egr3, a transcriptional regulator whose expression is coupled to MAPK 
signalling (Eldredge, et al., 2008; Li, et al., 2011), has been implicated in NGF 
promotion of axonal growth via MAPK signalling. Using a method employed by 
Glebova and Ginty, Bax was eliminated and sympathetic neuron death was 
prevented (Glebova and Ginty, 2004) allowing for analysis of the effect of deleting 
Egr3 on target innervation. Mice with simultaneous loss of Bax and Egr3 had 
atrophic sympathetic neurons, dysautonomia (autonomic dysfunction) and 
sympathetic target tissue innervation abnormalities. Target tissue innervation was not 
effected uniformly, with some tissues showing severe sympathetic innervation 
abnormalities, while in other tissues no innervation abnormalities were observed. 
The conclusion was Egr3 is required for normal terminal axon extension, branching 
and target tissue innervation of sympathetic neurons following NGF induction of 
MAPK signalling (Eldredge, et al., 2008; Li, et al., 2011).  
 
3.5.6 p75NTR 
Like GITR, p75NTR is a member of the TNFRSF and binds all members of the 
neurotrophin family (Frade and Barde, 1998; Rodriguez-Tebar, et al., 1990). 
p75NTR consists of an extracellular, transmembrane and cytoplasmic domain, the 
latter of which contains  a ‘death’ domain similar to other members of this family 
(Liepinsh, et al., 1997).  
 p75NTR is expressed by developing sympathetic neurons at low levels as 
they project along NT-3-expressing vasculature and other intermediate targets of 
sympathetic neurons, however these levels peak upon innervation of final target 
fields (Verdi and Anderson, 1994; Wyatt and Davies, 1995). At the stage of peak 
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expression of p75NTR, sympathetic neurons become less sensitive to NT-3 
indicating that p75NTR is involved in the switch in neuron responsiveness from NT-
3 to NGF (Kuruvilla, et al., 2004). The expression of p75NTR is dependent on NGF, 
demonstrated by the dramatic decrease in p75NTR expression in the absence of NGF 
in sympathetic neurons (Kuruvilla, et al., 2004).  
 p75NTR induces cell death and cell survival depending on the cellular 
context. p75NTR promotes cell death by apoptosis in a ligand-independent and 
dependant manner. Ligand-independent p75NTR-mediated cell apoptosis occurs in 
cell lines and neurons from DRG while ligand-dependant p75NTR-mediated cell 
death occurs in proprioceptive, sympathetic and oligodendrocytes neurons in vitro, 
and neurons of the developing retina, spinal cord, sympathetic ganglia and 
cholinergic basal forebrain nuclei in vivo (Frade and Barde, 1998). Following ligand 
binding, the intracellular region of p75NTR interacts with NRIF to transduct the cell 
death signal as seen by a reduction in cell death of the developing retina of NRIF -/- 
mice to the same extent as in p75NTR -/- and NGF -/- mice (Casademunt, et al., 
1999). In support of the Deppmann et al 2008 study mentioned above, p75NTR 
induced apopotic cell death in sympathetic neurons and therefore contributed to 
normal developmental elimination of neurons as seen by excess SCG neurons in 
p75NTR -/- mice during the apoptotic period (Bamji, et al., 1998). BDNF is 
synthesized by sympathetic neurons upon NGF exposure resulting in sympathetic 
neuron cell death (Deppmann, et al., 2008). BDNF binding to p75NTR in 
sympathetic neurons results in JNK activation, specifically, JNK3, which then causes 
a transcriptional up-regulation of the metalloprotease TACE/ADAM17 leading to 
receptor cleavage. The freed intracellular domain (ICD) prolongs the activation of 
JNK, ultimately resulting in apoptosis (Kenchappa, et al., 2010).  
 p75NTR promotes the survival of sensory and sympathetic neurons by 
increasing the neurons sensitivity to NGF as seen by a 2- to 3-fold decreased 
sensitivity to NGF in embryonic and postnatal DRG and SCG neurons from p75NTR 
deficient mice (Lee, et al., 1994b). p75NTR increases the binding affinity in addition 
to the internalisation of NGF and TrkA, demonstrated by kinetic analysis in which a 
25-fold increase in rate of association between NGF and TrkA when TrkA is co-
expressed with p75NTR compared to when TrkA is expressed alone in PC12 cell 
lines (Mahadeo, et al., 1994). The high affinity site formation between NGF and 
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TrkA has been attributed to the interaction between the transmembrane and 
cytoplasmic domains of TrkA and p75NTR where p75NTR alters the conformation 
of TrkA to generate high affinity NGF binding (Esposito, et al., 2001). Recently, the 
juxtamembrane ICD of p75NTR was found to be required to potentiate TrkA-
mediated signalling (Matusica, et al., 2013). Furthermore, the ICD of p75NTR 
modulated the binding of NGF to TrkA by significantly increasing the amount of 
NGF bound to TrkA-expressing cells, with no change in the surface expression of 
either p75NTR or TrkA receptors (Matusica, et al., 2013). p75NTR-mediated 
activation of the transcription factor nuclear factor kappa B (NF-B) plays a role in 
enhancing the survival response of developing sensory neurons to NGF. Antibodies 
that block binding of NGF to the p75NTR prevented NGF-induced NF-B activation 
and reduced the NGF survival response in sensory neurons of embryonic mouse 
trigeminal ganglia (Hamanoue, et al., 1999).  
 In addition, p75NTR exhibits growth promoting effects in different neuronal 
populations. Decreased p75NTR expression by antisense oligonucleotides in media 
resulted in a reduction in the growth of chick embryonic sensory neurons (Wright, et 
al., 1992). p75NTR supports axonal growth of some sympathetic neurons as seen by 
lack of sympathetic innervation of the pineal gland and reduced or absent innervation 
of  footpad sweat glands in p75NTR-/- mice  (Lee, et al., 1994a).  
 
3.5.7 NF-B 
NF-B is a regulator of axonal growth in developing sympathetic neurons (Gutierrez 
and Davies, 2011), but is most well known for its role in the immune system. In the 
immune system, NF-B regulates the expression of genes involved in innate and 
adaptive immune responses, inflammatory responses, cell survival and cell 
proliferation (Hayden, et al., 2006; Liang, et al., 2004; Tergaonkar, 2006).  
 NF-κB is a transcription factor consisting of homodimers or heterodimers of 
a family of five structurally related proteins: p65 (RelA); RelB; c-Rel; p50 and p52, 
of which the p50/p65 heterodimer is predominant in many cell types, including the 
nervous system (Karin, 1999). These protein subunits are related through an N-
terminal, 300 amino acid, DNA binding/dimerization domain, called the Rel 
homology domain (RHD), through which they can form homodimers and 
heterodimers that bind to 9-10 base pair DNA sites, known as κB sites, in the 
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promoter and enhancer regions of genes, thereby modulating gene expression (Chen, 
et al., 1998). p65 (RelA), c-Rel and RelB contain C-terminal transcriptional 
activation domains (TADs), which enables them to activate target gene expression. 
In contrast, p50 and p52 do not contain C-terminal TADs; therefore, p50 and p52 
repress transcription unless they are bound to a protein containing a TAD, such as 
RelA, c-Rel, RelB or Bcl-3 (a related transcriptional co-activator). Unlike the other 
NF-κB family members, p50 and p52 are derived from larger precursors, p105 and 
p100, respectively (Chen and Greene, 2004; Hayden and Ghosh, 2004; Hoffmann, et 
al., 2006; Rothwarf and Karin, 1999). A more recent study demonstrated that 
another essential subunit of NF-κB, ribosomal protein S3 (RPS3), cooperates with 
Rel dimers to achieve full binding and transcriptional activity. As an integral 
component, RPS3 plays a critical role in determining the DNA binding affinity and 
regulatory specificity of NF-κB (Wan, et al., 2007). 
 There are two signalling pathways leading to the activation of NF-κB known 
as the canonical or classical pathway (Hayden and Ghosh, 2004) and the non-
canonical or alternative pathway (Bonizzi and Karin, 2004). The two types of NF-B 
activation pathways differ in respect to the types of activating stimuli; the I kappa B 
kinase (IKK) components involved and the targeted NF-B subunits. In both 
pathways, NF-κB is held in an inactive form in the cytosol by interaction with a 
member of the I kappa B (IκB) family of inhibitory proteins IκBα, IκBβ, IκBε, IκBγ, 
of which IκBα and IκBβ are the most abundant (Hacker and Karin, 2006). Upon 
stimulation by extracellular inducers, IκB kinase complex (IKK complex) consisting 
of catalytic kinase subunits IKK and/or IKK and the regulatory non-enzymatic 
scaffold protein NEMO/IKKis phosphorylated (Karin and Ben-Neriah, 2000) 
which leads to ubiquitination and proteosome-mediated degradation of IκB or 
ubiquitination without proteosomal-mediated degradation, depending on the pathway 
(Karin and Ben-Neriah, 2000). This results in the liberation of the NF-κB subunit, 
which translocates to the nucleus, where they bind to κB sequences in the promoter 
and enhancer regions of responsive genes. NF-κB activation leads to the expression 
of the IkBα gene, which consequently sequesters NF-κB subunits and terminates 
transcriptional activity unless a persistent activation signal is present (Baldwin, 
1996; Chen, et al., 1998; Hacker and Karin, 2006; Karin, 1999; Perkins, 2007).  
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 In the canonical pathway (Figure 3.6), NF-κB proteins RelA, c-Rel, RelB and 
p50 are activated by IKKβ which phosphorylates IκB at serines 32 and 36 leading to  
subsequent ubiquitination and proteasome-mediated degradation of IκB, resulting in 
the translocation of the liberated NF-κB subunit to the nucleus where it binds to κB 
elements in the promoter and enhancer regions of responsive genes, resulting in gene 
induction or gene repression (Bonizzi and Karin, 2004; Gilmore, 2006; Hayden and 
Ghosh, 2004; Karin, 1999; Scheidereit, 2006; Tergaonkar, 2006).   
 
Figure 3.6: The canonical NF-B pathway  
Ligand-receptor binding leads to the recruitment and activation of an IKK complex comprising IKK 
and IKK catalytic subunits and two molecules of NEMO/IKK. The IKK complex then 
phosphorylates IB at serine 32 and 36, leading to the ubiquitination and proteosome-mediated 
degradation of IB. NF-κB is then freed from IκB allowing for its translocation to the nucleus to 
activate target genes regulated by κB sites. 
 
In the non-canonical pathway (Figure 3.7), NF-κB protein p100/RelB complex is 
activated by NF-B inducing kinase (NIK)-mediated phosphorylation of IKK, 
which (without requiring IKK or NEMO) phosphorylates p100 at tyrosine 42 
(Tyr42) to trigger ubiquitination without proteasome-mediated degradation and 
processing of p100 (Senftleben, et al., 2001; Xiao, et al., 2001) leading to subsequent 
translocation of the liberated NF-κB to the nucleus where it binds to κB elements in 
the promoter and enhancer regions of responsive genes, resulting in gene induction 
or gene repression (Bonizzi and Karin, 2004).  
36 
 
 
Figure 3.7: The non-canonical NF-B pathway 
Ligand-receptor binding leads to the activation of NIK, which phosphorylates and activates an IKK  
complex which in turn phosphorylates p100 leading to the liberation of p52/RelB.  This heterodimer 
subsequently translocates to the nucleus to activate target genes regulated by κB sites. 
 
3.5.8 NF-B and neurite growth 
NF-B signalling has been shown to regulate the axonal growth of developing 
sympathetic neurons (Gutierrez, et al., 2008; Nolan, et al., 2011). However, the first 
evidence of NF-B signalling in the regulation of axonal growth came from studies 
on sensory neurons of the PNS. NF-B is required for the promotion of growth in 
developing sensory neurons in mice (Gallagher, et al., 2007; Gavalda, et al., 2009b; 
Gutierrez and Davies, 2011; Gutierrez, et al., 2005; Gutierrez, et al., 2008). 
Developing sensory neurons require BDNF and ciliary neurotrophic factor (CNTF) 
for neurite growth (Gavalda, et al., 2009b; Gallagher, et al., 2007). However, the 
pathways used by these neurotrophins differ. BDNF/NF-B signalling is required for 
neurite growth in embryonic sensory neurons, whereas NF-B signalling in neurite 
growth is BDNF-independent in postnatal neurons (Gavalda, et al., 2009b). CTNF 
activation of NF-B is found in postnatal sensory neurons (Gallagher, et al., 2007), 
where CTNF employs tyrosine phosphorylation of IB and involves spleen 
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tyrosine kinase (SYK) phosphorylation to promote sensory neurite growth 
(Gallagher, 2007). The developmental switch in pathway requirements for BDNF 
from embryonic to late embryonic and postnatal sensory neurons is interesting. In 
embryonic sensory neurons, BDNF activates NF-B via tyrosine phosphorylation of 
IB by Src kinase. The promotion of neurite growth in E18 and P1 nodose neurons 
does not require BDNF to activate canonical NF-B signalling via serine 
phosphorylation of IB, i.e. NF-B signalling is BDNF-independent in these 
neurons (Gutierrez, et al., 2005). The reason behind this developmental switch in 
signalling requirements of these neurons is currently being investigated. 
  
In developing sympathetic neurons of the PNS, NF-B signalling has the 
opposite effect in that it is involved in the inhibition of axonal growth (Gutierrez, et 
al., 2008). Basal levels of NF-B activity are present in sympathetic neurons from 
the SCG of neonatal mice (Gutierrez, et al., 2008; Nolan, et al., 2011). When this 
level of NF-B activity is enhanced, there is a reduction in sympathetic neurite 
growth (Gutierrez, et al., 2008). The growth inhibitory effects of NF-B in 
sympathetic neurons have been shown to be mediated through a canonical pathway 
in which activated IKK phosphorylates IB, leading to its ubiquitination and 
proteosome-mediated degradation, allowing the liberated p65/p50 dimer to 
translocate to the nucleus (Gutierrez, et al., 2008). A number of signals activate this 
pathway, including tumour necrosis factor  (TNF) (Gutierrez, et al., 2008). Upon 
binding to TNF receptor-1 (TNFR1), TNF recruits several adapter proteins such as 
TNFR1-associated death domain proteins (TRADDs); receptor interacting protein 1 
(RIP1) and TNFR-associated factors (TRAFs 2 and 5) and the IKK complex 
(Gutierrez and Davies, 2011). p65, a known substrate of IKKβ (Sakurai et al, 1999), 
is phosphorylated at serine 536 following TNFtreatment resulting in elevated 
levels of phospho-S536-p65 which is required for the growth inhibitory effects of 
NF-B activation in these neurons (Gutierrez, et al., 2008). More recently it has 
been shown that this basal level of NF-B activity present in SCG neurons can be 
modified by other factors present in the SCG such as interleukin-1 (IL-1β) (Nolan, 
et al., 2011). Nolan et al found that exogenous IL-1β acts directly on the axons of 
developing sympathetic neurons to inhibit their growth via NF-κB signalling. Basal 
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levels of NF-B do not negatively influence axonal growth in developing 
sympathetic neurons (Gutierrez, et al., 2008) and given that there are factors in these 
neurons that enhance NF-B activity resulting in axonal growth inhibition such as 
IL-1β (IL-1β is synthesised in sympathetic ganglia neurons) (Nolan, et al., 2011), it 
is possible that there are also factors in these neurons that prevent the elevation of 
NF-B activity and therefore prevent growth inhibition. 
 
3.6 GITR 
GITR (TNFRSF18), the 18th member of the TNFRSF, is a type I transmembrane 
protein, first identified in 1997 in T-cell hybridomas that were treated with 
dexamethasone, a synthetic member of the glucocorticoid class of steroid drugs that 
has anti-inflammatory and immunosuppressant properties (Nocentini, et al., 1997). 
GITR is activated by its specific ligand GITRL, a type II transmembrane protein 
(Bossen, et al., 2006; Gurney, et al., 1999; Kim, et al., 2003a; Kwon, et al., 1999; 
Ronchetti, et al., 2004; Tone, et al., 2003; Yu, et al., 2003). GITR and its specific 
ligand GITRL have recently been implicated in NGF-promoted growth and target 
innervation of developing sympathetic neurons (O'Keeffe, et al., 2008), however 
GITRL-GITR signalling is most well known for its role in the immune system where 
it is involved in regulating innate and acquired immune responses (Krausz, et al., 
2007; Nocentini and Riccardi, 2005). 
 
3.6.1 GITR in the immune system 
GITR is expressed in a number of cells in the immune system. GITR is expressed at 
high levels in effector T cells, Treg cells and activated NKCs (Cosmi, et al., 2003; 
Kanamaru, et al., 2004; Kim, et al., 2006; Kohm, et al., 2004; McHugh, et al., 2002; 
Ronchetti, et al., 2004; Scotto, et al., 2004; Stephens, et al., 2004; Uraushihara, et 
al., 2003; Zelenika, et al., 2002); at medium levels in naïve effector T cells, NKCs, 
mast cells, eosinophils, basophils, activated B cells, activated 
monocytes/macrophages and activated DCs (Cuzzocrea, et al., 2006; Hanabuchi, et 
al., 2006; Kanamaru, et al., 2004; Kim, et al., 2006; Kohm, et al., 2004; McHugh, et 
al., 2002; Nakae, et al., 2006; Ronchetti, et al., 2004; Santucci, et al., 2007; Shimizu, 
et al., 2002; Wang, et al., 2005) and at low levels in B cells, 
monocytes/macrophages and osteoclasts (Cuzzocrea, et al., 2006; Hanabuchi, et al., 
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2006; Santucci, et al., 2007; Shimizu, et al., 2002; Shin, et al., 2006). GITRL, the 
specific ligand for GITR, is expressed at high levels in activated DCs, activated 
monocytes/macrophages and endothelial cells (Cardona, et al., 2006; Hanabuchi, et 
al., 2006; Nardelli, et al., 2006; Suvas, et al., 2005), at medium levels in DCs, 
moncytes/macrophages, B cells and activated T cells (Hanabuchi, et al., 2006; Kim, 
et al., 2003a; Kwon, et al., 1999; Shin, et al., 2003; Stephens, et al., 2004; Tone, et 
al., 2003; Yu, et al., 2003) and at low levels in eosinophils and basophils 
(Hanabuchi, et al., 2006).  
In non-lymphoid tissue, mouse GITR (mGITR) mRNA is expressed at high 
levels in lung, kidney and small intestine tissue and at low levels in liver, ovary, 
brain, testis, adipose tissue, muscle and heart tissue (Krausz, et al., 2007). In 
addition, GITR expression can be detected on osteoclast precursor cells, 
keratinocytes and retinal pigment epithelial (RPE) cells (Kim, et al., 2004; Shin, et 
al., 2005; Wang, et al., 2005). Human GITR (hGITR) is expressed in a similar 
pattern in lung, brain, kidney and liver tissue (Gurney, et al., 1999; Kwon, et al., 
1999). 
 
3.6.2 GITR acts as a costimulatory molecule 
The activation of T cells depends on specific antigens and T-cell antigen receptors 
(TCRs) ligation on T cells or on recognition of antibody-coated target cells sensed 
by NKCs. The outcome of this recognition is determined by costimulatory molecules 
that provide signals that amplify, complement, and modulate signals from TCR or 
NKCs.  Costimulation is described as a pathway of intercellular communication that 
depends on the expression of complementary glycoproteins on the surface of 
interacting cells (Zhu, et al., 2011).  
 GITR is a costimulating molecule (Ronchetti, et al., 2004). GITR 
costimulation increases activation and proliferation of TCR-triggered CD4+ and 
CD8+ T-cells  (Esparza and Arch, 2005a; Kanamaru, et al., 2004; Ronchetti, et al., 
2004; Stephens, et al., 2004; Tone, et al., 2003). The proliferation response of CD4+ 
and CD8+ peripheral T cell subpopulations was potentiated when a GITR costimulus 
was added to an anti-CD3 stimulus. In addition, the expression of the main 
activation-induced receptor (IL-2R) and production of IL-2 and IFN were 
increased more with a GITR costimulus than with anti-CD3 alone (Ronchetti, et al., 
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2004). GITR also inhibits the suppressive function of CD4+/CD25+ Tregs cells. 
Agonist anti-GITR antibody reverses the suppressive effect of Treg cells (McHugh, 
et al., 2002; Nocentini, et al., 1997; Shimizu, et al., 2002). GITR can inhibit Treg 
activity directly (Nocentini and Riccardi, 2005) or indirectly by increasing T effector 
cell activation and increasing resistance to Tregs cells (Shevach and Stephens, 2006). 
 
3.6.3 GITR in the nervous system 
Recently, GITR and GITRL have been shown to be expressed in the developing 
mouse SCG (O'Keeffe, et al., 2008). Peak levels of GITR and GITRL mRNA can be 
detected in SCG neurons from E15-P1, shortly after the onset of naturally occurring 
neuronal death in these neurons, when sympathetic axons have begun to innervate 
and branch in their targets (Glebova and Ginty, 2004; O'Keeffe, et al., 2008; Wright, 
et al., 1983; Wyatt, et al., 1997). GITR and GITRL are expressed on all neuronal 
cells in the SCG and co-localise with -III tubulin and TrkA in P0 SCG neurons 
(O'Keeffe, et al., 2008). To determine the role of GITRL-GITR in developing 
sympathetic neurons, GITRL-GITR signalling was inhibited in a number of ways 
including antisense knockdown of GITR, targeted deletion of GITR and blocking 
GITRL-GITR interaction using a decoy GITR-IgG, all of which reduced the ability 
of NGF to promote neurite growth from these neurons without affecting their 
survival (O'Keeffe, et al., 2008). These growth promoting effects of GITR were 
found only in the immediate postnatal stage of development (P1-3), indicating that 
GITR is required for the growth of sympathetic axons of neonatal SCG neurons 
(O'Keeffe, et al., 2008). 
 In terms of the mechanism of GITRL-GITR signalling in developing 
sympathetic neurons, GITR-IgG experiments suggest that GITRL-GITR signalling 
operates via an autocrine route. Blocking GITRL-GITR interaction at the level of 
individual neurons with function blocking GITR-IgG inhibits NGF-promoted neurite 
growth. In addition, the immunohistochemical staining pattern of GITRL in vivo is 
also consistent with autocrine GITRL-GITR signalling in sympathetic neurons. 
GITRL and GITR are clearly co-expressed in neurons of the SCG however GITRL 
immunoreactivity was undetectable in intermediate and distal SCG targets such as 
cranial arteries, nasal mucosa and iris (O'Keeffe, et al., 2008) 
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 It is well established in the immune system that GITR acts as a costimulatory 
molecule to regulate effector T cell (Esparza and Arch, 2005a; Kanamaru, et al., 
2004; Ronchetti, et al., 2004; Stephens, et al., 2004; Tone, et al., 2003) and Treg cell 
activity (McHugh, et al., 2002; Nocentini, et al., 1997; Nocentini and Riccardi, 
2005; Shevach and Stephens, 2006; Shimizu, et al., 2002). To investigate whether 
GITR acted in a costimulatory fashion in SCG neurons as it does in T lymphocytes, 
SCG neurons were grown with the broad-spectrum, irreversible caspase inhibitor 
Boc-D-FMK to prevent the neurons from dying in the absence of NGF and treated 
with agonist GITRL-IgG. GITRL-IgG treatment had no effect on the smaller neurite 
arbors of these neurons in the absence of NGF suggesting GITR cannot promote 
growth of SCG neurons alone and works in a costimulatory manner with NGF 
(O'Keeffe, et al., 2008). In terms of the in vivo relevance of these findings, GITR 
signalling was found to be required for proper establishment of sympathetic 
innervation as seen by a reduction of sympathetic innervation in the iris and nasal 
muscosa (organs which normally receive dense sympathetic innervation) of GITR -/- 
mice compared to wild type litter mate controls (O'Keeffe, et al., 2008). 
 
3.6.4 GITR signalling  
TNF Receptor Associated Factors (TRAFs) are adapter proteins that transmit 
extracellular signals upon recruitment to the cytoplasmic domains of TNFRs, such as 
GITR, where they serve as foci for the induction of molecular events including NF-
B and MAPK activation (Arch, et al., 1998; Dempsey, et al., 2003). GITR binds 
and activates several TRAFs resulting in the activation or inhibition of NF-B and 
MAPK pathways (Esparza and Arch, 2005a; Gurney, et al., 1999; Kwon, et al., 
1999). TRAF 4 enhances NF-B activation triggered by GITR (Esparza and Arch, 
2004). When TRAF 4 was co-expressed with GITR and GITRL in a human 
embryonic kidney cell line (HEK 293 cells), receptor-induced NF-B activation was 
significantly increased. Expression of TRAF 4 in the absence of GITR-induced 
signalling did not affect NF-B activity, indicating that TRAF 4 is involved in 
GITR-triggered NF-B signal transduction (Esparza and Arch, 2004). TRAF 2 
inhibits NF-B activation triggered by GITR. Transfection with an overexpression 
plasmid containing full length TRAF 2 significantly reduced NF-B activation 
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triggered by GITR in HEK 293 cells (Esparza and Arch, 2005b). In the immune 
system GITR triggers the activation of MAPK signalling cascades including ERK, 
JNK and p38 (Esparza and Arch, 2005a; Esparza, et al., 2006; Ronchetti, et al., 
2004). TRAF 5, triggered by GITR, activates NF-B in addition to specific subsets 
of MAPKs including p38 and ERK. TRAF 5 deficiency results in diminished GITR-
induced activation of NF-B, p38 and ERK and enhances antigen-dependent T cell 
proliferation (Esparza, et al., 2006).  
 In developing sympathetic neurons, GITR also activates ERK signalling 
(O'Keeffe, et al., 2008). NGF-promoted ERK1/2 phosphorylation is almost 
eliminated in neurons from GITR -/- mice. Agonist GITRL-IgG enhances NGF-
promoted ERK1/2 phosphorylation, however GITR induction of ERK1/2 did not 
occur in the absence of NGF. This effect of GITR signalling on NGF-promoted ERK 
activation in the nervous system mirrors the costimulatory role of GITR in the 
immune system, where GITR/CD3-stimulation promoted ERK1/2 activation in T 
cells (Ronchetti, et al., 2004).  
 
3.7 Clinical importance of correct development of the SNS 
As described earlier, sympathetic neurons innervate organs of the immune system 
including the thymus, spleen, lymph nodes and bone marrow (Figure 3.4) (Felten, et 
al., 1985; Meltzer, et al., 1997; Panuncio, et al., 1999). Sympathetic neurons release 
catecholamines that bind receptors of target immune B and T cells (Kohm and 
Sanders, 2001) and regulate a variety of immune processes including leukocyte 
activation, cytokine production, and cell trafficking (Cole, et al., 1999; Cole, et al., 
1998; Kammer, 1988; Madden, et al., 1995; Ottaway and Husband, 1994; Sanders 
and Straub, 2002). The importance of the development of sympathetic neurons and 
their impact on immune system function is highlighted by an autonomic peripheral 
neuropathy called Hereditary Sensory Autonomic Neuropathy (HSAN) IV described 
below.  
 Autonomic peripheral neuropathies are one of four types of peripheral 
neuropathies which are characterised by trauma or disease to nerves of the PNS. 
Other peripheral neuropathies include mononeuropathies in which one nerve is 
affected (Ghali, et al., 2012); mononeuritis multiplex where one or more nerves are 
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affected and is associated with inflammatory conditions (Makol and Grover, 2008) 
and polyneuropathies (Centner, et al., 2013; Lee, et al., 2013) affecting multiple 
nerves in the body. Peripheral autonomic neuropathies affect neurons of the ANS 
and as a result can affect all systems of the body. Peripheral autonomic neuropathies 
can be acquired by disease such as diabetes (Kamenov and Traykov, 2012) or 
inherited such as in Familial amyloid polyneuropathy (FAP) (Plante-Bordeneuve 
and Said, 2011);  Fabry disease (Tuttolomondo, et al., 2013); Porphyrias (Trier, et 
al., 2013) and Hereditary sensory autonomic neuropathies (HSANs). HSAN IV is 
one of five neuropathies of the HSAN spectrum. HSAN IV results from TrkA 
mutations and defective TrkA/NGF signalling affecting the development of 
sympathetic and sensory neurons of the PNS (Rotthier, et al., 2012) and therefore is 
the most relevant of the HSAN spectrum to the current topic however HSAN I, II, III 
and V will be discussed briefly.  
 HSAN I is an inherited autosomal dominant disease due to a mutation in the 
gene for Serine palmitoyltransferase, long chain base subunit 1 (SPTLC1) located on 
chromosome 9q22.1-22. The SPTLC1 gene provides instructions for making a 
subunit of an enzyme called serine palmitoyltransferase (SPT) which is involved in 
making fats called sphingolipids. Sphingolipids are important components of cell 
membranes and play a role in many cell functions such as protein processing and 
transport. Onset of HSAN I is in the 2nd to 4th decade of life and symptoms include 
paresthesia, numbness, weakness, muscle wasting, and heel ulcers (Axelrod and 
Gold-von Simson, 2007). HSAN II is an inherited autosomal recessive disease, due 
to a mutation in the gene for WNK lysine deficient protein kinase 1 (WNK1) located 
on chromosome 12p13.33. The WNK1 gene provides instructions for making 
multiple isoforms of the WNK1 protein. The different WNK1 isoforms are important 
in several functions in the body, including blood pressure regulation and pain 
sensation. Onset of HSAN II is in infancy and early years of life. Symptoms include 
absence of pain, thermal, touch, and pressure sensation. There is sensory loss and 
depressed deep tendon reflex (DTR) in some patients (Axelrod and Gold-von 
Simson, 2007; Lafreniere, et al., 2004). HSAN III, also known as familial 
dysautonomia, or Riley Day syndrome, is an inherited autosomal recessive disease, 
due to a mutation in the gene for inhibitor of kappa light polypeptide gene enhancer 
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in B-cells, kinase complex-associated protein (IKBKAP) located on chromosome 
9q31. The IKBKAP gene provides instructions for making a protein called IKK 
complex-associated protein (IKAP) which is found in a variety of cells throughout 
the body, including brain cells and believed to play a role in transcription of proteins 
that affect cell cytoskeleton and movement, important in the development of cells. 
HSAN III has an onset in infancy and early years of life. Symptoms include absence 
or reduced pain and temperature sensation but normal touch sensation. Additional 
features include recurrent gastrointestinal upsets, little lacrimation, anhidrosis, no 
sensation of tongue, depressed or absent DTR, temperature fluctuations, recurrent 
fractures, osteomyelitis, gait difficulties, Charcot joints, ligamentous laxicity and 
scoliosis (Axelrod and Gold-von Simson, 2007; Bar-On, et al., 2000). HSAN V is an 
inherited autosomal recessive disease, due to a mutation in the gene for NGF located 
on chromosome 1p13. Symptoms include absence of pain; however normal touch, 
pressure and vibration sensation is present. Additional features include fractures, 
bone necrosis, osteochondritis and neuropathic joint destruction (Minde, et al., 
2004). 
 
3.7.1  HSAN IV 
HSAN IV, also known as ‘Congenital Insensitivity to Pain with Anhidrosis’ (CIPA), 
‘Familial dysautonomia type II’ or ‘congenital sensory neuropathy with anhidrosis’ 
is a rare autosomal recessive disorder (Toscano and Andria, 2001) first reported in 
1963, when two siblings presented with an inability to feel pain and to sense 
temperature (Swanson, 1963). HSAN IV results from mutations in the gene for TrkA 
located on chromosome 1q21-22 (Indo, et al., 1996). Mutations occur in the 
extracellular (NGF binding) and intracellular (signal transduction) domains of TrkA 
(Mardy, et al., 1999). TrkA mutations have been reported in HSAN IV patients from 
different ethnic groups, including families of Ecuadorian and Japanese descent 
(Mardy, et al., 1999), Israeli-Bedouin Tribes (Shatzky, et al., 2000) and a patient of 
Spanish origin (Sarasola, et al., 2011). These mutations result in impairment of NGF 
binding to TrkA or of signal transduction following NGF binding. As a result, in this 
condition, subsets of sensory and sympathetic neurons do not develop normally. In 
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consequence, neuropathological findings include an absence of small unmyelinated 
fibres, a decrease in number of myelinated fibres in peripheral nerves, an absence of 
nociceptive innervation of the epidermis and diminished sympathetic innervation of 
eccrine sweat glands. These anatomical findings explain the physiological basis 
underlying the main symptoms of HSAN IV, pain insensitivity and inability to sweat 
(anhidrosis) in HSAN IV patients (Langer, et al., 1981; Swanson, et al., 1965). 
Additional clinical characteristics of HSAN IV, which illustrate the diverse roles of 
NGF/TrkA signalling in the PNS and CNS, are episodic fevers, self-mutilation and 
mental retardation. HSAN IV patients are prone to bone fractures and slow healing; 
joint dislocations and deformities; skin infections; impaired immune responses and 
renal failure (Indo, et al., 1996). 
 Reduced immune responses, including reduced T and B lymphocytes 
proliferation and cytokine (IL-2) production, and NKC activity in the spleen are 
associated with a decline in sympathetic innervation in the secondary lymphoid 
organs, spleen and lymph nodes in aged female rats (ThyagaRajan, et al., 2011). 
TrkA is expressed by many cells of the immune system including neutrophils, mast 
cells, and B and T lymphocytes (Marshall, et al., 1990; Melamed, et al., 1996; 
Otten, et al., 1989). Mutations in TrkA have also been found to result in defective 
lymphocyte signalling which may explain why HSAN IV patients have a greater 
incidence of infection than age matched controls. Specifically, B cells have defective 
TrkA phosphorylation and consequently display defects in cytoskeleton assembly 
and MAP kinase activation (Melamed, et al., 2004). One TrkA mutation (1926-ins-
T) is associated with impaired neutrophil chemotaxis, which may contribute to the 
greater incidence of infection in patients with HSAN IV (Beigelman, et al., 2009).  
 
3.7.2 GITR and clinical applications 
In the immune system, GITR can enhance T cell activation and inhibition of Treg 
cells (McHugh, et al., 2002; Shimizu, et al., 2002). Thus, agonist anti-GITR 
treatment can potentially overcome tolerance to self- and tumor-antigens, making it 
an attractive target for development as a cancer immunotherapy. Agonist anti-GITR 
treatments have been found effective in enhancing T cell-mediated anti-tumor 
activity in vivo. Agonist anti-GITR monoclonal antibody, (DTA-1), induced the 
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regression of small established B16 melanoma tumors in mice (Cohen, et al., 2010). 
Recently, an agonist anti-human GITR mAb (TRX518) has been developed by 
Tolerex Inc. (now GITR Inc), and similar to anti-GITR, provides potent 
costimulation to human lymphocytes in vitro. A dose-escalation (route of 
administration: I.V.)  phase I clinical trial for unresectable stage III or IV malignant 
Melanoma or other solid tumors is currently recruiting at Memorial Sloan-Kettering 
Cancer Center (New York, NY) using TRX518 (NCT01239134) (Melero, et al., 
2013). 
  
3.8 Objectives of the present study 
In the PNS, GITR has recently been shown to be crucial for NGF-promoted growth 
of developing sympathetic neurons (O'Keeffe, et al., 2008). The discovery of this 
previously unknown signalling loop that is essential for the ability of NGF to 
promote axonal growth has revealed a new regulatory element in target field 
innervation in the developing SNS, however the exact mechanism by which GITR 
regulates NGF signalling is unknown. This study intends to answer basic biological 
questions regarding the molecular mechanism of GITR in the peripheral SNS in an 
early step toward identifying whether strategies targeting GITR have potential 
therapeutic benefit in promoting neurite growth. There are four sets of interrelated 
aims in this Thesis: 
 To determine if GITR increases the sensitivity of sympathetic neurons to 
NGF.  
 To identify the region of GITR required for the enhancement of NGF-
promoted growth. 
 To investigate the signalling pathways downstream of the GITR. 
 To determine how extensively GITR is involved in regulating peripheral 
innervation in the sympathetic nervous system.  
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4.0 Materials and Methods 
 
4.1  Animals husbandry  
The animals sacrificed for tissue in the present studies were C57bl/6, CD-1 and SV-
129 mice and were sourced from the Biological Unit in UCC and University of 
Perugia, Italy (Professor Carlo Ricarrdi). No animals underwent any surgical 
procedures for experimental purposes. All mice were treated humanely at all times 
under the “The Animals (Scientific Procedures) Act 1986”. 
 
4.2  Tissue Culture 
All primary cell cultures were prepared from freshly dissected superior cervical 
ganglia (SCG) tissue from Postnatal day 1 and 2 (P1 & 2) mice and carried out in a 
sterile laminar Class II flow cabinet (Microflow: Biological Safety Cabinet) using 
aseptic techniques. Primary cell cultures were maintained in a humidified 
atmosphere containing 5% CO2 at 37˚C. 
 
4.2.1 Superior cervical ganglia dissection 
Postganglionic sympathetic neurons of the SCG are an extensively used, 
experimentally tractable model for studying the molecular basis of axonal growth 
and target innervation in developing sympathetic neurons (Gutierrez, et al., 2008; 
Nolan, et al., 2011; O'Keeffe, et al., 2008). Mice aged P1 were used as peak levels of 
both GITR and ligand are expressed in the developing SCG on P1, shortly after the 
onset of naturally occurring neuronal death in the SCG, when sympathetic axons 
have begun to innervate and branch extensively in their targets (O'Keeffe, et al., 
2008). P1 mice were sacrificed by decapitation using a sterile scissors and 
transferred to a 90mm Petri dish (Fannin Healthcare) containing ice-cold Hank’s 
Balanced Salt Solution (HBSS) (with sodium bicarbonate and without phenol red, 
Ca2+ or Mg2+, Sigma) and kept on ice. Further dissections were carried out using a 
dissection microscope (Leica Wild M8) in a fume hood (Brassaire). Using the 
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dissecting microscope for accurate visualisation, heads were anchored anteriorly at 
the level of the nose using forceps, and the superior aspect of heads were transected 
using scissors and removed to expose the cerebral cortex. The cerebral cortex was 
then removed to expose the occipital bone and proximal vertebrae. Heads were then 
bisected in a saggital plane with scissors, using the centre of the occipital bone and 
vertebrae as a landmark and placed in a second Petri dish containing fresh HBSS. 
The medial/internal surface of the bisected head was orientated superiorly and 
proximal cervical vertebrae (levels C1-3) were carefully removed by cutting at 
superior and inferior intervertebral joints to expose the translucent SCG located at 
the bifurcation of the common carotid artery. The ganglion was carefully removed 
using forceps and placed in a third petri dish containing fresh HBSS. Using 
electrolytically sharpened tungsten needles, any attached extraneous tissue was 
removed from the SCG which were then transferred to a 15ml tube (Greiner Bio-
One) containing fresh HBSS. 
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Figure 4.1: Superior cervical ganglia dissection procedure 
Head is placed in a Petri dish containing fresh HBSS (A) and anchored using forceps (B). The 
superior aspect of the head is transected using scissors, lifted away and cortex is removed to expose 
the proximal cervical vertebrae (C). The head is bisected in a saggital plane by scissors using the 
centre of the vertebrae as a guide (D). Once bisected, the right and left sides of the head are placed in 
a fresh Petri dish where the internal or medial aspect of the head is facing superiorly (E). The 
proximal cervical vertebrae are removed to expose the underlying SCG located at the bifurcation of 
the common carotid artery (F, G). The SCG is removed using a forceps and placed into a Petri dish 
containing fresh HBSS. The SCG is cleaned of extraneous tissue using tungsten needles (H). 
 
4.2.2 Tissue culture procedures 
SCG were incubated in 1ml of trypsin (Sigma) for 20min at 37ºC. Cells were then 
washed X2 with 2mls F12 solution (1.06g F12 powder (Invitrogen); 10% Fetal calf 
serum (Sigma); 1% Penicillin/streptomycin solution (Sigma); made up to 100ml 
deionised H2O; filter sterilized, pH 7.2-7.4) to inhibit trypsin action. Ganglia were 
then washed X2 in growth media (Dulbecco’s Modified Eagle Medium (DMEM: 
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Sigma); 1% penicillin/streptomycin; 1% glutamine (Sigma); 1% N2 (Invitrogen); 2% 
B27 (Invitrogen) and 10ng/ml NGF (R&D Systems)). SCG were then gently 
triturated 6-10 times using a sterile pipette tip in the second wash of growth media 
forming a single cell suspension. 
 
4.2.2.1 P1 SCG neuronal growth 
SCG cells were obtained and cell suspension prepared as described in 4.2.1 and 
4.2.2. 5μl of cell suspension (cells in second wash of growth media) was transferred 
to a 90mm Petri dish (Fannin Healthcare) and cell density was assessed under a light 
microscope (Leica). Assessment of cell density helps to determine the volume of cell 
suspension required per well for growth analysis. Higher density (~50,000/well) of 
cells makes it more difficult to analyse cell growth and therefore a lower cell density 
(~50,000/well) is required for growth analysis than for survival transfection and 
immunocytochemistry experiments. An appropriate amount of cell suspension was 
added to the growth media. 80µl of cell solution in media was added to each well. 
Cells were grown overnight in sterile 4-well tissue culture 35.0/10mm (Greiner Bio-
One) dishes in 37ºC. Plates were coated with polyornitine (500μg/ml, Sigma) and 
laminin (1mg/ml, (Sigma) diluted in 1ml of HBSS with phenol red and without Ca2+ 
or Mg2+ (Invitrogen) Sigma). 
 
4.2.2.2 P1 SCG neuronal survival in different concentrations of NGF 
SCG cells were obtained and cell suspension prepared as described in 4.2.1 and 
4.2.2. Cells were plated at high density (~50,000/well) in growth media containing 
varying concentrations of NGF (10, 4, 1, 0.2, 0.04, 0.01 and 0 ng/ml). Cells were 
grown for 3, 24, 48 and 72h at 37°C. At the end of each time point, the number of 
surviving neurons was counted. At the end of time points 24, 48 and 72h, the number 
of surviving cells were counted and calculated as a percentage of the number of cells 
that survived at 3h.  
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4.2.2.3 P1 SCG neuron growth response in different concentrations of NGF 
SCG cells were obtained and cell suspension prepared as described in 4.2.1 and 
4.2.2. Cells were plated at low density (number of cells per well per dish was not 
counted, however it was ensured that neurons have enough room to extend 
processes) in growth media containing varying concentrations of NGF (10, 4, 1, 0.2, 
0.04, 0.01 and 0 ng/ml) and Caspase III inhibitor (Boc-D-FMK) (4ug/ml; 
Calbiochem) to prevent cell death in cultures treated with low NGF concentrations. 
Cells were treated with recombinant mouse GITR ligand/TNFSF18 (1ug/ml; R&D 
Systems) (rmGITRL) and mouse GITR Ligand/TNFSF18 Antibody, Polyclonal rat 
IgG (5ug/ml; R&D Systems) (GITRL-IgG). rmGITRL has been found to costimulate 
mouse T cell proliferation in the presence of anti-CD3, while GITRL-IgG neutralises 
GITRL induced proliferation in mouse CD4+ T cells (Tone, et al., 2003). Cells were 
left to grow overnight on polyornitine and laminin coated 35mm dishes in 37°C. The 
next day cells were immunocytochemically stained for the neuronal marker -III 
tubulin (Section 4.3), imaged using an inverted fluorescence microscope (Olympus 
IX70 Provis attached to an Olympus DP70 camera) and growth was determined 
using sholl analysis (Gutierrez, et al., 2008) (Section 4.6). 
 
4.2.2.4 P1 SCG neuron transfections 
All transfections were performed using a microporater (Neon, Invitrogen) 
(Gutierrez, et al., 2008). During transfection, a number of electrical pulses at a set 
voltage and duration were applied to the cells causing a transient reversible 
breakdown of the cellular membrane. This resulted in the formation of pores which 
can allow exogenous molecules, such as DNA, siRNA, antibodies, peptides or drugs 
to enter the cell. Equipment settings or parameters include: voltage (V), pulse width 
or duration (ms) and number of pulses applied. 
SCG cells were obtained and cell suspension prepared as described in 4.2.1 and 4.2.2 
with the following changes. SCG cells were dissociated in 1ml of trypsin for 20-23 
min. Cells were then washed X2 with 2ml of transfection media (DMEM; 1% 
glutamine; 1% N2; 2% B27; 10ng/ml NGF) containing 10% Fetal calf serum to 
52 
 
inhibit trypsin action and then washed X2 in 2ml of PBS. Cells were gently triturated 
in resuspension buffer (Invitrogen) until dissociated. 12l of resupension buffer was 
used per transfection. A red fluorescent plasmid (RFP) or an enhanced green 
fluorescent plasmid (EGFP) (0.5g) was added to the cell suspension in order to 
identify transfected cells. To estimate the relative level of NF-κB activation, neurons 
were transfected with a plasmid expressing GFP under the control of an NF-κB 
promoter (Gutierrez, et al., 2008). The cell suspension was then equally divided into 
treatment groups and appropriate plasmids (1g) were added to cell suspensions 
(Table 4.1). Following optimization, the most effective transfection parameters were 
determined to be 1100 volts, 30ms and 2 pulses. Once transfected at these 
parameters, cells were added to transfection media and grown overnight on 
polyornitine and laminin coated 35mm dishes in 37°C. The next day, cells were 
imaged using an inverted fluorescence microscope (Olympus IX70 Provis attached 
to an Olympus DP70 camera) and growth was determined using Sholl analysis 
(Gutierrez, et al., 2008) (Section 4.6). Images to obtain mean somal fluorescence 
intensity in cultures transfected with B reporter was obtained using Zeiss Axioplan 
confocal microscope and mean somal intensity was determined using LSM510 
software (Gutierrez, et al., 2008). 
 
2.2.2.3.1 Plasmids 
Plasmids were provided by Dr. Gutteriez, School of Biosciences, Cardiff University 
and Professor Riccardi from the Department of Clinical and Experimental Medicine, 
Pharmacology, University of Perugia, Italy. 
All plasmids used were derived from pcDNA3.1 (Invitrogen) and included those 
expressing GITR, Antisense GITR, GITRδK, GITRδZ, GITRδW, GITRL, 
GITRLδW, GITR2, GITR4, GITR5, IB Antisense GITR, IKKB dominant 
negative (DN) and p65.  
Specific regions of the GITR cytoplasmic domain are missing in mutant plasmids 
GITRK, GITRZ and GITRW. The intracellular region of GITRL is missing in 
mutant plasmid GITRLW. Two putative phosphorylation sites were identified using 
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In silico analysis programs including DISPHOS; NetPhos 2.0; GPS Predictor 
software programs. Putative phosphorylation sites identified were Thr190 and 
Ser199 (amino acid 12 and 21). In addition, basic residues, Cys186-Glu189 (CPRE) 
(amino acids 8-11), conserved among the "GITR sub family" of receptors (CD27, 
OX40, 4-1BB) were identified (Krausz, et al., 2007). Mutant plasmids of GITR were 
then created in which insertions replaced these sites. In GITRδ2, Cys186-Glu189 
(CPRE), (amino acids 8 to 11), were replaced with alanines. In GITRδ4, Thr190 and 
Ser199, (amino acid 12 and 21) were replaced with alanines. In GITRδ5, Thr190 and 
Ser199, (amino acid 12 and 21), were replaced with glutamic acid. 
Plasmids were shipped on Whatman 3mm thickness paper and cut out. 50μl of 
10mM Tris pH 7.6 was added, mixture was vortexed and left to re-hydrate for 5min. 
Following brief centrifugation, the supernatant liquid was used to transform 
competent bacteria. 
Plasmids  Sequences  
GITR  
(cytoplasmic region)  
IWQLRRQHMCPRETQPFAEVQLSAEDA 
CSFQFPEEERGEQTEEKCHLGGRWP  
GITRK  IWQLRRQHMCPRETQPFAEVQLSAEDA 
CSFQFPEEERG  
GITRZ IWQLRRQHMCPRETQPFAEVQLS  
GITRW  IW  
GITRL  MEEMPLRESSPQRAERCKKSWLLCIVA 
LLLMLLCSLGTLIYTSLKPTAIESCMVK 
FELSSSKWHMTSPKPHCVNTTSDGKLK 
ILQSGTYLIYGQVIPVDKKYIKDNAPFVV 
QIYKKNDVLQTLMNDFQILPIGGVYELH 
AGDNIYLKFNSKDHIQKNNTYWGIILMP 
DLPFIS  
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GITRLW  WLLCIVALLLMLLCSLGTLIYTSLKP 
TAIESCMVKFELSSSKWHMTSPKPHCV 
NTTSDGKLKILQSGTYLIYGQVIPVDKK 
YIKDNAPFVVQIYKKNDVLQTLMNDFQ 
ILPIGGVYELHAGDNIYLKFNSKDHIQKN 
NTYWGIILMPDLPFIS  
GITR2  IWQLRRQHMAAAATQPFAEVQLSAEDA 
CSFQFPEEERGEQTEEKCHLGGRWP  
GITR4  IWQLRRQHMCPREAQPFAEVQLAAEDA 
CSFQFPEEERGEQTEEKCHLGGRWP  
GITR5  IWQLRRQHMCPREEQPFAEVQLEAEDA 
CSFQFPEEERGEQTEEKCHLGGRWP  
Table 4.1 Plasmids and amino acid sequences used in transfection experiments 
 
4.3 Immunochemistry  
4.3.1 Immunocytochemistry (ICC) 
SCG cells were cultured as described in 4.2.1 and 4.2.2. The following day, cells 
were fixed in 1ml ice cold methanol (VWR) per dish for growth cultures or 4% 
paraformaldehyde (PFA) per dish for transfection cultures for 10min, washed X3 
with 1ml PBS and blocked with 1ml 5% Bovine Serum Albumin (BSA) (Sigma) in 
PBS for 1h at room temperature (RT) to block antibodies binding to non-specific 
sites. Cultures were incubated with desired primary antibody diluted in 1% BSA in 
PBS and left overnight at 4ºC. Primary antibodies used included those directed 
against: Tyrosine hydroxylase (TH); Tyrosine kinase A (TrkA); phospho-TrkA; 
Glucocorticoid-induced tumour necrosis factor receptor (GITR); GITR Ligand 
(GITRL); β-III tubulin; phospho-ERK1/2; and phospho-pSer536-p65 (phospho-p65 
subunit of NF-B) (Table 4.2). The following day, the primary antibody was 
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removed and cultures were washed X3 in 1ml PBS and incubated with the 
appropriate secondary antibody diluted in 1% BSA in PBS for 2h at RT (Table 2.3). 
Cultures were washed for 5min with DAPI (Sigma) in PBS (1:5000 dilution) for 
nuclear staining before final washes X2 of PBS. Photomicrographs were taken on an 
Olympus 1X70 Provis Inverted Fluoresence Microscope attached to an Olympus 
DP70 camera and Zeiss Axioplan confocal microscope. Sholl analysis was 
performed on -III tubulin stained neurons (Gutierrez, et al., 2008) (Section 4.6). 
 
Name  Labels  Raised 
in  
Working 
dilution  
Supplier  
-III tubulin  Post-mitotic neurons  Mouse  1:200  Promega  
TH Sympathetic neurons Rabbit  1:100  Millipore  
TrkA  Tyrosine kinase A Rabbit  1:200  Millipore 
p-TrkA Phosphorylated TrkA Rabbit 1:50 Millipore 
GITR Glucocorticoid-tumour necrosis factor receptor (GITR) Goat  1:100  Santa cruz  
GITRL GITR Ligand  Goat  1:100  Santa cruz  
Phospho- 
ERK1/2 
Phosphorylated ERK1/2 Rabbit  1:100  Cell signalling  
Phospho- 
pSer536-
p65  
Phosphorylated p65 (subunit of NF-B) on residue 
Serine 536  
Rabbit  1:50  Cell signalling  
Table 4.2 Primary antibodies used in immunocytochemistry experiments 
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Antibody type  Reactivity  Host  Working dilution  Supplier  
Alexa fluor 488  Mouse  Goat  1:500  Invitrogen  
Alexa fluor  594  Goat  Donkey  1:500  Invitrogen  
Alexa fluor 488  Rabbit  Goat  1:500  Invitrogen  
Alexa fluor 594  Rabbit  Goat  1:500  Invitrogen  
Table 4.3 Secondary antibodies used in immunocytochemistry experiments 
 
4.3.2 Immunohistochemistry (IHC) 
P1 pups were decapitated and the heads were placed in 4% paraformaldehyde for 
24h. They were then rinsed in PBS before being cryoprotected in a 30% sucrose 
solution until tissue sinks. Samples were then equilibrated in 1:1 sucrose : OCT for 
2h at 4°C before freezing in OCT. Whole heads were transversely sectioned at a 
thickness of 15μm and each section was placed on a superfrost plus slide (Thermo 
Scientific). Sections were permeablized in 1% Triton X-100 before blocking with 
5% goat serum for 1h at RT. Sections were then stained for TH overnight (Table 4.2) 
before visualisation with appropriate secondary antibody (Table 4.3).  
 
4.3.3 Whole mount organ IHC 
Whole mount DAB-TH immunohistochemistry was performed on sympathetic target 
organs including trachea, heart, stomach, small intestines, ureter and bladder. 
Following decapitation, organs were dissected from P1 SV-129 GITR+/+ and GITR-
/- mice and fixed overnight in 4% PFA. The next day organs were dehydrated in 
50% methanol and 80% for 1h each. Endogenous peroxidise activity in organs was 
quenched by placing organs in 80% methanol /20% Dimethyl Sulfoxide (Sigma) /3% 
Hydrogen peroxide (H2O2) (Merck) overnight at 4ºC. The next day the organs were 
rehydrated in 50% methanol, 30% methanol and PBS for 1h each at RT. Organs 
were incubated in blocking solution containing 4% BSA and 1%Triton X (Sigma) in 
PBS overnight at 4°C. The next day, the organs were incubated with rabbit anti-TH 
primary antibody (Millipore; 1:250 in 4% BSA in 1% Triton X/PBS) and left on a 
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rocker for 72h at 4°C. Organs were then washed X3 in 1% Triton X-100/PBS for 2h 
followed by incubation with secondary antibody anti-rabbit TH horseradish 
peroxidise (HRP) IgG (Promega; 1:300 in 4% BSA in 1% Triton X/PBS) and left on 
a rocker overnight at 4ºC. The next day, organs were washed X3 in 1% Triton X-
100/PBS for 2h followed by incubation in Diaminobenzidine (DAB) (Sigma: 
0.5mg/ml) and placed on a rocker overnight at 4ºC. The following day, organs were 
fixed in 4% PFA for 1h at RT and then rinsed in PBS and dehydrated in 50% and 
80% for 2h each and 100% methanol overnight. The next day, organs were cleared in 
benzyl benzoate/benzyl alcohol (Sigma; 2:1) for 1h at RT. The organs were then 
imaged using a dissecting microscope (Olympus SZX7). A modified line incept 
method was used to analyse axonal branching and density (Mayhew, 1991). 
  
4.4 Protein quantification 
4.4.1 Protein extraction from cells 
P1 SCG cells from SV-129 GITR+/+ and GITR-/- mice were cultured in a 96-well 
plate (Corning Incorporated). 200μl of a high density cell solution (as described in 
section 4.2.2), was pipetted into each well and incubated at 37°C overnight. Wild 
type cells were treated with GITRL-IgG (1ug) for 1h. Medium was carefully 
removed and 100μl of RIPA buffer (50mM Tris-HCl; 150mM NaCl; 2mM EDTA; 
0.5% Na-Deoxycholate; 0.1% SDS and 1% Triton X), 10μl of phenylmethylsulfonyl 
fluoride (PMSF), 10μl sodium orthovanadate and 10μl sodium fluoride was added to 
lyse the cells. The plate was incubated on ice for 1h and the bottom of each well was 
scratched with a pipette tip to detach any remaining adhering cells. This RIPA buffer 
containing the protein was then transferred into individually labelled 0.5ml 
eppendorf tubes (Sarstedt) and stored at -20°C. 
 
4.4.2 Western blotting   
A 5% sodium dodecyl sulphate (SDS)–polyacrylamide electrophoresis stacking gel 
cast above a 10% resolving gel was used to separate proteins for Western blotting. 
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Samples were prepared by adding a chosen concentration of protein (~20mg) to an 
equal volume of sample buffer (0.25M Tris-HCl pH 6.8; 8% SDS; 30% Glycerol; 
0.02% Bromophenol Blue) and boiled for 5 min to denature the protein. 15µl of each 
sample was loaded into the gel alongside 3-5μl of molecular weight protein 
standards (Bio-Rad). Electrophoresis was initiated by applying 150V for 60 min to 
the running apparatus (Bio-Rad) containing Tris-glycine running buffer with SDS 
(Sigma). Electrophoretic transfer to the membrane was carried out at 100V for 60 
min using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, CA-USA) 
while immersed in transfer buffer (5.85g Tris-base; 2.93g glycine and 50ml 
methanol in 1L distilled water). After transfer, the membrane was incubated in a 5% 
BSA blocking solution for 60 min on a rocker (~55 oscillations/min) at RT and then 
washed briefly in PBS with 1% TWEEN (Fisher Scientific). The primary antibodies 
used were mouse antiserum to β-III-tubulin (1mg/ml, Promega: 1:10,000), rabbit 
anti-phospho-S536-p65 (1:1000; Cell Signalling); rabbit anti-phospho IKK (1:1000; 
Cell Signalling) and rabbit anti-phospho ERK1/2 (1:1000; Cell Signalling). The 
membrane was incubated in one of these overnight at 4°C. The blot underwent 6 
washes in PBS containing 0.05% Tween (PBS-T: 6 X 5 min) before detection with 
the relevant peroxidase-linked secondary antibodies (Promega) and ECL-plus 
(Amersham).  
 
4.5     Analysis of mRNA expression 
4.5.1  RNA extraction 
SCG were dissected from P1 SV-129 GITR+/+ and GITR-/- mice and placed in a 
tube containing ice-cold HBSS. The tube was centrifuged at 500 rpm for 2 min, the 
supernatant was discarded and the tissue pellet stored immediately at -80˚C until 
required. Total RNA was extracted using the RNeasy kit (Qiagen) according to the 
manufacturer’s instructions. 700μl of RLT buffer + 0.7μl β-mercaptoethanol (Sigma) 
was added to 20mg of tissue in a 1.5ml eppendorf (Sarstedt). A needle (Sterican®) 
and syringe (BD Plastipak™) were used to break up tissue and the tube was 
centrifuged for 3min @ full speed using an eppendorf 5415C centrifuge. The 
supernatant was transferred to another tube where an equal volume of 70% ethanol 
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(J.T. Baker) was added. This mixture was placed in a spin cup and spun for 15s @ 
10,000rpm. Flow through was discarded. DNA was digested using an RNase-Free 
DNase Set (Qiagen). The membrane of the spin cup was washed X2 in RPE buffer 
and spun @ 10,000rpm. Flow through was discarded. RNA was eluted in 50μl of 
nuclease-free water (Ambion) by spinning it for 1 min @ 10,000 rpm. RNA 
concentration was maximized by passing elute through the membrane a second time. 
RNA concentration in ng/μl was determined by using a Spectrophotometer 
(ND1000; NanoDrop Technologies, Inc).  
 
4.5.2 cDNA synthesis 
cDNA synthesis was performed using an ImProm-II Reverse Transcription System 
(Promega). A volume of sample that contained 1μg of RNA was determined and an 
RNA mix was made up using this volume, together with 0.5μl oligo dTs, 0.5μl 
random primers and nuclease-free water to make up a total volume of 11.5μl. A 
negative control was also prepared for each sample. The tubes were placed at 65°C 
for 5min in a PCR machine (Bio-Rad MJ Mini™ Personal Thermal Cycler). A 
mastermix containing 5X buffer (4μl), MgCl2 (2μl), dNTPs (1μl: 10mM) and RNase 
inhibitor (0.5μl) was made up and 7.5μl was added to each tube followed by 1μl 
Reverse Transcriptase (RT) enzyme. Negative controls received 1μl nuclease-free 
water instead of RT. Tubes were placed at 37°C for 90min before dropping to 4°C. 
cDNA was stored at 4°C for 1-2 days and subsequently used in Reverse 
Transcriptase-Polymerase Chain Reaction (RT-PCR). 
 
4.5.3 Reverse transcriptase – polymerase chain reaction 
RT-PCR was carried out using a GoTaq Flexi DNA Polymerase system (Promega). 
20.75μl of mastermix containing 5μl 5X PCR buffer, 1.5mM MgCl2 (IL-1α primer 
only requires 0.5mM), 1.25mM PCR dNTPs and 10.25μl nuclease-free water was 
added to each tube. 2μl of cDNA, 2μl of desired sense and anti-sense primer and 
0.25μl Taq polymerase were also added. A negative control containing negative RT 
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cDNA was also prepared for each primer. RT-PCR was carried out using mouse 
SCG tissue from P1 GITR+/+ and GITR-/- SV129 mice. Primer sequences and 
predicted product size is presented in table 4.4 and PCR primer programs used in 
table 4.5. 
Target mRNA  Forward primer (5’-3’ direction)  Reverse primer (5’-3 direction)  Size (bp)  
GAPDH  TGGCACAGTCAAGGCTGAGA  CTTCTGAGTGGCAGTGATGG  388  
IL-1α  GGCTCACTTCATGAGAACTGC  TGAACTCCTGCTTGACGATCC  289  
IL-1RI AGATGGAAGGACCTATGATG  TGCAGCATCTGACGACAGGA  641  
IL-1RII GGCAAGGAATACAACATCAC  TGGTTGTCAGTCGGTAGCTT  530  
TNF  AGAACTCCAGGCGGTGTCTGT  CCTTGTCCCTTGAAGAGAACC  367  
TNFRI  CCCAGGACTCAGGTACTGCCGT  CAGAGTGGGGTTGAAGCCGG  244  
TNFRII  GATGAGAAATCCCAGGATGCAGTAGG  TGCTACAGACGTTCACGATGCAGG  264  
IGF-1  GGACCAGAGACCCTTTGCGGG  GGCTGCTTTTGTAGGCTTCAGTGG  210  
IGF-1R1  ACTGACCTCATGCGCATGTGCTGG CTCGTTCTTGCGGCCCCCGTTCAT  345  
TrkA  TCAACAAATGTGGACGGAGA  GTGGTGAACACAGGCATCAC  197  
Table 4.4 List of RT-PCR primer sequences and predicted product size 
 
Target mRNA  Denaturation  Annealing Extension Cycles (#) 
GAPDH  95°C x 30s  55°C x 30s 72°C x 60s 25  
IL-1α  95°C x 30s  55°C x 30s 72°C x 60s 32  
IL-1R1 95°C x 40s  54°C x 40s 72°C x 30s 30  
IL-1R2 95°C x30s  55°C x 30s 72°C x 60s 30  
TNFα  95°C x 30s  55°C x 30s 72°C x 60s 32  
TNFR1 95°C x 40s 54°C x 40s 72°C x 30s 30  
TNFR2 95°C x 60s  59°C x 60s 72°C x 60s 30  
IGF-1 94°C x 60s  58°C x 45s 72°C x 60s 42  
IGF-1R1  94°C x 60s 60°C x 45s 72°C x 60s 40  
TrkA  95°C x 40s  58°C x 60s 72°C x 60s 40  
Table 4.5 Semi-quantitative RT-PCR conditions for primers 
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4.5.4 Agarose gel electrophoresis 
PCR products were run on a 1.5% agarose gel. Gels were made using 1.5g agarose 
(Sigma) and 100ml 1X TAE buffer and dissolved by heating in a microwave 
(GoldStar Multiwave Oven). Safeview™, to label the DNA, was added to molten gel 
and poured into the gel tray to set for 30min. The gel tray was then lowered into the 
gel rig (Peqlab biotechnologie GmbH) and immersed in 1X TAE. 100bp ladder (7μl; 
New England Biolabs) and 10μl of each sample were loaded and gel was run at 
100V for 1-1.5h on a Bio-Rad Power Pac 200. The gel was imaged with a UV 
transluminator with UVI Pro software and the gel was safely disposed of according 
to lab safety protocols. 
 
4.6 Growth analysis 
Each culture was performed at least three times (n=3) with 30-50 images per group 
taken using Olympus 1X70 Provis Inverted Fluoresence Microscope attached to an 
Olympus DP70 camera. All images were saved as jpegs and appropriate scale bars 
were added using Photoshop. Growth was determined by length of neurites and 
number of branches using Sholl analysis. Sholl analysis provides a graphic 
illustration of neurite length and branching with distance from the cell body 
(Gutierrez, et al., 2008). 
 
4.7 Statistics 
Statistical analysis was performed using the computer-based statistical package 
GraphPad Prism (GraphPad, US). Two-tailed unpaired Student’s t-test was used to 
compare the mean of two groups as appropriate. Experiments comparing multiple 
groups were analysed using a one-way ANOVA with Tukey’s post hoc test. Data are 
expressed as mean ± standard error of the mean (SEM) and deemed significant when 
P < 0.05. 
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5.0   Determination of the role of GITR in the growth of developing 
sympathetic neurons 
 
5.1 Aims 
 To confirm the expression of GITR and GITRL in P1 SCG neurons using  
immunocytochemistry 
 To investigate the sensitivity of developing sympathetic neurons to NGF in 
response to GITR activation. 
 To determine the region of GITR required for the growth promoting effects 
of GITRL-GITR signalling 
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5.2 Abstract 
NGF is the prototypic neurotrophin required for the survival and growth of neurons 
of the developing PNS. The action of NGF is mediated through receptors TrkA and 
p75NTR. Recently, GITR of the TNFRSF has been identified as a receptor crucial 
for NGF-promoted axon extension and target innervation of NGF-dependant 
sympathetic neurons of the developing PNS. However, the precise regions of GITR 
responsible for mediating this effect are unknown. We aimed to explore this further 
using plasmids expressing mutant forms of the GITR receptor. To do this, neurons 
isolated from the SCG of P1 C57 mice, were transfected with mutant forms of GITR 
by microporation and axonal growth of these neurons was determined using Sholl 
analysis. Results indicated that GITRL-GITR signalling requires the extracellular 
region of GITRL and the juxtamembrane intracellular region of GITR. Using point-
specific mutants of potential important residues identified by In Silico analysis, we 
found in addition that constitutive phosphorylation of Tyr190 and Ser199 sites 
(amino acids 12 and 21) of the identified growth promoting domain (GPD) of the 
intracellular GITR resulted in the inhibition of NGF-promoted growth of neonatal 
sympathetic neurons. In conclusion, this study shows that the growth promoting 
effects of GITR are mediated by a growth-promoting domain located at the 
juxtamembrane region of the intracellular region of GITR, in which sites Tyr 190 
and Ser 199, appear to play a role in the regulating axonal growth of developing 
sympathetic neurons. 
 
5.3 Introduction 
The growth of axons to and within their targets during development of the PNS is 
controlled by a variety of extrinsic and intrinsic signals (Glebova and Ginty, 2005; 
Harrington and Ginty, 2013; Honma, et al., 2002; Markus, et al., 2002; Thompson, 
et al., 2004).  One of the key regulators of axonal growth in the PNS is NGF. In the 
PNS, postganglionic sympathetic neurons require a constant supply of target-derived 
NGF, in order to survive, and maintain their connections (Glebova and Ginty, 2004; 
Harrington and Ginty, 2013; Levi-Montalcini and Angeletti, 1968). Within the target 
regions innervated by these neurons, NGF acts locally on axon terminals to promote 
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their growth, branching and refinement of connections (Campenot, et al., 1994; 
Edwards, et al., 1989).  NGF elicits its effects by binding two receptors; the p75NTR 
of the TNFRSF and TrkA of the family of Trk receptors (Reichardt, 2006). p75NTR 
increases the specificity and binding affinity of TrkA to NGF in the promotion of 
neuronal survival and growth (Chao and Hempstead, 1995). 
 GITR is a transmembrane protein that is activated by its specific ligand, 
GITRL (Bossen, et al., 2006; Gurney, et al., 1999; Kim, et al., 2003a; Kwon, et al., 
1999; Ronchetti, et al., 2004; Tone, et al., 2003; Yu, et al., 2003). Like the p75NTR, 
GITR is a member of the TNFRSF, however unlike p75NTR, GITR does not contain 
a death domain. Upon activation, GITR recruits TRAF molecules, which bind to the 
intracellular region or the TRAF binding site of GITR causing subsequent activation 
of intracellular pathways to elicit functional responses (Esparza and Arch, 2004; 
Esparza, et al., 2006; Ronchetti, et al., 2004; Zhou, et al., 2008). In the immune 
system GITR functions as a costimulatory molecule and is involved in the regulation 
of innate and acquired immune responses (Krausz, et al., 2007; Nocentini and 
Riccardi, 2005). GITR activation amplifies the activation and proliferation of T cell 
antigen receptor (TCR)-triggered T cells (CD4+ and CD8+) (Esparza and Arch, 
2005a; Kanamaru, et al., 2004; Ronchetti, et al., 2004; Stephens, et al., 2004; Tone, 
et al., 2003).  
 Recent data also describes new roles for GITR during nervous system 
development (O’Keeffe et al. 2008).  Interestingly, GITR was found to act in a 
costimulatory manner in the enhancement of NGF-promoted axon growth and target 
innervation of neonatal sympathetic neurons (O'Keeffe, et al., 2008). Furthermore, 
GITRL-GITR signalling was found to exert its growth promoting effects during the 
immediate postnatal stages of development (P1-3) and operates via an apparent 
autocrine route as both GITRL and GITR were found to be expressed on the 
neuronal soma both in vitro and in vivo rather than being expressed on the neurites or 
in distal targets (O'Keeffe, et al., 2008).  
 The mechanism through which GITRL-GITR facilitates NGF-promoted axon 
growth was shown to centre on a GITR-mediated facilitation of NGF-promoted 
ERK-activation (O'Keeffe, et al., 2008). Enhanced axonal growth and branching 
produced by agonist GITRL-IgG treatment in P1 SCG neurons is completely 
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abolished when neurons are treated with ERK1/2 blocker U0126 demonstrating that 
the enhanced ERK1/2 activation brought about by stimulating GITR (with GITRL-
IgG) is responsible for the increase in NGF-promoted axonal growth.  However the 
precise region of the GITR receptor that regulates this effect is unknown. In this 
chapter we sought to determine the region of GITR required for its enhancement of 
NGF-promoted growth and to determine if GITR activation increased sympathetic 
neuron’s sensitivity to NGF. 
 
5.4 Results 
5.4.1 GITR and GITRL are expressed by P1 mouse SCG neurons.  
In order to confirm the expression of GITR and GITRL in neonatal mouse 
sympathetic neurons, immuncytochemical staining for GITR and GITRL was 
performed. The SCG were removed from P1 C57 mice, dissociated, and plated in a 
defined media containing 10ng/ml NGF and grown overnight at 37°C. The following 
day, cells were fixed and immunocytochemically stained for GITR (Figure 5.1 A) 
and GITRL (Figure 5.1B). Both GITR and GITRL were located in the extranuclear 
region consistent with transmembrane proteins (Nocentini, et al., 1997), (confirmed 
by co-staining with nuclear stain DAPI) of neuronal cells (confirmed by co-
localisation with neuronal stain -III tubulin) (O'Keeffe, et al., 2008) of the SCG. 
 
5.4.2  Dose response of NGF effects on survival of P1 mouse SCG neurons. 
NGF is required for the survival of developing sympathetic neurons (Levi-
Montalcini, 1987). The p75NTR increases the sensitivity of developing neurons to 
NGF as part of the TrkA/p75NTR high affinity receptor complex that mediates the 
pro-survival effects that NGF exerts on these neurons (Chao and Hempstead, 1995). 
As GITR is a member of the same family as p75NTR and promotes the growth and 
target innervation of NGF-dependant neurons (O'Keeffe, et al., 2008), it is possible 
that GITR may also increase the sensitivity of SCG neurons to NGF in a similar 
fashion to p75NTR. Before we examined this, a baseline for the NGF requirements 
of P1 SCG for survival and growth was first established. P1 SCG neurons were 
grown in a defined media containing different concentrations of NGF (0.01, 0.04, 
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0.2, 1, 4 and 10ng/ml) and grown for 24, 48 and 72h at 37°C. The effect on survival 
was examined by counting the numbers of neurons surviving at each time point (24, 
48 and 72h) and calculated as a percentage of number of neurons that survived at 3h. 
A significant increase in survival (***P ≤  0.001, **P ≤  0.01) was evident in cells 
grown in 4-10ng/ml NGF after 24h (Figure 5.2 A), 48h (Figure 5.2 B) and 72h 
(Figure 5.2 C) compared to untreated controls.  
 
5.4.3 Dose response of NGF effects on the growth of P1 mouse SCG neurons.  
Similar to 5.4.2, where a baseline of NGF requirements for P1 SCG neurons survival 
was established, we performed a similar experiment to determine the effects of 
varying concentrations of NGF on axonal growth. To prevent cell death, a cell-
permeable, irreversible, broad-spectrum caspase inhibitor III from Calbiochem was 
added to the medium.  P1 SCG neurons were grown in a defined media containing 
0.01, 0.04, 0.2, 1, 4 and 10ng/ml NGF overnight at 37°C followed by growth 
assessment using Sholl analysis. There was a significant increase in neurite length in 
neurons treated with 0.2, 1, 4 and 10ng/ml compared with untreated controls (***P ≤  
0.001, *P ≤  0.05) (Figure 5.3 A, C, D). In addition, there was a significant increase 
in neurite branching in neurons treated with 0.2, 1, 4 and 10ng/ml compared to 
untreated controls (***P ≤  0.001, *P ≤  0.05) (Figure 5.3 B, C, D).  
 
5.4.4  A GITRL antagonist reduces NGF-promoted axonal growth at an NGF 
concentration of 1ng/ml and 4ng/ml.  
Baseline growth experiments (5.4.3) identified 4-10ng/ml NGF as concentrations 
that induce a significant increase in sympathetic neuronal growth. Previously, the 
p75NTR was found to increase neuron’s sensitivity to NGF at low (2.5ng/ml) and 
not high (10ng/ml) concentrations of NGF (Lee, et al., 1994b). Given that GITR is 
from the same super family, it may function similarly and affect a neuron’s 
sensitivity to NGF at different concentrations of NGF. For this reason, we next 
examined the effect of GITRL-GITR signalling on the sensitivity of neurons to NGF 
grown in 1ng/ml. P1 SCG cells were treated with two commercially available 
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compounds; agonist recombinant GITRL (rmGITRL) (1g/ml) or antagonist 
GITRL-IgG (5g/ml) and grown overnight in a defined media containing 1ng/ml 
NGF at 37°C. The following day, cells were fixed and immunocytochemically 
stained for the neuronal marker -III tubulin. The extent of growth of neurons was 
determined using Sholl analysis. Agonist rmGITRL treatment of neurons grown in 
1ng/ml NGF had no effect on length of neurites (Figure 5.4 A), branching (Figure 
5.4 B) or Sholl profiles (Figure 5.4.C) of these neurons. Representative line drawings 
represent these results (Figure 5.4 D). Antagonist GITRL-IgG treatment of neurons 
grown in 1ng/ml NGF had no effect on length of neurites (Figure 5.4 A), however 
antagonist GITRL-IgG treatment did result in a significant reduction in branching 
(**P ≤  0.01) recovered with combination treatment with Agonist rmGITRL    
(Figure 5.4 B), in addition to a reduction in Sholl profiles, reflected in representative 
line drawings of neurons grown in 1ng/ml NGF (Figure 5.4 C, D).  
 
5.4.5 A GITRL antagonist does not reduce NGF-promoted axonal growth at an 
NGF concentration of 4ng/ml.  
In continuing to investigate whether GITRL-GITR signalling affects a neuron’s 
sensitivity to NGF using different concentrations of NGF, we next examined the 
effect of GITRL-GITR signalling on the growth of neurons in 4ng/ml NGF. P1 SCG 
cells were treated with agonist rmGITRL (1g/ml) or antagonist GITRL-IgG 
(5g/ml) and grown overnight in a defined media containing 4ng/ml NGF at 37°C. 
The following day, cells were fixed and immunocytochemically stained for the 
neuronal marker -III tubulin. The extent of growth of neurons was determined 
using Sholl analysis. Treatment of neurons with agonist rmGITRL, grown in 4ng/ml 
NGF had no effect on length of neurites (Figure 5.5 A) or branching (Figure 5.5 B), 
reflected in Sholl profiles (Figure 5.5 C) and representative line drawings of treated 
neurons (Figure 5.5 D). Similarly, antagonist GITRL-IgG treatment of neurons 
grown in 4ng/ml NGF had no effect on neurite length (Figure 5.5 A) or branching 
(Figure 5.5 B). Sholl profiles (Figure 5.5 C) and representative line drawings of 
treated neurons (Figure 5.5 D) display no change in growth compared to control-
treated neurons grown in 4ng/ml NGF. 
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5.4.6 A GITRL antagonist does not reduce NGF-promoted axonal growth at an 
NGF concentration of 10ng/ml.  
To further examine if GITRL-GITR signalling affects sympathetic neuron’s 
sensitivity to NGF, P1 SCG cells were treated with agonist rmGITRL (1µg/ml) or 
antagonist GITRL-IgG (5µg/ml) and grown overnight in a defined media containing 
10ng/ml NGF at 37°C. The following day, cells were fixed and 
immunocytochemically stained for the neuronal marker -III tubulin. The extent of 
growth of neurons was determined using Sholl analysis. Treatment with agonist 
rmGITRL had no effect on neurite length (Figure 5.6 A), branching (Figure 5.6 B) or 
Sholl profiles of neurons (Figure 5.6 C) in media containing 10ng/ml NGF. These 
results are reflected in representative line drawings of neurons treated with 
rmGITRL and grown in 10ng/ml NGF (Figure 5.6 D). Neurons treated with 
antagonist GITRL-IgG and grown in 10ng/ml NGF also showed no change in neurite 
growth (Figure 5.6 A), branching (Figure 5.6 B) or Sholl profile (Figure 5.6 C) when 
compared with control treated neurons. This is clear by line drawings from 
photomicrographs taken of these treated neurons (Figure 5.6 D). 
 
5.4.7 Enhancement of axonal growth by GITRL-GITR signalling does not require 
the intracellular tail of GITRL.  
We next examined the regions of GITR or GITRL that are required for the growth 
promoting effects of GITRL-GITR signalling. Firstly, we transfected P1 SCG 
neurons with overexpression vectors for GITRL and antisense GITR following 
which neurons were grown in media containing 10ng/ml NGF. This concentration of 
NGF (10ng/ml) has been used previously in similar experiments that examined the 
effect of GITRL-GITR signalling on the growth of neonatal sympathetic neurons 
(O'Keeffe, et al., 2008). Overexpression of GITRL resulted in a significant increase 
in neurite length (**P ≤  0.01) (Figure 5.7 A). This result is reflected in the Sholl 
profile of neurons where GITRL is over expressed (Figure 5.7 B) and in line 
drawings of GITRL-transfected neurons (Figure 5.7 C). When cells were transfected 
with a plasmid expressing antisense GITR, there was a significant decrease in neurite 
length (**P ≤  0.01) (Figure 5.7 A), where the reduction in the complexity of 
neurons transfected with antisense GITR is seen by the Sholl profiles of these 
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neurons (Figure 5.7 B) and representative line drawings of neurons (Figure 5.7 C) 
compared to controls.  In the immune system GITRL-GITR signalling can occur in a 
“forward” manner whereby the signalling is mediated downstream of GITR 
following ligand binding, but it can also be ‘reversed’. This means that signalling is 
via the intracellular tail of GITR ligand and not the receptor (Bae, et al., 2008). To 
investigate if this is the case in the developing SCG neurons, an expression vector 
overexpressing a mutated version of GITRL (GITRLW), in which the intracellular 
tail of GITRL was deleted (a kind gift from Prof. Carlo Riccardi, University of 
Perugia, Italy) was transfected into P1 SCG neurons which were then grown 
overnight in a defined media containing 10ng/ml NGF and the effect on axonal 
growth was examined.  There was no decrease in the growth of GITRLW-
transfected neurons compared to controls (i.e. cells transfected with empty plasmid) 
(where length of neurites from cells transfected with control versus GITRLW = 
1295 ± 189m versus 1568 ± 168m) demonstrated by the Sholl profile (Figure 5.7 
D) and representative line drawings of transfected neurons (Figure 5.7 E). This result 
indicates that the intracellular region of GITRL is not responsible for the growth 
promoting effects of GITRL-GITR signalling in P1 SCG neurons.  
 
5.4.8 GITRK does not affect axonal growth of P1 SCG neurons.  
GITR is a type I transmembrane protein consisting of intracellular, transmembrane 
and extracellular regions (Nocentini, et al., 1997). Result 5.4.7 indicates that GITRL-
GITR activates intracellular signalling via GITR and not GITRL. Plasmids 
expressing mutated GITR proteins with specific deletions in the intracellular region 
of GITR, designation GITRK, GITRZ, and GITRW, were used to identify the 
growth promoting domain (GPD) of GITR (plasmids were a kind gift from Prof. 
Carlo Riccardi, University of Perugia, Italy).  
P1 SCG neurons were transfected with a plasmid expressing GITRK which 
expresses a GITR protein lacking the sequence EQTEEKCHLGGRWP from the 
intracellular region (Figure 5.8 A), together with a GFP expression plasmid (to 
visualise transfected neurons) and grown overnight in a defined media containing 
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10ng/ml NGF at 37°C. Neurons transfected with GITRK displayed no change in 
neurite length (Figure 5.8B) or branching (Figure 5.8C) compared with their control-
transfected counterparts. These results are reflected in the Sholl profile (Figure 5.8 
D) and line drawings (Figure 5.8 E) of transfected neurons compared with controls. 
This result indicates that the GPD of GITR is not located at the 
EQTEEKCHLGGRWP region of the intracellular portion of GITR. 
 
5.4.9 GITRZ does not affect neurite length of P1 SCG neurons.   
In continuing to investigate the region of GITR responsible for its growth promotion 
effects, P1 SCG neurons were transfected with a plasmid expressing GITRZ which 
expresses a GITR protein lacking the sequence 
AEDACSFQFPEEERGEQTEEKCHLGGRWP from the intracellular region (Figure 
5.9 A). GITRZ-transfected neurons displayed no change in neurite length (Figure 
5.9 B) compared with controls. However that was a significant difference in 
branching compared with controls (P < 0.05). This result is reflected in the Sholl 
profile (Figure 5.9 D) and line drawings (Figure 5.9 E) of transfected neurons 
compared to controls. As high significant differences are not reported in both length 
and branching in trasnfected neurons compared to controls, this result indicates that 
the GPD of GITR is not located at the 
AEDACSFQFPEEERGEQTEEKCHLGGRWP region of the intracellular portion of 
GITR. 
 
5.4.10 Axonal growth of P1 mouse SCG neurons is mediated by a juxtamembrane 
region of GITR.  
To further investigate the region of GITR responsible for its growth promotion 
effects in sympathetic neurons, P1 SCG neurons were transfected with a plasmid 
expressing GITRW that expresses a GITR protein in which the juxtamembrane 
region of GITR; 
QLRRQHMCPRETQPFAEVQLSAEDACSFQFPEEERGEQTEEKCHLGGRWP 
has been deleted (Figure 5.10 A) and the effect on growth of neurons was examined. 
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GITRW-transfected cells displayed a significant reduction in neurite length (***P ≤  
0.001) (Figure 5.10 B) and branching (***P ≤  0.001) compared to controls (Figure 
5.10 C). The reduction in the growth of sympathetic neurons as a consequence of 
GITRW transfection is demonstrated by the Sholl profile (Figure 5.10 D) and line 
drawings (Figure 5.10 E) of transfected neurons compared with controls. This result 
indicates that a juxtamembrane region, hereafter referred to as the GPD, of the 
intracellular domain of GITR is responsible for mediating the growth-promoting 
effects of GITRL-GITR signalling in developing SCG neurons. 
 
5.4.11 In Silico analysis of the GPD of GITR.  
Using In Silico analysis, a collaborating laboratory lead by Professor Carlo Riccardi, 
identified potential phosphorylation sites in the GPD of GITR. In Silico analysis 
software programs included DISPHOS; NetPhos 2.0 and GPS Predictor programs. 
The putative phosphorylation sites identified were Tyr190 and Ser199 (amino acid 
12 and 21 of the GPD) (Figure 5.11 B). In addition, there are basic residues Cys186-
Glu189 (CPRE) (amino acids 8-11) present in the GPD (Figure 5.11 B) that are 
conserved among the "GITR sub family" of receptors (CD27, OX40, 4-1BB) and are 
potentially involved in mediating protein-protein interactions (Krausz, et al., 2007). 
Also, this sequence of residues is located next to a tyrosine residue (Tyr190) and as 
such may promote the recruitment of specific kinase enzymes for the 
phosphorylation of that residue. GITR expression plasmids were then created in 
which the potential phosphorylation sites and conserved basic residues of the “GITR 
sub family” were mutated (a kind gift from Prof. Carlo Riccardi, University of 
Perugia, Italy). Figure 5.11 C depicts the GITR proteins with mutations of the 
putative phosphorylation sites and conserved basic residues in the GPD of GITR. In 
GITRδ2, Cys186-Glu189 (CPRE), (amino acids 8 to 11), of the GPD were replaced 
with alanines which may act to inhibit the mediation of protein-protein interactions 
and / or the recruitment of specific kinases to Tyr190 and therefore inhibit 
phosphorylation at this residue. In GITRδ4, Tyr190 and Ser199, (amino acid 12 and 
21 of the GPD), were replaced with alanines which should act to inhibit 
phosphorylation at these sites. In GITRδ5, Tyr190 and Ser199, (amino acid 12 and 
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21 of the GPD), were replaced with glutamic acid which should act to cause 
constitutive phosphorylation at these sites. 
5.4.12 The CPRE (amino acids 8 to 11) site of the GPD of GITR does not mediate 
its growth promoting effects.  
P1 SCG neurons were transfected with GITRδ2 (mutant in which Cys186-Glu189, 
CPRE (amino acids 8 to 11) of the GPD were replaced with alanines which should 
inhibit the mediation of protein-protein interactions and / or the recruitment of 
specific kinases to Tyr190 and therefore inhibit phosphorylation at this residue) 
(Figure 5.12 A) were grown overnight in a defined media containing 10ng/ml NGF 
at 37°C and the effect on axonal growth was examined. Transfected cells exhibited 
no change in neurite length (Figure 5.12 B) or branching (Figure 5.12 C) compared 
to controls. This result is reflected in the Sholl profile (Figure 5.12 D) and line 
drawings (Figure 5.12 E) of transfected neurons. This result indicates that the 
inhibition of protein-protein interactions at these residues and / or the recruitment of 
specific kinases to Tyr190 and therefore the inhibition of phosphorylation at this 
residue of the GPD do not regulate GITRL-GITR promoted growth of P1 SCG 
neurons. 
 
5.4.13 Inactivating mutation of Tyr190 and Ser199 of the GPD of GITR does not 
inhibit axonal growth.  
P1 SCG neurons transfected with GITRδ4 (mutant in which Tyr190 and Ser199, 
(amino acid 12 and 21) of the GPD were replaced with alanines which should inhibit 
phosphorylation at these sites) (Figure 5.13 A) were grown overnight in a defined 
media containing 10ng/ml NGF at 37°C and the effect on axonal growth was 
examined. Transfected cells displayed no change in neurite length (Figure 5.13 B) or 
branching (Figure 5.13 C) compared to controls which is reflected in the Sholl 
profile (Figure 5.13 D) and line drawings (Figure 5.13 E) of transfected neurons. 
This result indicates that inhibition of phosphorylation at Tyr190 and Ser199, (amino 
acids 12 and 21) sites of the GPD of GITR has no effect on the growth promoting 
role of GITRL-GITR signalling in P1 SCG neurons. 
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5.4.14 Constitutive phosphorylation of Tyr190 and Ser199 of the GPD of GITR 
inhibits axonal growth.  
P1 SCG neurons transfected with GITRδ5 (mutant in which Tyr190 and Ser199, 
(amino acid 12 and 21) of the GPD were replaced with glutamic acid causing sites to 
be constitutively phosphorylated) (Figure 5.14 A) were grown overnight in a defined 
media containing 10ng/ml NGF at 37°C and the effect on growth examined. 
Interestingly, there was a significant reduction in neurite length (*P ≤ 0.05) (Figure 
5.14 B) and branching (**P ≤ 0.01) compared to controls (Figure 5.14 C). The 
reduction in growth of these neurons is reflected in the Sholl profile (Figure 5.14 D) 
and line drawings (Figure 5.14 E) of transfected neurons. This result indicates that 
continuous phosphorylation at Tyr190 and Ser199 (amino acids 12 and 21) sites of 
the GPD of GITR has a growth inhibitory effect on P1 SCG neurons. 
 
5.4.15 Summary of Chapter 5.0.  
Schema in Figure 5.15 illustrates a summary of chapter 5.0 results. In developing 
sympathetic neurons, GITRL activates GITR via the extracellular tail of GITR . This 
causes subsequent activation of GITR, of which the intracellular region is 
responsible for the growth promoting effects of GITR. Specifically, the 
juxtamembrane region of cytoplasmic GITR is responsible for these growth 
promoting effects and has been termed the GPD of GITR. Constitutive 
phosphorylation at sites Tyr190 and Ser199, (amino acids 12 and 21) of the GPD 
results in the inhibition of growth in P1 SCG neurons suggesting these sites are 
involved in the regulation of GITRL-GITR signalling in the promotion of growth of 
developing NGF-dependant sympathetic neurons of the PNS. 
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Figure 5.1: Expression of GITR and GITRL by P1 neonatal sympathetic neurons.  P1 SCG 
neurons were grown for 24h in 10ng/NGF. Brightfield images (Top left corner of A and B) identify 
sympathetic neurons. Cells were fixed and immunocytochemically stained for (A) GITR (red) or (B) 
GITRL (red) together with-III tubulin (green) and counterstained with DAPI (blue). Scale bar 
50µm. 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
Figure 5.2: Dose response of the effect of NGF on the survival of P1 mouse SCG neurons after 
varying times in culture.  P1 SCG neurons were grown in media containing 0.01, 0.04, 0.2, 1, 4 and 
10ng/ml NGF for (A) 24h, (B) 48h and (C) 72h at 37°C. Control cultures were also grown in the 
absence of NGF. The survival of neurons at time points 24, 48 and 72h was calculated as a percentage 
of neurons that survived at 3h. Statistical comparisons: ** P ≤ 0.01, *** P ≤ 0.001 compared to 
controls was found using one way ANOVA and post hoc Tukey’s test.  
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Figure 5.3: Dose response of the effect of NGF on the growth of P1 mouse SCG neurons after 
varying times in culture.  P1 SCG neurons were grown in media containing 0.01, 0.04, 0.2, 1, 4 and 
10ng/ml NGF for 24h at 37°C. Control cultures were also grown in the absence of NGF. Axonal 
growth was analysed using Sholl analysis. (A, B) Graphical representations of, (A) total neurite length 
and (B) total neurite branching in P1 SCG neurons grown in varying doses of NGF. (C) Sholl profiles 
of neurons grown in varying doses of NGF. (D) Representative photomicrographs of P1 SCG neurons 
grown in varying doses of NGF. Means ± standard error of 100-150 neurons per condition shown. 
Statistical comparisons: *P ≤ 0.05, *** P ≤ 0.001 compared to controls was found using one way 
ANOVA and post hoc Tukey’s test. Scale bar = 50µm.  
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Figure 5.4:  Axonal growth of P1 SCG neurons grown in 1ng/ml of NGF is significantly reduced 
following treatment with GITRL-IgG. P1 SCG neurons were treated with rmGITRL (1mg) or 
GITRL-IgG (5mg) and grown overnight in 1ng/ml NGF at 37°C. Control cultures were also grown in 
which only NGF was present. Axonal growth was analysed using Sholl analysis. (A, B) Graphical 
representations of, (A) total neurite length and (B) total neurite branching in P1 SCG neurons treated 
with rmGITRL or GITRL-IgG and grown overnight in 1ng/ml NGF. (C) Sholl profiles of neurons 
treated with rmGITRL or GITRL-IgG and grown overnight in 1ng/ml NGF. (D) Representative line 
drawings of P1 SCG neurons treated with rmGITRL or GITRL-IgG and grown overnight in 1ng/ml 
NGF. Means ± standard errors of 40-90 neurons per condition are shown. Statistical comparisons: *** 
P < 0.001 compared to controls was found using one way ANOVA and post hoc Tukey’s test. Scale 
bar = 50µm.  
 
 
79 
 
 
Figure 5.5:  Axonal length of P1 mouse SCG neurons grown in 4ng/ml of NGF was reduced 
following treatment with GITRL-IgG but not rmGITRL. P1 SCG neurons were treated with 
rmGITRL (1µg) or GITRL-IgG (5µg) and grown overnight in 4ng/ml NGF in 37°C.  Control cultures 
containing 4ng/ml NGF were also grown. Axonal growth was analysed using Sholl analysis. (A, B) 
Graphical representations of, (A) total neurite length and (B) total neurite branching of P1 SCG 
neurons treated with rmGITRL or GITRL-IgG and grown overnight in 4ng/ml NGF. (C) Sholl 
profiles of neurons treated with rmGITRL or GITRL-IgG and grown overnight in 4ng/ml NGF. (D) 
Representative line drawings of P1 SCG neurons treated with rmGITRL or GITRL-IgG and grown 
overnight in 4ng/ml NGF. Means ± standard errors of 40-90 neurons per condition is shown. 
Statistical comparisons: * P < 0.05 compared to controls was found using one way ANOVA and post 
hoc Tukey’s test. Scale bar = 50µm.  
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Figure 5.6:  Axonal growth of P1 mouse SCG neurons grown in 10ng/ml of NGF was not 
affected following treatment with rmGITRL or GITRL-IgG.  P1 SCG neurons were treated with 
rmGITRL (1µg) or GITRL-IgG (5µg) and grown overnight in 10ng/ml NGF in 37°C.  Control 
cultures containing 10ng/ml NGF were also grown. Axonal growth was analysed using Sholl analysis. 
(A, B) Graphical representations of, (A) total neurite length and (B) total neurite branching of P1 SCG 
neurons treated with rmGITRL or GITRL-IgG and grown overnight in 10ng/ml NGF. (C) Sholl 
profiles of neurons treated with rmGITRL or GITRL-IgG and grown overnight in 10ng/ml NGF. (D) 
Representative line drawings of P1 SCG neurons treated with rmGITRL or GITRL-IgG and grown 
overnight in 10ng/ml NGF. Means ± standard errors of 40-90 neurons per condition are shown. 
Statistical comparisons: No significant differences compared to controls were found using one way 
ANOVA and post hoc Tukey’s test. Scale bar = 50µm.  
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Figure 5.7: GITRL-GITR signalling may promote axonal growth via ligand-receptor binding at 
the extracellular domain of GITRL. P1 SCG neurons were transfected with a GFP plasmid (to 
visualise transfected neurites) together with GITRL (to promote GITRL-GITR signalling), antisense 
GITR (to inhibit GITRL-GITR signalling) and GITRLδW (in which in the intracellular portion of 
GITRL is missing) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown 
in which P1 SCG neurons were transfected with control or empty plasmid. Axonal growth was 
analysed using Sholl analysis. (A) Graphical representation of total neurite length of P1 SCG neurons 
transfected with GITRL and antisense GITR. (B) Sholl profiles of neurons transfected with GITRL or 
antisense GITR and grown overnight in 10ng/ml NGF. (C) Representative line drawings of P1 SCG 
neurons transfected with GITRL or antisense GITR and grown overnight in 10ng/ml NGF. (E) Sholl 
profile of neurons transfected with GITRLW and grown overnight in 10ng/ml NGF. (D) 
Representative line drawings of P1 SCG neurons transfected with GITRLW and grown overnight in 
10ng/ml NGF. Length of neurites from cells transfected with control versus GITRLW = 1295 ± 
189mm versus 1568 ± 168mm. Means ± standard errors of 40-90 neurons per condition are shown. 
Statistical comparisons: **P  ≤  0.01 compared to controls was found using one way ANOVA and 
post hoc Tukey’s test for multiple comparisons. Scale bar = 50µm.  
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Figure 5.8: The EQTEEKCHLGGRWP region of GITR does not mediate its growth promoting 
effects.  P1 SCG neurons were transfected with a GFP plasmid (to visualise transfected neurites) 
together with GITRδK (in which the portion of the cytoplasmic region of GITR, 
EQTEEKCHLGGRWP, was missing) and grown overnight in 10ng/ml NGF at 37°C. Control cultures 
were also grown in which P1 SCG neurons were transfected with control or empty plasmid. Axonal 
growth was analysed using Sholl analysis. (A) Primary structure of intracellular tail of GITR and 
portion deleted in GITRδK mutant. Graphical representations of, (B) total neurite length and (C) total 
neurite branching of P1 SCG neurons transfected with GITRδK and grown overnight in 10ng/ml 
NGF. (D) Sholl profile of neurons transfected with GITRδK and grown overnight in 10ng/ml NGF. 
(E) Representative line drawings of P1 SCG neurons transfected with GITRδK and grown overnight 
in 10ng/ml NGF. Means ± standard errors of >150 neurons per condition are shown. Statistical 
comparisons: *P ≤ 0.05 compared to controls was found using an unpaired student t-test. Scale bar = 
50µm.  
 
83 
 
 
Figure 5.9: The AEDACSFQFPEEERGEQTEEKCHLGGRWP of GITR region of GITR does 
not mediate its growth promoting effects.  P1 SCG neurons were transfected with a GFP plasmid 
(to visualise transfected neurites) together with GITRδZ (in which the portion of the cytoplasmic 
region of GITR, AEDACSFQFPEEERGEQTEEKCHLGGRWP, was missing) and grown overnight 
in 10ng/ml NGF at 37°C. Control cultures were also grown in which P1 SCG neurons were 
transfected with control or empty plasmid. Axonal growth was analysed using Sholl analysis. (A) 
Primary structure of intracellular tail of GITR and portion deleted in GITRδZ mutant. Graphical 
representations of, (B) total neurite length and (C) total neurite branching of P1 SCG neurons 
transfected with GITRδZ and grown overnight in 10ng/ml NGF. (D) Sholl profile of neurons 
transfected with GITRδZ and grown overnight in 10ng/ml NGF. (E) Representative line drawings of 
P1 SCG neurons transfected with GITRδZ and grown overnight in 10ng/ml NGF. Means ± standard 
errors of >150 neurons per condition are shown. Statistical comparisons: No significant differences 
compared to controls were found using an unpaired student t-test. Scale bar = 50µm.  
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Figure 5.10:  The growth promoting effects of GITR signalling require the juxtamembrane 
region of GITR. P1 SCG neurons were transfected with a GFP plasmid (to visualise transfected 
neurites) together with GITRδW (in which the portion of the cytoplasmic region of GITR, 
QLRRQHMCPRETQPFAEVQLSAEDACSFQFPEEERGEQTEEKCHLGGRWP is missing) and 
grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in which P1 SCG 
neurons were transfected with control or empty plasmid. Axonal growth was analysed using Sholl 
analysis. (A) Primary structure of intracellular tail of GITR and portion deleted in GITRδW mutant. 
Graphical representations of, (B) total neurite length and (C) total neurite branching of P1 SCG 
neurons transfected with GITRδW and grown overnight in 10ng/ml NGF. (D) Sholl profile of neurons 
transfected with GITRδW and grown overnight in 10ng/ml NGF. (E) Representative line drawings of 
P1 SCG neurons transfected with GITRδW and grown overnight in 10ng/ml NGF. Means ± standard 
errors of >150 neurons per condition are shown. Statistical comparisons: ***P  ≤  0.001 compared to 
controls was found using an using unpaired student t-test. Scale bar = 50µm.  
 
85 
 
 
Figure 5.11: The growth promoting domain of GITR is located in the juxtamembrane region of 
the intracellular portion of GITR. (A) Schema showing the Growth promoting domain (GPD) of 
transmembrane GITR, located in the juxtamembrane region of the intracellular portion of GITR. (B) 
Site 1 consists of basic residues present in the GPD that are conserved among the "GITR sub family" 
of receptors (including CD27, OX40, 4-1BB). These sites are potentially involved in mediating 
protein-protein interactions and / or the recruitment of specific kinases to Tyr190. (B) Site 2 
consisting of Tyr190 and Ser199 (amino acid 12 and 21 of the GPD) were identified as putative 
phosphorylation sites using In Silico analysis by DISPHOS; NetPhos 2.0 and GPS Predictor software 
programs. (C) Schema describing mutants of basic residues and the putative phosphorylation sites in 
the GPD of GITR. In GITRδ2, Cys186-Glu189 (CPRE), (amino acids 8 to 11), of the GPD were 
replaced with alanines. In GITRδ4, Tyr190 and Ser199, (amino acid 12 and 21 of the GPD), were 
replaced with alanines. In GITRδ5, Tyr190 and Ser199, (amino acid 12 and 21 of the GPD), were 
replaced with glutamic acid.  
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Figure 5.12:  The growth promoting effects of GITR signalling are not mediated by the CPRE 
(amino acids 8 to 11) site of the GPD of GITR.  P1 SCG neurons were transfected with a GFP 
plasmid (to visualise transfected neurites) together with GITRδ2 (mutant in which Cys186-Glu189, 
CPRE (amino acids 8 to 11) of the GPD were replaced with alanines) and grown overnight in 10ng/ml 
NGF at 37°C. Control cultures were also grown in which P1 SCG neurons were transfected with 
control or empty plasmid. Axonal growth was analysed using Sholl analysis. (A) Primary structure of 
GPD of GITR in which a portion is replaced in GITRδ2 mutant. Graphical representations of, (B) 
total neurite length and (C) total neurite branching of P1 SCG neurons transfected with GITRδ2 and 
grown overnight in 10ng/ml NGF. (D) Sholl profile of neurons transfected with GITRδ2 and grown 
overnight in 10ng/ml NGF. (E) Representative line drawings of P1 SCG neurons transfected with 
GITRδ2 and grown overnight in 10ng/ml NGF. Means ± standard errors of >150 neurons per 
condition are shown. Statistical comparisons: No significance difference compared to controls was 
found using an unpaired student t-test. Scale bar = 50µm.  
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Figure 5.13:  The growth promoting effects of GITR signalling are not affected by the inhibition 
of phosphorylation at Tyr190 and Ser199, (amino acids 12 and 21), sites of the GPD of GITR.  
P1 SCG neurons were transfected with a GFP plasmid (to visualise transfected neurites) together with 
GITRδ4 (mutant in which Tyr190 and Ser199, (amino acid 12 and 21) of the GPD were replaced with 
alanines) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in which 
P1 SCG neurons were transfected with control or empty plasmid. Axonal growth was analysed using 
Sholl analysis. (A) Primary structure of GPD of GITR in which a portion is replaced in GITRδ4 
mutant. Graphical representations of, (B) total neurite length and (C) total neurite branching of P1 
SCG neurons transfected with GITRδ4 and grown overnight in 10ng/ml NGF. (D) Sholl profile of 
neurons transfected with GITRδ4 and grown overnight in 10ng/ml NGF. (E) Representative line 
drawings of P1 SCG neurons transfected with GITRδ4 and grown overnight in 10ng/ml NGF. Means 
± standard errors of >150 neurons per condition are shown. Statistical comparisons: No significance 
difference compared to controls was found using an unpaired student t-test. Scale bar = 50µm.  
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Figure 5.14: Constitutive phosphorylation of residues at Tyr190 and Ser199, (amino acids 12 
and 21), sites of the GPD of GITR inhibits axonal growth.  P1 SCG neurons were transfected with 
a GFP plasmid (to visualise transfected neurites) together with GITRδ5 (mutant in which Tyr190 and 
Ser199, (amino acid 12 and 21) of the GPD were replaced with glutamic acid) and grown overnight in 
10ng/ml NGF at 37°C. Control cultures were also grown in which P1 SCG neurons were transfected 
with control or empty plasmid. Axonal growth was analysed using Sholl analysis. (A) Primary 
structure of GPD of GITR in which a portion is replaced in GITRδ5 mutant. Graphical representations 
of, (B) total neurite length and (C) total neurite branching of P1 SCG neurons transfected with 
GITRδ5 and grown overnight in 10ng/ml NGF. (D) Sholl profile of neurons transfected with GITRδ5 
and grown overnight in 10ng/ml NGF. (E) Representative line drawings of P1 SCG neurons 
transfected with GITRδ5 and grown overnight in 10ng/ml NGF. Means ± standard errors of >150 
neurons per condition are shown. Statistical comparisons: **P ≤ 0.01 and * P ≤ 0.05 compared to 
controls was found using an unpaired student t-test. Scale bar = 50µm.  
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Figure 5.15:  Schematic model showing GITRL-GITR binding and subsequent events during 
axonal growth in P1 mouse SCG neurons.  This schematic model shows the proposed subsequent 
events following GITRL-GITR binding in P1 SCG neurons. GITRL-GITR binding stimulates the 
GPD of GITR, located in the intracellular region of GITR. The growth promoting region of GITR is 
involved in the promotion of axonal growth of P1 SCG neurons in the presence of NGF. However, 
when residues Tyr190 and Ser199, (amino acid 12 and 21) sites of the GPD of the intracellular region 
of GITR are constitutively phosphorylated, there is a reduction in axonal growth in P1 SCG neurons.  
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5.5 Discussion 
GITR is the 18
th
 member of the TNFRSF and is well known for its role in the 
immune system in which it regulates innate and acquired immune response 
responses (Barao, 2012; Nocentini, et al., 1997; Ronchetti, et al., 2004). In the 
developing PNS the role of GITR is just beginning to be elucidated. GITR appears to 
function in a costimulatory manner with NGF to promote the growth of developing 
sympathetic neurons of the PNS (O'Keeffe, et al., 2008), however the way in which 
GITR promotes the growth of sympathetic neurons and the region responsible for the 
growth promoting effects of GITR was not yet fully known. Thus the aim of this 
chapter was to investigate whether GITRL-GITR signalling increased sympathetic 
neurons sensitivity to NGF thereby facilitating NGF-promotion of growth in these 
neurons and to identify the region of GITR responsible for its growth promoting 
effects in developing sympathetic neurons of the PNS.  
 We hypothesised that GITR, being a relative of the p75NTR, may increase a 
neuron’s sensitivity to a given concentration of NGF.  p75NTR is a member of the 
TNFRSF and increases the sensitivity of sensory and sympathetic neurons to NGF 
(Lee, et al., 1994b). This is shown by decreased sensitivity for embryonic DRG and 
postnatal SCG neurons to NGF in p75NTR deficient compared to wild type mice. 
There is a significant reduction in the % survival of postnatal SCG neurons from 
p75NTR deficient mice in a range of NGF concentrations compared with controls. 
The EC50 required for the survival of neurons was greater in p75NTR-deficient SCG 
neurons (150 pg/ml/0.15ng/ml) than for wild-type neurons (50 pg/ml/0.05ng/ml) (P 
≤ 0.05, t-test) (Lee, et al., 1994b). GITR is a member of the same family as p75NTR 
and therefore it is possible that GITRL-GITR signalling increases the sensitivity of 
sympathetic neurons to NGF, thereby facilitating NGF-promotion of growth.  To 
address this possibility, we first examined the % survival of P1 SCG neurons in a 
range of NGF concentrations after 1, 2 and 3 days as a baseline experiment. There 
was a dose response to NGF for the survival of neurons over the three days. This is 
in agreement with similar early studies on P1-3 rat sympathetic neurons derived from 
the SCG which demonstrated that in the absence of NGF, neurons do not survive 
past day one. When treated with a concentration of 0.5-1ng/ml NGF, P1-3 rat 
sympathetic neurons survived for up to 4 days. With an increase in NGF 
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concentration, there is an increase in cell survival but this effect reached saturation at 
0.5μg/ml. The lowest NGF concentration, capable of sustaining neuronal survival for 
3-4 weeks was found to be 10ng/ml (Chun and Patterson, 1977). This is the 
concentration of NGF used in the subsequent neuronal cultures in this study. 
Lockhart et al report findings that also reflect a similar dose response effect of NGF, 
although at lower dosages to the current study. Following testing 0; 0.5; 5; 50ng/ml, 
they reported that 5ng/ml was saturating for the survival of sympathetic neurons. 
However it must be noted that the form of NGF used in this study was a non-
recombinant form of NGF and as such would be less active that the form of NGF 
used in the current study (Lockhart, et al., 1997). 
 GITR promotes growth but not the survival of postnatal sympathetic neurons 
(O'Keeffe, et al., 2008) and therefore to investigate whether GITR affects the 
sensitivity of neurons to NGF, we examined the effect GITRL-GITR signalling on 
the growth of developing sympathetic neurons in a range of NGF concentrations.  
Growth of non-treated developing sympathetic neurons was dose responsive where 
growth increased with higher NGF concentrations (Figure 5.3). This result is in 
agreement with Chun and Patterson who also found a dose response in which 
neuronal growth increased with concentrations of NGF from 0.05-.5μg/ml (Chun 
and Patterson, 1977). Following on from these baseline experiments, we looked at 
the effect of stimulation or inhibition of GITRL-GITR signalling by treating neurons 
with agonist rmGITRL and antagonist GITRL-IgG antibodies grown in media 
containing 1, 4 and 10ng/ml NGF. Only cells grown in 1ng/ml NGF demonstrated a 
response to antagonist GITRL-IgG, in which there was a reduction in branching in 
treated P1 SCG neurons (**P ≤ 0.001) (Figure 5.4 B). Neurons displayed no 
response to treatment with agonist rmGITRL at any concentration of NGF (Result 
5.4, 5.5, 5.6). These results indicate that GITRL-GITR signalling may affect the 
sensitivity of SCG neurons to NGF at low levels of NGF as neutralising GITRL-
GITR signalling in SCG neurons treated with 1ng/ml NGF and not 10ng/ml reduced 
the branching of these neurons. p75NTR increases a neuron’s sensitivity to TrkA in 
the presence of 1ngml of NGF (Horton, et al., 1997) and does so via modulating 
NGF/TrkA binding (Barker and Shooter, 1994). Binding of NGF to TrkA is reduced 
by disrupting NGF/p75NTR binding in PC12 cells by an anti-p75NTR antibody or 
by excess BDNF (Barker and Shooter, 1994) while p75NTR accelerates TrkA 
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mediated signalling (Canossa, et al., 1996). Recently, the intracellular domain of 
p75NTR (p75ICD) was shown to interact with TrkA and modulate the binding of 
NGF to TrkA, significantly increasing the amount of NGF bound to TrkA-
expressing cells (Matusica, et al., 2013). Given that GITR is from the same super 
family, it may function similarly and the present results may indicate that GITR 
increases the sensitivity of these neurons to TrkA at low (1ngml) NGF 
concentrations (i.e. 1ng/ml). Repeating the above experiment on SCG cells from 
GITR-deficient mice in place of GITRL antibody treatments in a range of NGF 
concentrations would provide a more sensitive approach to investigating the effect of 
GITRL-GITR signalling on P1 SCG neurons to NGF.  
 In the immune system, “reverse” signalling through GITRL has been shown 
to occur in plasmacytoid DCs (pDCs) whereby GITRL-GITR signalling activates an 
intracellular signalling pathway, namely the NF-
through the GITR receptor (Grohmann, et al., 2007). To investigate if reverse 
GITRL-GITR signalling occurs in sympathetic neurons, P1 SCG neurons were 
of GITRL is missing). Transfected cells were unaffected in terms of growth (Figure 
5.7 E, F) suggesting one interpretation that GITRL-GITR signalling is not reversed 
and activation of intracellular pathways is through the receptor, GITR and not 
GITRL. To further investigate the presence of reverse signalling, staining for ligand 
(GITRL) and receptors (GITR) by immunocytochemistry and immunohistochemistry 
in the sympathetic cell bodies, postganglionic fibres and targets could be performed. 
Kisiswa et al 2013 found that tyrosine hydoxylase–positive sympathetic fibers of 
SCG target tissues (submandibular salivary gland, nasal turbinate tissue and iris), 
were clearly labeled by anti-TNFα (Ligand), but were not labeled by anti-TNFR1 
(receptor) suggesting the possibility that TNFR1 might act as a reverse-signaling 
ligand for TNFα. To examine the possibility that GITR reverse signaling might 
influence the growth of sympathetic axons, one of the methods employed by Kisiswa 
et al could be used. Kisiswa et al cultured P0 SCG neurons with NGF to sustain their 
survival with and without a divalent TNFR1 divalent TNFR1-Fc chimera (in which 
the extracellular domains of two TNFR1 molecules are linked to the Fc part of a 
human IgG1 antibody), shown to be a potent reverse-signaling ligand for TNFα, and 
grew cells for 24h. Sholl analysis revealed that the TNFR1-Fc chimera treated 
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neurons had significantly greater neurite length number of branch points and Sholl 
profiles that those grown with NGF alone. This result indicated that TNFa reverse 
signaling promotes sympathetic axon growth. 
 
The region of intracellular GITR responsible for the activation of intracellular 
pathways resulting in growth promoting effects in developing sympathetic neurons is 
not known. P1 SCG neurons were transfected with plasmids containing mutant 
versions of the intracellular region of GITR (GITRK, GITRZ and GITRW). Cells 
transfected with GITRW displayed a significant reduction in neurite length (***P ≤ 
0.001) (Figure 5.10 B) and branching (***P ≤ 0.001) (Figure 5.10 B, C) compared 
with controls. This was not seen in cells transfected with GITRZ (Figure 5.9 B, C). 
Cells transfected with GITRK demonstrated an increase in branching (*P ≤ 0.05). 
This is interesting and indicates that this region may be involved in the regulation of 
GITR promotion of growth as when it is deleted growth in terms of branching is 
enhanced. However, given the strength of significance in the reduction in length and 
branching (***P ≤ 0.001) in cells transfected with GITRW, results indicate that the 
region of GITR involved in NGF-promotion of developing sympathetic neuronal 
growth is located in the juxtamembrane region of the cytoplasmic or intracellular 
region of GITR (Figure 5.10 A), now termed the GPD of GITR. GITR, like other 
TNFRSF members, is a type I transmembrane protein consisting of a cytoplasmic, a 
transmembrane and an extracellular domain. Murine and human GITR genes 
comprise 5 exons (Nocentini, et al., 2000). The first 3 exons encode the extracellular 
domain; exon 4 encodes a small part of the extracellular domain, the transmembrane 
domain and part of the cytoplasmic domain while exon 5 encodes the cytoplasmic 
domain. mGITR is located on chromosome 4 and hGITR on chromosome 1 
(Gondek, et al., 2005; Nocentini, et al., 2000). The cytoplasmic domain of mGITR 
and hGITR is respectively 52 and 53 amino acid residues long, and shows a high 
degree of homology, in addition to function, with the cytoplasmic domains of OX40, 
4-1BB and CD27 which lead to the definition of a new sub family of the TNFRSF 
(Nocentini, et al., 2000). The homology covers two domains, domain 1, the sequence 
next to the –COOH terminus of the transmembrane region, and domain 2, close to 
the –COOH terminus of the proteins.  GITR binds TRAF proteins, including TRAF 
1, 2, 3 and 5, in order to activate subsequent intracellular pathways (Cohen, et al., 
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2010; Esparza and Arch, 2005a; Gurney, et al., 1999; Hauer, et al., 2005; Kwon, et 
al., 1999; Schaer, et al., 2012). The TRAF binding site of members of the TNFRSF 
is located in domain 2 (Park, et al., 1999), and is located outside the region of the 
GPD. The intracellular region and TRAF binding site of GITR outside the GPD was 
disrupted in cells transfected with GITRK and GITRZ in chapter 5.0 and these 
cells grew normally (Figure 5.8 and 5.9). This suggests that GITRL-GITR signalling 
in developing sympathetic neurons is TRAF independent. Perhaps different adapter 
molecules are involved in the GITRL-GITR signal transduction in sympathetic 
neurons. In NK cells of the immune system, differential regulation of the NK cell 
receptor 2B4 is mediated by different adaptor molecules in mice and humans 
(Lanier, 2005). In addition, differences in murine and human GITRL oligomerics 
(e.g., primarily dimers in mouse vs. trimers and superclusters in human) (Nocentini, 
et al., 2012) may contribute to different responses by the receptor-bearing cells.  
 
Basic residues conserved amongst the GITR sub family, possibly involved in 
protein-protein interactions were identified by Krausz et al and putative 
phosphorylation sites in the GPD of GITR were identified by In Silico analysis. 
Cys186-Glu189 (CPRE), (amino acids 8 to 11) are basic residues present in the GPD 
that are conserved among the "GITR sub family" of receptors (CD27, OX40, 4-1BB) 
(Krausz, et al., 2007) and are potentially involved in mediating protein-protein 
interactions  and / or the recruitment of specific kinases to Tyr190 and therefore 
possibly inhibit phosphorylation at this residue. The putative phosphorylation sites 
identified are Tyr190 and Ser199 (amino acid 12 and 21 of the GPD) (Figure 5.11). 
Mutant plasmids of conserved residues and putative phosphorylation sites were 
created and transfected into P1 SCG neurons (Figure 5.11, 5.12, 5.13, 5.14). 
Interestingly, only cells transfected with mutant GITR5, in which Tyr190 and 
Ser199 (amino acid 12 and 21 of the GPD) was replaced with glutamic acid, acting 
to constitutively phosphorylate these sites, showed a response. P1 SCG cells 
transfected with GITR5 displayed a significant decrease in neurite length (**P ≤ 
0.01) (Figure 5.14 B) and branching (*P ≤ 0.05) (Figure 5.14 C) compared to 
controls. Phosphorylation at these sites negatively influence the growth of these 
neurons suggesting (i) these residues maybe responsible for the regulation of GITR-
promoted growth of NGF-dependant neurons and (ii) another molecule / pathway 
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must be involved to allow for the growth promotion effects of GITR. As discussed 
earlier, the juxtamembrane region of p75NTR was recently found to be necessary for 
p75NTR to enhance TrkA mediated growth of sympathetic neurons (Matusica, et al., 
2013). Perhaps the juxtamembrane of GITR may be necessary for GITR-mediated 
growth by enhancement of TrkA and thus provide an alternate route to the TRAF 
dependant pathway in GITR signalling in NGF-dependant developing sympathetic 
neurons. These possibilities will be explored in chapter 6.0. 
 
Results from chapter 5.0 offer a greater depth of understanding of the mechanism of 
GITRL-GITR signalling in NGF-dependant sympathetic neurons of the developing 
PNS. In short, we have learned GITRL-GITR binding and activation is possible via 
the extracellular region of GITRL, however additional experiements to eliminate 
reverse signalling through GITRL needs to be investigated. The region and possible 
phosphorylation sites of GITR responsible for regulating the growth promoting 
effects of GITRL-GITR signalling exists in the juxtamembrane region of the 
receptor. The next step will be to further elucidate the intracellular pathways 
involved in GITRL-GITR signalling in the promotion of growth of developing NGF-
dependant sympathetic neurons of the PNS. 
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6.0 Dual-regulation of ERK and NF-B signalling by GITR in the 
regulation of axonal growth in developing sympathetic 
neurons. 
 
6.1 Aims  
 To investigate the effect of GITRL-GITR signalling on phospho-TrkA. 
 
 To examine the effect of GITRL-GITR signalling on NF-B activity. 
 
 To examine the effect of the GPD of GITR on ERK1/2 activity. 
 
 To examine the effect of the GPD of GITR on TrkA phosphorylation. 
 
 Investigate whether putative phosphorylation sites of the GPD are involved 
in GITRL-GITR regulation of NF-B, ERK1/2 and TrkA phosphorylation. 
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6.2 Abstract 
GITR is essential for NGF-dependant neurite growth in neonatal sympathetic 
neurons. However the signalling pathways downstream of GITR involved in the 
growth of these neurons are largely unknown. In the immune system, GITR regulates 
both NF-B and MAPK pathways. In the PNS, GITR is required for the activation of 
ERK1/2 of the MAPK pathway, which is necessary for NGF-promoted neurite 
growth of developing sympathetic neurons. In chapter 5.0 of this thesis, the region of 
GITR responsible for its growth promoting effects was found to be located in the 
juxtamembrane region of intracellular GITR and this region has been termed the 
growth promoting domain (GPD). Here we investigate the effect of GITRL-GITR 
signalling and the contribution of the GPD of GITR, on NF-B, ERK1/2 and TrkA 
activity. SCG neurons from P1 mice were transfected with plasmids expressing 
GITRL, IKKDN and mutated forms of GITR (GITRK, GITRZ, GITRW) and 
the effect on NF-B, ERK1/2 and TrkA signalling was examined. Activation of 
GITRL-GITR signalling inhibited NF-B and promoted the activation of ERK1/2 
signalling while inhibition of GITRL-GITR signalling increased NF-B dependant 
gene transcription and decreased ERK1/2 activation resulting in a reduction in 
neurite growth. In addition, SCG cells transfected with a GITR mutant in which 
phosphorylation of sites Thr190 and Ser199 (amino acid 12 and 21 of the GPD) were 
replaced with glutamic acid, resulted in a reduction of TrkA activity. These findings 
indicate that while TrkA is negatively affected by constitutive phosphorylation of 
specific GPD sites, GITRL-GITR signalling regulates the growth of NGF-dependant 
neonatal sympathetic neurons of the PNS via an inverse modulation of NF-B and 
ERK1/2 signalling providing an optimal growth environment for developing 
sympathetic neurons. 
 
6.3 Introduction 
GITR is a type 1 transmembrane protein and member of the TNFRSF. Although well 
characterised in the immune system for its role in innate and acquired immune 
responses (Krausz, et al., 2007), GITR also has an important role in the development 
of the PNS in which it facilitates NGF-promoted growth of neonatal sympathetic 
neurons in a costimulatory manner (O'Keeffe, et al., 2008).  
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 The exact mechanism by which GITR promotes NGF-dependant growth of 
sympathetic neurons is largely unknown. GITR has previously been shown to 
facilitate NGF-induced activation of ERK1/2 in the promotion of sympathetic 
neuronal growth, as there was a significant reduction in NGF-induced ERK1/2 
activation in sympathetic neurons of GITR-/- mice (O'Keeffe, et al., 2008). In 
addition, the growth promoting effects of enhanced GITR signalling in NGF-
dependant sympathetic neurons is achieved by facilitating NGF-induced ERK1/2 
phosphorylation, as a reduction in GITRL-GITR promoted growth was abolished 
when enhanced ERK1/2 phosphorylation was blocked with known MEK inhibitor 
U0126 (O'Keeffe, et al., 2008).  In the immune system, GITR potentiates the 
proliferative response of CD8+ and CD4+ T lymphocyte subpopulations when added 
with an anti-CD3 stimulus. This costimulation of GITR with anti-CD3 enhanced 
anti-CD3-induced ERK1/2 phosphorylation (Ronchetti, et al., 2004). This was 
demonstrated by higher levels of phosphorylated ERK1/2 following stimulation with 
anti-CD3 plus anti-GITR when compared with anti-CD3 alone. The increase in 
MAPK levels was observed in GITR+/+ but not in GITR–/– cells. The mechanism 
by which GITR facilitates ERK1/2 activation following costimulation with NGF or 
anti-CD3 is as yet unknown. As a member of TNFRSF, GITR may act in the same 
way as its fellow TNFRSF member p75NTR and promote NGF-dependant growth of 
neurons by interacting with the NGF receptor, TrkA and potentiate binding of NGF 
to TrkA, leading to increased neurite outgrowth in sympathetic neurons as a result of 
enhanced ERK1/2 signalling (Matusica, et al., 2013) .  
 In recent years, NF-B has been identified as a key regulator of sympathetic 
axonal growth (Gutierrez and Davies, 2011; Gutierrez, et al., 2008; Nolan, et al., 
2011). Basal levels of NF-B activity are found in neonatal sympathetic neurons 
(Gutierrez, et al., 2008; Nolan, et al., 2011) and when this activity is enhanced by 
transfecting cells with plasmids expressing IKKβ, p65, p65/p50, or by treatment with 
TNFα, this results in a significant inhibition in neonatal SCG neurite growth 
(Gutierrez, et al., 2008). This growth inhibitory effect of NF-B appears to be 
mediated via phosphorylation of p65 at serine 536 (Gutierrez, et al., 2008). 
Subsequently it was shown that there are factors present in SCG neurons and targets, 
such as IL-1 that can enhance NF-B activity resulting in the inhibition of neurite 
growth of these neurons (Nolan, et al., 2011). Data collected on NF-B in 
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developing sympathetic neurons to date suggests phospho-S536-p65 must be 
elevated above a certain threshold before it exerts a growth inhibitory effect. It is 
possible that GITR signalling is required to inhibit NF-B to “allow” axonal growth 
to occur. GITR has previously been shown to inhibit NF-B signalling via binding 
TRAF 2. HEK 293 cells transfected with a plasmid overexpressing TRAF 2 resulted 
in the inhibition of NF-B activity (Esparza and Arch, 2005b). Given the research to 
date, it is plausible that GITR facilitates NGF-promoted growth via promoting 
NGF/TrkA binding and ERK1/2 signalling in developing sympathetic neurons while 
dampening down the growth inhibitory effects of NF-B allowing for an optimal 
environment for axonal growth in these neurons. In this chapter, we aim to explore 
this possibility in P1 SCG neurons by activating or inhibiting GITRL-GITR activity 
using treatments, knock out models and transfection methods and examine the 
effects on TrkA, ERK1/2 and NF-B signalling.  
 
6.4 Results 
6.4.1 GITRL-GITR signalling does not affect phospho-TrkA in P1 mouse SCG 
neurons.  
p75NTR is a member of the same family as GITR (TNFRSF) and has previously 
been shown to enhance sympathetic neuron’s sensitivity to NGF at low (< 10ng/ml 
NGF) but not high (10ng/ml NGF) concentrations of NGF (Lee, et al., 1994b). 
Recently, p75NTR has been found to increase sympathetic neurons sensitivity to 
NGF by interacting with and potentiating binding of NGF to TrkA-expressing cells 
leading to increased neurite outgrowth in sympathetic neurons (Matusica, et al., 
2013). In chapter 5.0, inhibition of GITRL-GITR by antagonist GITRL-IgG resulted 
in a decrease in neurite branching in P1 SCG cells grown in 1ng/ml NGF but did not 
affect branching in cells grown in 4 or 10ng/ml NGF indicating that GITR may 
enhance sympathetic neurons sensitivity to NGF at <10ng/ml concentrations. To 
investigate if GITRL-GITR signalling affects TrkA signalling in neurons grown in 
1ng/ml NGF, P1 SCG neurons were treated with antagonist GITRL-IgG and grown 
overnight in media containing 1ng/ml NGF and the effect on the expression of 
phospho-TrkA was examined. Treatment of neurons with antagonist GITRL-IgG had 
no effect on phospho-TrkA levels of neurons as demonstrated by Figure 6.1 B in 
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which the levels of mean fluorescence of phospho-TrkA were not different to 
controls. This result is reflected in photomicrographs of phospho-TrkA in neurons 
(Figure 6.1 A). This result indicates that GITRL-GITR signalling may affect the 
growth of SCG neurons at low subsaturating levels of NGF. However, inhibition of 
GITRL-GITR signalling by antagonist GITRL-IgG appears to have no effect on 
phospho-TrkA signalling in these neurons grown in media containing 1ng/ml NGF. 
 
6.4.2 GITRL-GITR signalling regulates NF-B activity in P1 SCG neurons.  
GITR is known to activate or inhibit NF-B activity depending on the cellular 
context (Esparza and Arch, 2004; Esparza, et al., 2006), and NF-B has been 
implicated as a key regulator of axonal growth (Gutierrez and Davies, 2011; 
Gutierrez, et al., 2008). However the effect of GITRL-GITR signalling on NF-B 
activity in P1 SCG neurons has, to our knowledge, not been investigated. 
Overexpression of GITRL (Figure 6.2 A) and treatment with agonist GITRL-IgG 
(Figure 6.1 B) induced a reduction in NF-B activity as seen by a reduction in B-
reporter signal (Figure 6.2 A), phospho-IKK and phospho-p65 (Figure 6.2 B). 
Overexpression of GITRL caused a reduction (**P ≤ 0.01) in NF-B activity to the 
same extent as cells transfected with a mutated dominant negative IB (containing 
serine to alanine substitutions at residues 32 and 36, known to inhibit NF-B 
transcriptional activity (Roff, et al., 1996) (Figure 6.3 A). Conversely, when GITR is 
blocked using a function blocking antibody (GITR-IgG)(1ug/ml), there was a 
significant increase in NF-B activity (**P ≤ 0.01) (Figure 6.3 C). In addition, the 
expression of phospho-IKK and phospho-p65 was increased in GITR-/- SCG tissue 
compared to controls (Figure 6.3 D). To investigate the role of the GPD of GITR in 
the regulation of NF-B activity, cells were transfected with a mutant plasmid 
GITRW (in which the juxtamembrane region/GPD of GITR is missing) which 
resulted in an increase in NF-B activity (**P ≤ 0.01) (Figure 6.3 B). Together these 
results suggest GITRL-GITR signalling regulates NF-B activity in mouse P1 SCG 
neurons. 
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6.4.3 GITRL-GITR signalling regulates NF-B activity through the GPD of GITR 
in P1 SCG neurons.  
To investigate whether GITRL-GITR signalling regulates NF-B activity 
specifically through the GPD domain of GITR, P1 SCG cells were transfected with 3 
mutant plasmids of the intracellular region of GITR and the effect on nuclear NF-B 
activity, as assessed by levels of nuclear pSer536p65, was examined. Mutant 
plasmids included GITRK, GITRZ and GITRW. There was no change in NF-B 
activity in cells transfected with GITRK (in which the portion of the cytoplasmic 
region of GITR, EQTEEKCHLGGRWP, was missing) compared to non-transfected 
cells and control-transfected cells (Figure 6.4 B) which is reflected in 
photomicrographs of GITRK-transfected and control-transfected cells (Figure 6.4 
A). Similarly, cells transfected with GITRZ (in which the portion of the 
cytoplasmic region of GITR, AEDACSFQFPEEERGEQTEEKCHLGGRWP, was 
missing) displayed no change in nuclear NF-B activity compared to non-transfected 
and control-transfected cells (Figure 6.5 B). This result is also reflected in 
photomicrographs of GITRZ-transfected and control-transfected neurons (Figure 
6.5 A). However there was a significant increase in NF-B activity in cells 
transfected with GITRW (in which the GPD is missing) when compared to controls 
(***P ≤  0.001) and non-transfected cells (***P ≤  0.001) (Figure 6.6 C). The 
difference in nuclear NF-B activity in GITRW-transfected cells compared to 
control-transfected cells can be seen in photomicrographs (Figure 6.6 A) and at a 
higher magnification (Figure 6.6 B). Collectively, these results suggest that GITRL-
GITR signalling regulates NF-B activity via the GPD of GITR. 
 
6.4.4 Inhibition of IKK prevents the effects of GITR inhibition on growth in P1 
mouse SCG neurons.  
To determine if preventing enhanced NF-B activation could reverse the decrease in 
neurite growth following GITR inhibition, cells were co-transfected with plasmids 
expressing antisense GITR or GITRW (to inhibit GITRL-GITR signalling and 
induce a reduction in neurite growth) along with a K44A IKK dominant negative 
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(DN) plasmid (used because IKK is responsible for the growth inhibitory effects of 
NF-B in P1 SCG neurons (Gutierrez, et al., 2008)) and the effect on growth was 
determined. Cells transfected with antisense GITR or GITRW displayed the 
expected significant reduction in neurite length (** P ≤ 0.01) / (*** P ≤ 0.001) 
(Figure 6.7 A and 6.8 A) and branching (** P ≤ 0.001) / (*** P ≤  0.001) (Figure 6.7 
B and 6.8 B). However when antisense GITR or GITRW was co-transfected with 
IKKDN, cells displayed neurite length (Figure 6.7 A and 6.8 A) and branching 
(Figure 6.7 B and 6.8 B) comparable to control-transfected neurons. Growth profiles 
(Figure 6.7 C and 6.8 C) and representative line drawings (Figure 6.7 D and 6.8 D) 
of transfected neurons reflect these results. These results indicate that blocking NF-
B prevents the reduction in growth resulting from the inhibition of GITRL-GITR 
signalling and that the IKK-dependant NF-B activity is responsible for the 
inhibition of neurite growth resulting from endogenous GITR inhibition. 
 
6.4.5 P1 SCG cells overexpressing both GITRL and p65 demonstrate greater 
growth than cells expressing p65 alone however NF-B activity is comparable in 
these cells.  
P1 SCG cells transfected with plasmids overexpressing GITRL and p65 together 
exhibited significantly greater neurite length (*** P ≤ 0.001) (Figure 6.9 A) and 
branching (*** P ≤ 0.001) (Figure 6.9 B) compared to neurite length and branching 
in cells transfected with p65 alone. Cells transfected with GITRL alone displayed 
greater length (*** P ≤ 0.001) (Figure 6.9 A)  and branching (** P ≤ 0.01) (Figure 
6.9 B) compared to cells transfected with p65 and GITRL. Cells transfected with 
GITRL and p65 together displayed no difference in neurite length (Figure 6.9 A) or 
branching (Figure 6.9 B) when compared with control-transfected neurons. This is 
reflected in Sholl profiles (Figure 6.9 C) and representative line drawings (Figure 6.9 
D) of transfected neurons. Interestingly, when nuclear NF-B activity was assessed, 
by pSer536-p65 nuclear staining, cells transfected with both GITRL and p65 
together displayed significantly increased NF-B activity (*** P ≤ 0.001) compared 
to controls (Figure 6.10 B) to the same extent as those cells expressing p65 alone 
(*** P < 0.001) (Figure 6.10 B) (Figure 6.17 C). Given that the extent of growth in 
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transfected neurons does not correlate with extent of NF-B activity in these 
neurons, these results suggest GITR is initiating a second signal that opposes NF-B 
activity therby leading to NGF-promoted growth in these neurons. 
6.4.6 GITR regulates ERK1/2 phosphorylation via the GPD in P1 SCG neurons.  
The results in 6.4.5 suggest that GITR is initiating a second signal that opposes NF-
B activity leading to NGF-promoted growth in these neurons. GITR has been 
previously reported to facilitate NGF-induced ERK1/2 activation in the promotion of 
SCG neuronal growth (O'Keeffe, et al., 2008) and therefore ERK1/2 is a potential 
second signal. There is a reduction in phospho-ERK1/2 in cultured SCG neurons 
from GITR-/- compared to GITR+/+ mice (Figure 6.14 A). In addition, cells 
transfected with GITRW (plasmid in which the GPD of GITR is missing) displayed 
a significant reduction in phospho-ERK1/2 levels (*** P ≤ 0.001) (Figure 6.17 B) 
compared with non-transfected and control-transfected neurons. This result is 
represented by photomicrographs of GITRW and control-transfected neurons 
(Figure 6.17 A). This reduction in levels of phospho-ERK1/2 compared to non-
transfected and control-transfected neurons was not observed in cells transfected 
with GITRK (Figure 6.15 B) illustrated by photomicrographs of GITRK-
transfected and control-transfected neurons (Figure 6.15 A) or in cells transfected 
with GITRZ (Figure 6.16 B) reflected in photomicrograph images of GITRZ-
transfected and control-transfected neurons (Figure 6.16 A) (GITRK and GITRZ 
are plasmids in which regions of the cytoplasmic domain outside the GPD are 
missing (Figure 5.8 and Figure 5.9). These results indicate that the regulation of 
ERK1/2 by GITR is via the GPD of GITR. Indeed cells transfected with GITRL and 
p65 displayed a greater level of phospho-ERK1/2 activity compared to cells 
transfected with p65 alone (*** P ≤ 0.001) (Figure 6.18 D) and the same level of 
phospho-ERK1/2 as controls (Figure 6.18 A and D). When this is related to the 
effects on neurite length (Figure 6.9 A) (Figure 6.18 B) and branching (Figure 6.9 
B), it is clear that the extent of NGF-promoted growth was related to the level of 
phospho-ERK1/2 in these neurons which can in turn be modulated by altering NF-
B activity (Figure 6.19). 
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6.4.7  Putative phosphorylation sites of the GPD of GITR have no effect on 
phospho-p65 or phospho-ERK1/2 activity.  
The GPD of GITR regulates both phospho-p65 and phospho-ERK1/2 in neonatal 
sympathetic neurons (Figure 6.6 and 6.17). However the region of the GPD 
responsible for the inhibition/activation of these signalling pathways is unknown in 
neonatal sympathetic neurons. In Silico analysis identified putative phosphorylation 
sites in the GPD of GITR located at Thr190 and Ser199 (amino acid 12 and 21) of 
the GPD. In addition, there are basic residues, Cys186-Glu189 (CPRE) (amino acids 
8-11), present in the GPD that are conserved among the "GITR sub family" of 
receptors (CD27, OX40, 4-1BB) (Krausz, et al., 2007) and are potentially involved 
in mediating protein-protein interactions. Mutant plasmids were then created in 
which insertions replaced putative phosphorylation sites and conserved basic 
residues. Figure 5.11 C in chapter 5.0 illustrates schema describing mutants of 
putative phosphorylation sites and conserved basic residues of the GPD of GITR. In 
mutant GITRδ2, Cys186-Glu189 (CPRE), (amino acids 8 to 11), of the GPD were 
replaced with alanines which should inhibit the mediation of protein-protein 
interactions and / or the recruitment of specific kinases to Tyr190 and therefore 
inhibit phosphorylation at this residue. In mutant GITRδ4, Thr190 and Ser199, 
(amino acid 12 and 21 of the GPD), were replaced with alanines which should act to 
inhibit phosphorylation at these sites and in mutant GITRδ5, Thr190 and Ser199, 
(amino acid 12 and 21 of the GPD), were replaced with glutamic acid which should 
act to promote constitutive phosphorylation at these sites. P1 SCG cells were 
transfected with GITR2, GITR4 and GITR5 mutant plasmids and displayed no 
change in phospho-p65 levels compared to non transfected and control transfected 
neurons (Figure 6.11 B, Figure 6. 12 B and Figure 6.13 B). These results are 
represented by photomicrographs of transfected and control-transfected neurons 
(Figure 6.11 A, Figure 6.12 A and Figure 6.13 A). Similarly phospho-ERK1/2 levels 
in P1 SCG neurons were unchanged following transfection with GITR2, GITR4 
and GITR5 mutant plasmids when compared to non-transfected and control-
transfected neurons (Figure 6.20 B, Figure 6.21 B and Figure 6.22 B). Again, these 
results are reflected in photomicrographs of mutant-transfected and control-
transfected neurons (Figure 6.20 A, Figure 6.21 A and Figure 6.22 A). These 
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combined results indicate that GITRL-GITR regulation of NF-B and ERK does not 
involve the putative phosphorylation sites identified by In Silico analysis or the 
conserved basic residues of the GITR ‘sub family’ of receptors located in the GPD of 
GITR. 
 
6.4.8  Constitutive phosphorylation of residues at Thr190 and Ser199, (amino acids 
12 and 21 sites of the GPD) of GITR results in a reduction in TrkA expression.  
In chapter 5.0, we showed that constitutive phosphorylation at sites Thr190 and 
Ser199, (amino acids 12 and 21), sites of the GPD of GITR resulted in a significant 
reduction in growth of P1 SCG neurons (Figure 5.14). Given that phosphorylation at 
these sites had no effect on levels of phospho-p65 and phospho-ERK1/2 (Result 
6.4.7), we next investigated the effect of these sites on the levels of phospho-TrkA 
and TrkA. As already described, the TNFRSF member p75NTR increases 
sympathetic neurons sensitivity to NGF by interacting with and and potentiating 
binding of NGF to TrkA expressing cells leading to increased neurite outgrowth in 
sympathetic neurons (Matusica, et al., 2013). P1 SCG neurons were transfected with 
plasmids GITRW and GITR5 (transfection with both plasmids results in a 
reduction in growth in P1 SCG neurons) and the effect on the levels of both 
phospho-TrkA and TrkA was examined. TrkA is expressed in P1 SCG neurons as 
shown in Figure 6.24 and levels of TrkA (Figure 6.25 A and B)  but not phospho-
TrkA (Figure 6.23 A and B) are significantly reduced in P1 SCG neurons transfected 
with the GITR5 plasmid (** P ≤ 0.01) compared to non-transfected and control-
transfected neurons (Figure 6.24 B). However, TrkA levels are not significantly 
reduced in GITRW transfected cells (Figure 6.25 B). These results are reflected in 
photomicrograph images of GITR5 and GITRW-transfected and control-
transfected neurons (Figure 6.25 A).  
 Taken together these results indicate that GITRL-GITR signalling inhibits 
NF-Kb signalling and potentiates ERK1/2 signalling which is essential for NGF-
promoted neurite growth. In addition, phosphorylation of specific GPD residues 
negatively regulates P1 SCG TrkA expression and neuronal growth, in a manner 
independent of NF-B and ERK signalling. 
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Figure 6.1: GITRL-GITR signalling does not affect the phosphorylation of TrkA in P1 mouse 
SCG neurons.  P1 SCG cells were grown overnight in 1ng/ml NGF at 37°C in the presence or 
absence of antagonist GITRL-IgG (5g/ml). The following day, cultures were fixed and 
immunocytochemically stained for phospho-TrkA and analysis of mean fluorescence was performed. 
(A) Photomicrographs of control and GITRL-IgG treated P1 SCG dissociated cultures labelled for 
phospho-TrkA (red) and counterstained with -III tubulin (green). (B) Graphical representation of 
levels of phospho-TrkA in control and GITRL-IgG treated P1 SCG neurons. Means ± standard errors 
of 40-90 neurons per condition are shown. Statistical comparisons: No significant differences 
compared with control were found using an unpaired student t-test. Scale bar = 50µm.  
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Figure 6.2: Overexpression of GITRL inhibits NF-B activity in P1 mouse SCG neurons. P1 
SCG neurons were transfected with a RFP plasmid (to visualise transfected neurites) together with 
GITRL (to promote GITRL-GITR signalling) and B-GFP reporter (to measure NF-B dependant 
transcriptional activity) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also 
grown in which P1 SCG neurons were transfected with control or empty plasmid. (A) 
Photomicrographs of P1 SCG neurons transfected with control, GITRL and B-GFP reporter 
plasmids and grown overnight in 10ng/ml NGF. Scale bar = 50µm. (B) Representative Western blots 
showing levels of phospho-IKK, phospho-Ser536-p65 and -III Tubulin in protein extracts of P1 
mouse SCG neurons 24h after treatment with agonist GITRL-IgG (1g/ml) for 0 and 15 min (0’= 
untreated neurons).  
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Figure 6.3: GITRL-GITR signalling regulates NF-B-dependant transcriptional activity in P1 
mouse SCG neurons. P1 SCG neurons were transfected with a RFP and B-GFP reporter plasmids, 
together with a control, IB, GITRL, or GITRW expression plasmids or alternatively, neurons 
were treated with GITR-IgG (1g/ml) (function blocking antibody) and grown overnight in 10ng/ml 
NGF at 37°C. (A) Graphical representation of NF-B-dependant transcriptional activity in IB and 
GITRL transfected neurons and (B) GITRW transfected neurons compared to control transfected 
neurons. (C) Graphical representation of NF-B dependant-transcriptional activity in GITR-IgG 
treated neurons compared to controls. All data were obtained 24h after transfection and analysis of 
mean nuclear fluorescence intensity was performed. Means ± SEM of 50-90 neurons per condition 
shown. Statistical analysis: **P ≤ 0.01 compared with control, using unpaired student t-test and one 
way ANOVA and post-hoc Tukey’s. (D) Representative Western blots showing phospho-IKK, 
phospho-Ser536-p65 and -III Tubulin in GITR+/+ and GITR-/- P1 mouse SCG neurons grown for 
18h in 10ng/ml NGF.  
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Figure 6.4: GITRL-GITR signalling does not regulate NF-B activity in P1 mouse SCG neurons 
via the cytoplasmic region EQTEEKCHLGGRWP of GITR. P1 SCG neurons were transfected 
with a GFP plasmid (to visualise transfected neurons) together with GITRδK expression plasmid and 
grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in which P1 SCG 
neurons were transfected with control or empty plasmid. The following day, cultures were fixed and 
immunocytochemically stained for pSer536-p65 (phospho NF-B) and analysis of mean nuclear 
fluorescence was performed. (A) Photomicrographs of control and GITRK-transfected dissociated 
cultures of P1 SCG neurons labelled for phospho-NF-B (red) (B) Graphical representations of 
relevant differences in nuclear levels of phospho-NF-B in GITRK transfected, non-transfected and 
control-transfected P1 SCG neurons. Means ± standard errors of 40-90 neurons per condition are 
shown. Statistical comparisons compared with control: No significant differences were found using an 
unpaired student t-test. Scale bar = 50µm.  
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Figure 6.5: GITRL-GITR signalling does not regulate NF-B in P1 mouse SCG neurons via the 
cytoplasmic region AEDACSFQFPEEERGEQTEEKCHLGGRWP of GITR.  P1 SCG neurons 
were transfected with a GFP plasmid (to visualise transfected neurons) together with GITRδZ plasmid 
and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in which P1 SCG 
neurons were transfected with control or empty plasmid. The following day, cultures were fixed and 
immunocytochemically stained for pSer536-p65 (phospho-NF-B) and analysis of mean nuclear 
fluorescence was performed. (A) Photomicrographs of control and GITRZ-transfected dissociated 
cultures of P1 SCG neurons labelled for phospho-NF-B (red). (B) Graphical representations of 
relevant differences in nuclear levels of phospho-NF-B in GITRZ-transfected, non-transfected and 
control-transfected P1 SCG neurons. Means ± standard errors of 40-90 neurons per condition are 
shown. Statistical comparisons compared with control: No significant differences were found using an 
unpaired student t-test. Scale bar = 50µm.  
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Figure 6.6: GITRL-GITR signalling regulates NF-B in P1 mouse SCG neurons via the growth 
promoting domain of GITR. P1 SCG neurons were transfected with a GFP plasmid together with a 
control or GITRδW (in which the GPD of GITR, was missing) plasmid and grown overnight in 
10ng/ml NGF at 37°C. The following day, cultures were fixed and immunocytochemically stained for 
pSer536-p65 (phospho-NF-B) and analysis of mean nuclear fluorescence was performed. (A) 
Photomicrographs of control and GITRW-transfected dissociated cultures of P1 SCG neurons 
labelled for phospho-NF-B (red). (B) Photomicrographs of control and GITRW-transfected 
dissociated cultures of P1 SCG neurons labelled for nuclear stain DAPI (purple) and phospho-NF-B 
(red). (C) Graphical representations of relevant differences in nuclear levels of phospho-NF-B in 
GITRW-transfected, non-transfected and control-transfected P1 SCG neurons. Means ± standard 
errors of 40-90 neurons per condition are shown. Statistical comparisons compared with control: 
***P ≤ 0.001 using an unpaired student-test. Scale bar = 50µm. 
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Figure 6.7: Dominant negative IKK (IKKdn) prevents the growth inhibitory effects of 
antisense GITR on axonal growth. P1 SCG neurons were transfected with a GFP plasmid together 
with IKKdn and/or antisense GITR (to inhibit GITRL-GITR signalling and growth promotion in P1 
SCG neurons) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in 
which P1 SCG neurons were transfected with control plasmid. Axonal growth was analysed using 
Sholl analysis. (A, B) Graphical representations of, (A) total neurite length and (B) total neurite 
branching in P1 SCG neurons transfected with either IKKdn or antisense GITR or a combination of 
both and grown overnight in 10ng/ml NGF. (C) Sholl profiles of neurons transfected with either 
IKKdn or antisense GITR or a combination of both and grown overnight in 10ng/ml NGF. (E) 
Representative line drawings of P1 SCG neurons transfected with IKKdn, antisense GITR and both 
and grown overnight in 10ng/ml NGF. Means ± standard errors of >150 neurons per condition are 
shown. Statistical comparisons compared with control: **P ≤ 0.01 using one way ANOVA and post 
hoc Tukey’s test. Scale bar = 50µm. 
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Figure 6.8: IKKdn prevents the growth inhibitory effects of GITRδW on axonal growth in P1 
mouse SCG neurons. P1 SCG neurons were transfected with a GFP plasmid together with either 
IKKdn or GITRδW (lacking the GPD) and grown overnight in 10ng/ml NGF at 37°C. Control 
cultures were also grown in which P1 SCG neurons were transfected with control or empty plasmid. 
Axonal growth was analysed using Sholl analysis. (A, B) Graphical representations of, (A) total 
neurite length and (B) total neurite branching in P1 SCG neurons transfected with IKKdn, GITRδW 
and both and grown overnight in 10ng/ml NGF. (C) Sholl profiles of neurons transfected with either 
IKKdn or GITRδW or a combination of both and grown overnight in 10ng/ml NGF. (E) 
Representative line drawings of P1 SCG neurons transfected with either IKKdn or GITRδW or a 
combination of both and grown overnight in 10ng/ml NGF. Means ± standard errors of >150 neurons 
per condition are shown. Statistical comparisons compared with control: *** P ≤ 0.001 using one way 
ANOVA and post hoc Tukey’s test. Scale bar = 50µm.  
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Figure 6.9: P1 mouse SCG neurons expressing GITRL and p65 demonstrate greater growth 
compared to those expressing p65 alone and demonstrate reduced growth than those expressing 
GITRL alone. P1 SCG neurons were transfected with a GFP plasmid (to visualise transfected 
neurites) together with either GITRL overexpression plasmid or p65 overexpression plasmid or 
combination of both and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown 
in which P1 SCG neurons were transfected with control or empty plasmid. Axonal growth was 
analysed using Sholl analysis. (A, B) Graphical representations of, (A) total neurite length and (B) 
total neurite branching in P1 SCG neurons transfected with either GITRL or p65 or a combination of 
both and grown overnight in 10ng/ml NGF. (C) Sholl profiles of neurons transfected with either 
GITRL or p65 or a combination of both and grown overnight in 10ng/ml NGF. (D) Representative 
line drawings of P1 SCG neurons transfected with GITRL, p65 and both and grown overnight in 
10ng/ml NGF. Means ± standard errors of >150 neurons per condition are shown. Statistical 
comparisons: Statistical comparisons compared with control: *** P ≤ 0.001; ** P ≤ 0.01 using one 
way ANOVA and post hoc Tukey’s test. Scale bar = 50µm. 
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Figure 6.10: P1 mouse SCG neurons expressing GITRL and p65 display the same level of NF-
B activity as those expressing p65 alone.  P1 SCG neurons were transfected with a GFP plasmid 
together with either a control, GITRL and/or p65 expression plasmids and grown overnight in 
10ng/ml NGF at 37°C. The following day, cultures were fixed and immunocytochemically stained for 
pSer536-p65 (phospho-NF-B) and analysis of mean nuclear fluorescence was performed. (A) 
Photomicrographs of control GITRL, p65 and a combination of both GITRL and p65 transfected 
dissociated cultures of P1 SCG neurons labelled for phospho-NF-B (red). (B) Graphical 
representations of relevant differences in nuclear levels of phospho-NF-B in control, GITRL, p65 
and a combination of both GITRL and p65 transfected and non-transfected P1 SCG neurons. Means ± 
standard errors of >150 neurons per condition are shown. Statistical comparisons compared with 
control: *** P ≤ 0.001 using one way ANOVA and post hoc Tukey’s test. Scale bar = 50µm.  
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Figure 6.11: NF-B activity is not affected by the inhibition of phosphorylation at CPRE (amino 
acids 8 to 11 sites of the GPD) of GITR. P1 SCG neurons were transfected with a GFP plasmid (to 
visualise transfected neurites) together with GITRδ2 (mutant in which Cys186-Glu189, CPRE (amino 
acids 8 to 11 of the GPD) were replaced with alanines) and grown overnight in 10ng/ml NGF at 37°C. 
Control cultures were also grown in which P1 SCG neurons were transfected with control or empty 
plasmid. The following day, cultures were fixed and immunocytochemically stained for pSer536-p65 
(phospho-NF-B) and analysis of mean nuclear fluorescence was performed. (A) Photomicrographs 
of control and GITRδ2-transfected dissociated cultures of P1 SCG neurons labelled for phospho-NF-
B (red). (B) Graphical representations of relevant differences in nuclear levels of phospho-NF-B in 
control and GITRδ2-transfected and non-transfected P1 SCG neurons. Means ± standard errors of 
>150 neurons per condition are shown. Statistical comparisons compared with control: No significant 
differences were found using an unpaired student t-test. Scale bar = 50µm. 
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Figure 6.12: NF-B activity is not affected by the inhibition of phosphorylation at Thr190 and 
Ser199 (amino acids 12 and 21 sites of the GPD) of GITR. P1 SCG neurons were transfected with 
a GFP plasmid (to visualise transfected neurites) together with GITRδ4 (mutant in which Thr190 and 
Ser199, (amino acid 12 and 21 of the GPD) were replaced with alanines) and grown overnight in 
10ng/ml NGF at 37°C. Control cultures were also grown in which P1 SCG neurons were transfected 
with control or empty plasmid. The following day, cultures were fixed and immunocytochemically 
stained for pSer536-p65 (phospho-NF-B) and analysis of mean nuclear fluorescence was performed. 
(A) Photomicrographs of control and GITRδ4-transfected dissociated cultures of P1 SCG neurons 
labelled for phospho-NF-B (red). (B) Graphical representations of relevant differences in nuclear 
levels of phospho-NF-B in control and GITRδ4-transfected and non-transfected P1 SCG neurons. 
Means ± standard errors of >150 neurons per condition are shown. Statistical comparisons compared 
with control: No significant differences were found using an unpaired student t-test. Scale bar = 
50µm. 
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Figure 6.13: NF-B activity is not affected by the phosphorylation of residues at Thr190 and 
Ser199 (amino acids 12 and 21 sites of the GPD) of GITR. P1 SCG neurons were transfected with 
a GFP plasmid (to visualise transfected neurites) together with GITRδ5 (mutant in which Thr190 and 
Ser199, (amino acid 12 and 21 of the GPD) were replaced with glutamic acid) and grown overnight in 
10ng/ml NGF at 37°C. Control cultures were also grown in which P1 SCG neurons were transfected 
with control or empty plasmid. The following day, cultures were fixed and immunocytochemically 
stained for pSer536-p65 (phospho-NF-B) and analysis of mean nuclear fluorescence was performed. 
(A) Photomicrographs of control and GITRδ5-transfected dissociated cultures of P1 SCG neurons 
labelled for phospho-NF-B (red). (B) Graphical representations of relevant differences in nuclear 
levels of phospho-NF-B in control and GITRδ5-transfected and non-transfected P1 SCG neurons. 
Means ± standard errors of >150 neurons per condition are shown. Statistical comparisons compared 
with control: No significant differences were found using an unpaired student t-test. Scale bar = 
50µm. 
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Figure 6.14: GITRL-GITR signalling regulates ERK1/2 activity in P1 mouse SCG neurons. (A) 
Representative Western blots showing levels of phospho-ERK1/2 and -III Tubulin in protein extracts 
of GITR+/+ and GITR-/- P1 mouse SCG neurons grown for 18h in 10ng/ml NGF. 
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Figure 6.15: GITRL-GITR signalling does not regulate ERK1/2 phosphorylation in P1 mouse 
SCG neurons via the cytoplasmic region EQTEEKCHLGGRWP of GITR. P1 SCG neurons were 
transfected with a GFP plasmid (to visualise transfected neurites) together with GITRδK (in which the 
portion of the cytoplasmic region of GITR, EQTEEKCHLGGRWP, was missing) and grown 
overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in which P1 SCG neurons were 
transfected with control or empty plasmid. The following day, cultures were fixed and 
immunocytochemically stained for phospho-ERK1/2 and analysis of mean fluorescence was 
performed. (A) Photomicrographs of control and GITRδK-transfected dissociated cultures of P1 SCG 
neurons labelled for phospho-ERK1/2 (red). (B) Graphical representations of relevant differences in 
levels of phospho-ERK1/2 in control and GITRδK-transfected and non-transfected P1 SCG neurons. 
Means ± standard errors of >150 neurons per condition are shown. Statistical comparisons compared 
with control: No significant differences were found using an unpaired student t-test. Scale bar = 
50µm.  
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Figure 6.16: GITRL-GITR signalling does not regulate ERK1/2 phosphorylation in P1 mouse 
SCG neurons via the cytoplasmic region AEDACSFQFPEEERGEQTEEKCHLGGRWP of 
GITR. P1 SCG neurons were transfected with a GFP plasmid (to visualise transfected neurites) 
together with GITRδZ (in which the portion of the cytoplasmic region of GITR, 
AEDACSFQFPEEERGEQTEEKCHLGGRWP, was missing) and grown overnight in 10ng/ml NGF 
at 37°C. Control cultures were also grown in which P1 SCG neurons were transfected with control or 
empty plasmid. The following day, cultures were fixed and immunocytochemically stained for 
phospho-ERK1/2 and analysis of mean fluorescence was performed (A) Photomicrographs of control 
and GITRδZ-transfected dissociated cultures of P1 SCG neurons labelled for phospho-ERK1/2 (red). 
(B) Graphical representations of relevant differences in levels of phospho-ERK1/2 in control and 
GITRδZ-transfected and non-transfected P1 SCG neurons. Means ± standard errors of >150 neurons 
per condition are shown. Statistical comparisons compared with control: No significant differences 
were found using an unpaired student t-test. Scale bar = 50µm.  
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Figure 6.17: GITRL-GITR signalling regulates ERK1/2 phosphorylation in P1 mouse SCG 
neurons via the growth promoting domain of GITR. P1 SCG neurons were transfected with a GFP 
plasmid (to visualise transfected neurites) together with GITRδW (in which the GPD of GITR, was 
missing) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in which 
P1 SCG neurons were transfected with control or empty plasmid. The following day, cultures were 
fixed and immunocytochemically stained for phospho-ERK1/2 and analysis of mean fluorescence was 
performed. (A) Photomicrographs of control and GITRδW-transfected dissociated cultures of P1 SCG 
neurons labelled for phospho-ERK1/2 (red). (B) Graphical representations of relevant differences in 
levels of phospho-ERK1/2 in control and GITRδW-transfected and non-transfected P1 SCG neurons. 
Means ± standard errors of >150 neurons per condition are shown. Statistical comparisons compared 
with control: ***P ≤ 0.001 using an unpaired student t-test. Scale bar = 50µm.  
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Figure 6.18: GITRL-GITR signalling regulates ERK1/2 phosphorylation in P1 mouse SCG 
neurons via the growth promoting domain of GITR. P1 SCG neurons were transfected with a GFP 
plasmid (to visualise transfected neurites) together with GITRδW (in which the GPD of GITR, was 
missing) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in which 
P1 SCG neurons were transfected with control or empty plasmid. The following day, cultures were 
fixed and immunocytochemically stained for phospho-ERK1/2 and analysis of mean fluorescence was 
performed. (A) Photomicrographs of control and GITRδW-transfected dissociated cultures of P1 SCG 
neurons labelled for phospho-ERK1/2 (red). (B) Graphical representations of relevant differences in 
levels of phospho-ERK1/2 in control and GITRδW-transfected and non-transfected P1 SCG neurons. 
Means ± standard errors of >150 neurons per condition are shown. Statistical comparisons compared 
with control: ***P ≤ 0.001 using an unpaired student t-test. Scale bar = 50µm.  
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Figure 6.19: Schematic model showing proposed mechanism underlying the role of GITR in the 
promotion of axonal growth.  In P1 mouse SCG neurons receiving an adequate supply of NGF, 
ERK1/2 signalling is enhanced and NF-B signalling is inhibited, thus potentially providing an 
optimal cellular environment for axonal growth. 
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Figure 6.20: Phospho-ERK1/2 levels in P1 mouse SCG neurons are not affected by the 
inhibition of phosphorylation at CPRE (amino acids 8 to 11 sites of the GPD) of GITR. P1 SCG 
neurons were transfected with a GFP plasmid (to visualise transfected neurites) together with GITRδ2 
(mutant in which Cys186-Glu189, CPRE (amino acids 8 to 11 of the GPD) were replaced with 
alanines) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in which 
P1 SCG neurons were transfected with control or empty plasmid. The following day, cultures were 
fixed and immunocytochemically stained for phospho-ERK1/2 and analysis of mean fluorescence was 
performed. (A) Photomicrographs of control and GITRδ2-transfected dissociated cultures of P1 SCG 
neurons labelled for phospho-ERK1/2 (red). (B) Graphical representations of relevant differences in 
levels of phospho-ERK1/2 in control and GITRδ2-transfected and non-transfected P1 SCG neurons. 
Means ± standard errors of >150 neurons per condition are shown. Statistical comparisons compared 
with control: No significant differences were found using an unpaired student t-test. Scale bar = 
50µm.  
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Figure 6.21: Phospho-ERK1/2 levels in P1 mouse SCG neurons is not affected by the inhibition 
of phosphorylation at Thr190 and Ser199 (amino acids 12 and 21 sites of the GPD) of GITR. P1 
SCG neurons were transfected with a GFP plasmid (to visualise transfected neurites) together with 
GITRδ4 (mutant in which Thr190 and Ser199, (amino acid 12 and 21 of the GPD) were replaced with 
alanines) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in which 
P1 SCG neurons were transfected with control or empty plasmid. The following day, cultures were 
fixed and immunocytochemically stained for phospho-ERK1/2 and analysis of mean fluorescence was 
performed. Control cultures were also grown in which P1 SCG neurons were transfected with control 
or empty plasmid. (A) Photomicrographs of control and GITRδ4-transfected dissociated cultures of 
P1 SCG neurons labelled for phospho-ERK1/2 (red). (B) Graphical representations of relevant 
differences in levels of phospho-ERK1/2 in control and GITRδ4-transfected and non-transfected P1 
SCG neurons. Means ± standard errors of >150 neurons per condition are shown. Statistical 
comparisons compared with control: No significant differences were found using an unpaired student 
t-test. Scale bar = 50µm.  
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Figure 6.22: Phospho-ERK1/2 levels in P1 mouse SCG neurons is not affected by the 
phosphorylation of residues at Thr190 and Ser199 (amino acids 12 and 21 sites of the GPD) of 
GITR. P1 SCG neurons were transfected with a GFP plasmid (to visualise transfected neurites) 
together with GITRδ5 (mutant in which Thr190 and Ser199, (amino acid 12 and 21 of the GPD) were 
replaced with glutamic acid) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were 
also grown in which P1 SCG neurons were transfected with control or empty plasmid. The following 
day, cultures were fixed and immunocytochemically stained for phospho-ERK1/2 and analysis of 
mean fluorescence was performed. (A) Photomicrographs of control and GITRδ5-transfected 
dissociated cultures of P1 SCG neurons labelled for phospho-ERK1/2 (red). (B) Graphical 
representations of relevant differences in levels of phospho-ERK1/2 in control and GITRδ5-
transfected and non-transfected P1 SCG neurons. Means ± standard errors of >150 neurons per 
condition are shown. Statistical comparisons compared with control: No significant differences were 
found using an unpaired student t-test. Scale bar=50µm.  
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Figure 6.23: The levels of phospho-TrkA in P1 mouse SCG neurons are not affected by the 
constitutive phosphorylation of residues Thr190 and Ser199 (amino acids 12 and 21 sites of the 
GPD) of GITR. P1 SCG neurons were transfected with a GFP plasmid together with GITRδW or 
GITRδ5 (mutant in which Thr190 and Ser199, (amino acid 12 and 21 of the GPD) were replaced with 
glutamic acid) and grown overnight in 10ng/ml NGF at 37°C. Control cultures were also grown in 
which P1 SCG neurons were transfected with control or empty plasmid. The following day, cultures 
were fixed and immunocytochemically stained for phospho-TrkA and analysis of mean fluorescence 
was performed. (A) Photomicrographs of control, GITRδW and GITRδ5-transfected dissociated 
cultures of P1 SCG neurons labelled for phospho-TrkA (red). (B) Graphical representations of 
relevant differences in levels of phospho-TrkA in control, GITRδW and GITRδ5-transfected and non-
transfected P1 SCG neurons. Means ± standard errors of >150 neurons per condition are shown. 
Statistical comparisons compared with control: No significant differences were found using an 
unpaired student t-test. Scale bar = 50µm.  
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Figure 6.24: Expression of TrkA and GITR by P1 neonatal SCG neurons.  P1 SCG neurons were 
grown for 24h in 10ng/ml NGF. Cells were identified using Brightfield imaging (Upper left corner). 
Cells were fixed and immunocytochemically stained for TrkA and GITR. (A) TrkA (red) together 
with-III Tubulin (green) and counterstained with DAPI (blue) staining in P1 SCG neurons grown 
for 24h in 10ng/ml NGF. Scale bar 50µm. (B) GITR (red) and TrkA (green) staining in a 2m 
confocal optical slice through two P1 SCG neurons, grown for 24h in 10ng/ml NGF. Scale bar = 2µm.  
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Figure 6.25: TrkA expression in P1 mouse SCG neurons is reduced by constitutive 
phosphorylation of residues at Thr190 and Ser199 (amino acids 12 and 21 of the GPD) of GITR.  
P1 SCG neurons were transfected with a GFP plasmid (to visualise transfected neurites) together with 
GITRδW (in which the GPD of GITR, was missing) or GITRδ5 (mutant in which Thr190 and Ser199, 
(amino acid 12 and 21 of the GPD) were replaced with glutamic acid) and grown overnight in 
10ng/ml NGF at 37°C. Control cultures were also grown in which P1 SCG neurons were transfected 
with control or empty plasmid. The following day, cultures were fixed and immunocytochemically 
stained for TrkA and analysis of mean fluorescence was performed. (A) Photomicrographs of control, 
GITRδW and GITRδ5-transfected dissociated cultures of P1 SCG neurons labelled for TrkA (red). 
(B) Graphical representations of relevant differences in levels of TrkA in control, GITRδW and 
GITRδ5-transfected and non-transfected P1 SCG neurons. Means ± standard errors of >150 neurons 
per condition are shown. Statistical comparisons: **P ≤ 0.01 using one way ANOVA and post hoc 
Tukey’s test. Scale bar = 50µm. 
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Figure 6.26: Summary: Schema showing proposed dual mechanism underlying the role of 
GITR in the promotion of axonal growth. (A) In the presence of NGF, the GPD of GITR regulates 
axonal neurite growth of sympathetic neurons. GITR exhibits and a reciprocal modulation of ERK1/2 
and NF-B signalling where ERK1/2 signalling is enhanced and NF-B signalling is inhibited, 
providing an optimal cellular environment for axonal growth. Constitutive phosphorylation of specific 
GPD sites inhibit TrkA signalling, possibly acting as regulatory mechanism in GITRL-GITR 
promotion of NGF-mediated growth in developing sympathetic neurons.   
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6.5  Discussion 
NGF, essential for the growth of developing sympathetic neurons, mediates its action 
through receptors TrkA of the Trk family and p75NTR of the TNFRSF (Harrington 
and Ginty, 2013). Recently, it was discovered that p75NTR interacts with TrkA and 
potentiates NGF / TrkA binding to enhance axonal growth of postnatal sympathetic 
neurons (Matusica, et al., 2013). GITR, the 18th member of the TNFRSF, is a 
transmembrane glycoprotein present in many cells of the body and is activated by its 
specific ligand GITRL (Krausz, et al., 2007; Nocentini, et al., 1997). GITRL-GITR 
signalling is well known for its role in the immune system, where it regulates innate 
and acquired immune system responses through the activation and inhibition of 
intracellular pathways including NF-B and MAPK (Esparza and Arch, 2004; 
Esparza and Arch, 2005b; Esparza, et al., 2006; Ronchetti, et al., 2004). More 
recently, GITRL-GITR signalling was discovered to play a role in the development 
of the PNS where it is required for NGF-promotion of sympathetic neurite growth 
through activation of ERK1/2 of the MAPK pathway (O'Keeffe, et al., 2008). 
 
In chapter 5.0, the region of GITR responsible for its growth promoting effects in 
developing sympathetic neurons was identified and is located in the juxtamembrane 
region of the intracellular GITR. To further establish the molecular mechanisms 
behind GITR in promoting the growth of developing sympathetic neurons, this 
chapter aimed to examine the effect of the GPD of GITR on intracellular signalling 
pathways, including NF-B and ERK1/2.  
 
The enhancement of basal levels of NF-B, by factors such as TNF causes a 
reduction in neuronal growth in developing sympathetic neurons (Gutierrez, et al., 
2008; Nolan, et al., 2011). NF-B-mediated reduction in sympathetic neuronal 
growth is mediated through the canonical pathway in which activated IKK 
phosphorylates IB, leading to its ubiquitination and proteosome-mediated 
degradation, allowing the liberated p65/p50 dimer to translocate to the nucleus 
(Gutierrez, et al., 2008). Here, GITR and its specific ligand GITRL were found to be 
expressed in sympathetic neurons and stimulation or inhibition of GITRL-GITR 
signalling inhibited or activated NF-B activity respectively. GITR inhibited NF-B 
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allowing for normal sympathetic neurite growth which was demonstrated by 
alternative experiments where the reduction of neurite growth due to the inhibition of 
GITR was prevented when NF-B activity was inhibited. GITR inhibition of NF-B 
activity has been previously shown in the immune system (Esparza and Arch, 
2005b; Hauer, et al., 2005). In general, members of the TNFRSF such as GITR 
require TRAF molecules to activate or inhibit intracellular signalling pathways 
(Esparza and Arch, 2004; Esparza and Arch, 2005b; Hauer, et al., 2005). GITR 
inhibition of NF-B has been previously shown to involve the engagement of TRAF 
2 (Esparza and Arch, 2005b) and TRAF 3 (Hauer, et al., 2005). In this chapter, 
GITR inhibition of NF-B activity was mediated through the GPD of GITR. This 
was demonstrated by a significant increase in NF-B nuclear activity in cells 
transfected with a mutant plasmid in which the GPD of GITR was missing. 
However, GITR/TRAF binding sites are located outside the GPD of GITR (Krausz, 
et al., 2007). There was no effect on neurite growth or NF-B activity in cells 
transfected with mutant plasmids containing deletions of regions outside the GPD 
(GITRK and GITRZ plasmids) in this chapter. Deletions in these regions should 
have disrupted the TRAF binding sites of GITR. Therefore this suggests that GITR-
inhibition of NF-B in sympathetic neurons is TRAF-independent. The GPD is 
located in domain 1 of cytoplasmic GITR and TRAF binding sites are located in 
domain 2 (Krausz, et al., 2007). Working on the basis that GITR inhibits NF-B 
activity through domain 1 (the GPD), which does not contain the TRAF binding 
motif, perhaps it is possible that domain 1 modulates TRAF function indirectly 
(Krausz, et al., 2007). GITR does not bind TRAF 4 directly however it does activate 
NF-B signalling via TRAF 4. Esparza et al suggest that GITR activates NF-B 
signalling by modulating TRAF 4 activity by an adapter protein (Esparza and Arch, 
2005b).  Indeed another member of the TNFRSF, CD40, has previously been found 
to activate NF-B via a TRAF-independent mechanism. NF-B was activated in 
HEK293 cells transfected with CD40 mutants (in which TRAF binding was 
impaired) (Leo et al., 1999). Instead CD40 binds an adapter protein, MyD88, and 
indirectly mediates NF-B and ERK signalling pathways in these cells. Given that 
GITRL-GITR signalling regulates both NF-B and ERK signalling and this 
regulation appears to originate outside the TRAF-binding domain of GITR, it is 
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possible that GITR recruits an adapter protein to indirectly activate or inhibit these 
pathways. Further work to elucidate the full mechanism of GITR-mediated inhibition 
of NF-B activity is required. One way may be to scan for known adapter proteins 
used by TNFRSF (eg. MyD88) and examine the effect of transfection of GITRW 
on adapter proteins expression and subsequently, NF-B and ERK signalling by 
IHC, as used in the current study. 
 SCG cells transfected with GITRL and p65 together were larger than those 
transfected with p65 alone, however levels of nuclear NF-B activity was the same 
in cells expressing GITRL with p65 and p65 alone. This suggested that GITR is 
engaging a second signal that opposes NF-B growth-inhibitory effects allowing for 
NGF-promoted neurite growth. GITR has previously been shown to enhance 
ERK1/2 phosphorylation in cells of the immune system and the PNS (O'Keeffe, et 
al., 2008; Ronchetti, et al., 2004). In the SNS, GITR enhances NGF-activation of 
ERK1/2 resulting in neurite growth (O'Keeffe, et al., 2008). Here, we show GITR 
enhances ERK1/2 activation through the GPD of GITR. Interestingly, cells 
expressing GITRL and p65 had significantly higher and lower levels of phospho-
ERK1/2 respectively compared to controls while cells transfected with GITRL and 
p65 together had the same level of phospho-ERK1/2 as to controls. Once related to 
effects on neurite growth, it was clear that the extent of NGF-promoted neurite 
growth was related to the level of phospho-ERK1/2 which can in turn be modulated 
by NF-B signalling i.e. GITRL-GITR signalling exerted a reciprocal modulation of 
ERK1/2 and NF-B signalling which is essential for NGF promoted neurite growth.   
 GITR reciprocally modulates ERK1/2 and NF-B signalling for the 
promotion of neurite growth through the GPD of GITR. Putative phosphorylation 
sites in the GPD of GITR were identified by In Silico analysis as having the potential 
to activate or inhibit downstream pathways of GITR. However, cells transfected with 
mutant plasmids in which these sites were disrupted had no effect on NF-B or 
ERK1/2 signalling in sympathetic neurons. This indicates that these pathways are 
regulated by other unidentified sites in the GPD of GITR. Interestingly, cells 
transfected with a mutant plasmid in which two sites, Thr190 and Ser199, (amino 
acid 12 and 21 of the GPD) were constitutively phosphorylated resulted in a 
significant decrease in TrkA and not phospho-TrkA expression in neurons. Why 
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TrkA and not phospho-TrkA is affected in these transfected cells is not yet known. 
Perhaps this is due to timing. If we consider p75NTR as a model for GITR, the 
intracellular region of p75NTR induces a conformational change in TrkA prior to 
NGF binding (Esposito, et al., 2001; Matusica, et al., 2013) and this may be the case 
here. Cells transfected with the GITRW mutant exhibited a trend toward a decrease 
in TrkA expression in these neurons but this was not significant (Figure 6.25 B). 
Therefore from these results it cannot be concluded that removal of the GPD of 
GITR and constitutive phosphorylation and at the said sites reduced TrkA levels and 
subsequently neurite growth in these neurons. Constitutive phosphorylation mutation 
of Fas-associated death domain (FADD), an adaptor molecule for the TNFRSF and a 
distant relative of GITR, causes defective but not inhibition or absence of T cell 
proliferation (Osborn, et al., 2007). Constitutive phosphorylation mutation in the 
GPD of GITR results in defective neurite growth or growth inhibition. Given that 
constitutive phosphorylation at Thr190 and Ser199 reduced levels of TrkA, the high 
affinity receptor for NGF, regulation of phosphorylation at these sites of the GPD of 
GITR is important. Phosphorylation is regulated by phosphatases; such as dual 
specificity phosphatases (DUSPs) in the MAPK signal transduction pathway in 
which DUSPs dysphosphorylate both ERK 1 and 2 sites (Finch, et al., 2012). 
However, to our knowledge there are no known phosphatases or any other molecule 
that regulate the phosphorylation of Thr190 and Ser199 of the GPD of GITR in 
sympathetic neurons.   
 In summary, this chapter builds on chapter 5.0 which identified the growth 
promoting region of GITR for NGF-promoted neurite growth in sympathetic 
neurons. This chapter reveals that GITR promotes neurite growth through the GPD 
regulation of NF-B and ERK1/2 signalling pathway where GITR facilitates an 
inverse regulation of these pathways to provide an optimal growth environment for 
sympathetic neurons. Lastly, expression of NGF receptor TrkA is regulated by 
specific residues in the GPD and appears to have a growth inhibitory effect on the 
sympathetic neurons which may signify an unknown regulatory region of GITR 
whose function remains to be explored. 
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7.0  Heterogenous requirement for GITR in the regulation of 
peripheral target innervation of the sympathetic nervous 
system 
 
7.1 Aims 
 To determine the extent to which GITRL-GITR signalling regulates 
peripheral target innervation of the sympathetic nervous system 
 To investigate the changes in gene expression as a consequence of GITR 
signalling  
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7.2 Abstract 
There is a heterogenous requirement for NGF, whereby NGF is required in a non-
uniform manner, and NGF requirement differs depending on the target organ, in the 
promotion of growth and target innervation of sympathetic neurons of the PNS. 
GITR is crucial for NGF-promotion of growth and target innervation in the 
sympathetic nervous system. However this role of GITR has only been examined to 
date in postganglionic neurons of the SCG and their peripheral targets, namely the 
nasal mucosa and iris, of neonatal mice. To investigate the extent of the requirement 
for GITR in the regulation of NGF-promoted target innervation by other sympathetic 
neurons in the PNS, we examined neurite density and branching from P1 GITR-/- 
mice using whole mount immunohistochemistry for tyrosine hydroxylase (TH) as a 
way to identify sympathetic nerve terminals. These analyses revealed that there is a 
heterogenous requirement for GITR in the regulation of sympathetic innervation, 
GITR is required for NGF-promoted target innervation of the heart and bladder, but 
is not required for the normal innervation of the stomach, small intestine, trachea and 
urethra of P1 mice. In addition, we found that the expression of mRNAs encoding 
the pro-inflammatory cytokine TNF and insulin growth factor 1 receptor (IGF-
1R1) were upregulated in the SCG of GITR-/- mice compared to wildtype mice, 
possibly providing a link between GITR, inflammation and sympathetic neurite 
growth, in addition to identifying new molecules potentially involved in the 
regulation of neonatal neurite growth. 
 
7.3 Introduction 
NGF is required for the survival of sympathetic neurons in vivo (Angeletti and Levi-
Montalcini, 1971; Crowley, et al., 1994; Levi-Montalcini and Booker, 1960) and in 
vitro (Deshmukh and Johnson, 1997; Greene, 1977; Martin, et al., 1988). Past in 
vitro experiments have demonstrated the axonal growth promoting effects of NGF in 
sympathetic neurons (Atwal, et al., 2000; Cohen, et al., 1954; Deckwerth, et al., 
1996; Glebova and Ginty, 2004; Mains and Patterson, 1973). However the NGF 
requirement of sympathetic neurons for survival impeded efforts to examine the 
requirement for NGF in the promotion of axonal growth independent of its role in 
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survival in vivo. To circumvent the dramatic loss of sympathetic neurons seen in the 
NGF-/- mouse (Crowley, et al., 1994), Glebova and Ginty used concurrent 
elimination of pro-apoptotic family member, Bax, along with NGF, which allowed 
neurons to survive in the absence of NGF which then allowed them to investigate the 
effects of NGF deletion specifically on axonal growth. When the density of 
sympathetic innervation was examined in a variety of peripheral targets, it was found 
that sympathetic target innervation was absent in salivary glands and the eye; 
reduced in the heart and lungs; diminished in the spleen, stomach, small intestine, 
kidney, bladder and gonads, and unaffected in the trachea of neonatal Bax-/- NGF-/- 
mice (Glebova and Ginty, 2004). Collectively, and somewhat surprisingly, these 
results showed for the first time that there is a heterogenous requirement for NGF in 
the promotion of sympathetic neuron target innervation, despite its universal 
requirement for sympathetic neuronal survival, suggesting that other factors may be 
important for regulating target innervations. 
 Since 2004, additional factors have been shown to play a role in mediating 
axonal growth and target innervation of sympathetic neurons. NRP1, a receptor for 
guidance cues of the class 3 semaphorin (SEMA) family, have been shown to be 
expressed in sympathetic neurons and is involved in establishing normal target 
innervation of the heart and aorta in postnatal mice (Maden, et al., 2012). Wnt5a 
signalling, via the Ror receptor tyrosine kinase, derived from sympathetic neurons, 
and is required for target innervation in vivo. Deletion of Wnt5a results in 
sympathetic fibre extension and target field arborization deficits (Ryu, et al., 2013). 
Similarly, Egr3 is a NGF-induced transcriptional regulator, that is expressed within 
sympathetic neurons and is required for normal target innervations, as shown by 
target tissue abnormalities in  mice with sympathetic neuron-restricted Egr3 ablation 
(Quach, et al., 2013).  
It was previously shown that GITR and its ligand GITRL are co-expressed in 
neonatal sympathetic neurons and are required for in vivo growth and target 
innervation of mouse neonatal sympathetic neurons (O'Keeffe, et al., 2008). GITRL-
GITR signalling promotes the growth and target innervation of sympathetic neurons 
only in the presence of NGF, i.e. GITR acts as a costimulatory molecule to NGF in 
axonal growth and target innervation of sympathetic neurons (O'Keeffe, et al., 2008). 
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A role for GITRL-GITR signalling in NGF-promoted target innervation of 
sympathetic neurons has only been established in the nasal mucosa and the iris 
(O'Keeffe, et al., 2008). It is not yet known if the requirements of sympathetic 
neurons for GITRL-GITR signalling in mediating peripheral target innervation vary 
to the same extent as NGF (Glebova and Ginty, 2004). 
GITR is a relatively novel regulator of sympathetic neurite growth and changes in 
gene expression as a consequence of GITR signalling and how these changes affect 
neuronal growth is currently unknown. A number of factors inhibit neurite growth 
and include TNF (Gutierrez, et al., 2008; Neumann, et al., 2002), LIGHT 
(Gavalda, et al., 2009a) and RANKL (Gutierrez, et al., 2013). Treatment with TNF 
results in a significant inhibition of sympathetic neurite growth from neonatal mouse 
SCG neurons (Gutierrez, et al., 2008). The growth inhibitory effects induced by 
TNF are comparable to the growth inhibitory effects resulting from inhibition of 
GITRL-GITR signalling in neonatal mouse SCG neurons (Chapter 5.0 and 6.0). In 
this study we investigated the extent to which GITRL-GITR signalling is required 
for peripheral target innervation by symapthetic neurons in vivo. To do this, we used 
whole mount immunohistochemistry for TH on organs isolated from GITR-/- and 
GITR+/+ mice to identify sympathetic axons present in these targets.  In addition, 
using results from microarray studies performed in the lab, we also examined the 
expression of a number of mRNAs in SCG of GITR-/- and GITR+/+ mice using 
qualitative RT-PCR. 
 
7.4 Results 
7.4.1 TH is expressed by mouse SCG cells in vivo and in vitro 
In order to confirm in vivo expression of sympathetic neuronal marker TH in mouse 
SCG, P1 mice heads were fixed, transversely cryosectioned at a thickness of 15μm, 
and immunohistochemically stained for TH. Photomicrographs of TH-stained 
transverse section identifies the right and left SCG (white arrow) (Figure 7.1 A) 
located in close proximity to the common carotid artery (red arrow) (Figure 7.1 A). 
To confirm in vitro expression of TH, P1 SCG were removed, dissociated, plated in 
a defined media containing 10ng/ml NGF and grown overnight in 37°C. The 
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following day, cells were fixed and immunocytochemically stained for nuclear 
marker DAPI, neuronal marker -III tubulin and sympathetic neuronal marker TH 
(Figure 7.2 A). These results confirm TH expression in whole SCGs and dissociated 
cells from the SCG of P1 mice (Figure 7.1 A and 7.2 A). 
 
7.4.2 GITR is required for sympathetic NGF-target innervation of the heart and bladder of 
neonatal mice 
Previously it was found that organs of the peripheral nervous system have 
differential NGF requirements for target innervation (Glebova and Ginty, 2004). 
Since GITR is required for NGF-promoted growth of sympathetic neurons and target 
innervation of the nasal mucosa and iris, we investigated the extent of GITR 
requirement for target innervation in other peripheral target organs of the SNS. The 
extent of neurite density and branching was determined in the trachea, heart, 
stomach, small intestine, ureter and bladder of P1 GITR-/- mice using whole-mount 
DAB-TH immunostaining. Hearts from GITR-/- mice displayed a significant 
reduction in branching (** P<0.01) (Figure 7.4 C) but there was no reduction in 
neurite density (Figure 7.4 B) compared to heart from GITR+/+ mice. These results 
are reflected in whole mount images of the heart from GITR+/+ and GITR-/- mice 
(Figure 7.4 A). In addition, there was a significant reduction in sympathetic neurite 
density (** P<0.01) (Figure 7.8 B) and branching (* P<0.05) (Figure 7.8 C) in the 
bladder from P1 GITR-/- compared to GITR+/+ mice or controls. This reduction in 
both neurite density and branching is reflected in whole mount images of the bladder 
from GITR+/+ and GITR-/- mice (Figure 7.8 A). However, sympathetic neurite 
density or branching, in the trachea, stomach, small intestine and ureter was 
unaffected in GITR-/- mice compared to controls (Figure 7.3 B, C; Figure 7.5 B, C; 
Figure 7.6 B, C and 7.7 B, C). These results are represented by whole mount images 
of the trachea, stomach, small intestine and ureter from GITR +/+ and GITR-/- mice 
(Figure 7.3 A; Figure 7.5 A; Figure 7.6 A and 7.7 A). For a full table to compare 
target innervation of the trachea, heart, stomach, small intestine, ureters and bladder 
from GITR+/+ and GITR-/- mice, see table 7.1. 
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7.4.3 Inhibition of GITRL-GITR signalling resulted in an upregulation of TNF and IGF-
1R in P1 mouse SCG 
Neonatal SCG neurons treated with TNF display a significant reduction in neurite 
growth (Gutierrez, et al., 2008). Microarray studies performed on SCG tissue that 
was treated with 10ng/ml TNFidentified genes upregulated by treatment including 
IGF-1 and IGF-1R. Given that cells treated with TNF exhibit similar growth 
inhibitory effects as cells in which GITRL-GITR signalling is inhibited (Gutierrez, 
et al., 2008; O'Keeffe, et al., 2008), it is plausible that the same genes are affected by 
TNF treatment and GITRL-GITR inhibition. On this basis, we investigated 
changes, if any, in the expression of these genes in GITR-/- mice compared to 
GITR+/+ mice. Qualitative RT-PCR was performed on RNA extracted from 
neonatal GITR-/- and GITR+/+ SCG and expression of IGF-1, IGF-1R mRNAs was 
determined (Figure 7.9 A). In addition, the expression of cytokines IL-1, TNF-α 
and receptors IL-1R1, IL1R2, TNFR1, TNFR2 mRNAs was also examined, as 
cytokines have growth inhibitory effects in sympathetic neurons (Nolan, et al., 2011) 
(Figure 7.9 B). In chapter 5.0 and 6.0, constitutive phosphorylation of specific 
residues on the GITR GPD resulted in both a reduction in neurite growth and TrkA 
expression in P1 SCG neurons (Figure 5.14 and Figure 6.24) and therefore the 
expression of TrkA Mrna was also examined in P1 GITR-/- mice (Figure 7.9.C). RT-
PCR analysis revealed a qualitative upregulation of IGF-1R and TNFmRNAs in 
P1 SCG from GITR-/- mice compared to controls (Figure 7.9 A and B).  
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Figure 7.1: Expression of TH in the P1 neonatal SCG. P1 mice heads were fixed, cryoprotected 
and transversely cryosectioned at a thickness of 15μm. Sections were then stained for (A) TH (white 
arrow) located next to common carotid artery (red arrow). Photomicrographs display (R) right and (L) 
left SCG. Scale bar 50µm.  
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Figure 7.2: Expression of TH in cultured P1 neonatal SCG neurons. P1 SCG neurons were grown 
for 24h in 10ng/NGF. Cells identified by brightfield images (upper left). Cells were fixed and 
immunocytochemically stained for (A) neuronal marker DAPI (blue), -III Tubulin (green), TH (red) 
and counterstained with DAPI (blue). Scale bar 50µm.  
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Figure 7.3: Sympathetic innervation of the trachea is not affected in P1 GITR-/- mouse pups. 
(A) Representative images of P1 mouse trachea which was whole-mount DAB-TH immunostained 
showing the extent of innervation in GITR-/- compared to control GITR+/+ P1 mouse pups. (B) 
Quantification of nerve density using a modified line incept method to compare sympathetic 
innervation between GITR+/+ and GITR-/- P1 mouse pups. (C) Branching, where the number of 
bifurcations was measured in three randomly placed boxes of set size over the trachea micrographs, in 
GITR+/+ and GITR-/- P1 mouse pups. N = 3. Statistical comparisons: No statistical significant 
difference compared with controls was found using an unpaired student t-test Scale bar = 1mm. 
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Figure 7.4: Sympathetic branching within the heart is reduced in P1 GITR-/- mouse pups. (A) 
Representative images of P1 mouse heart which was whole-mount DAB-TH immunostained showing 
the extent of innervation of the heart in GITR-/- compared to control GITR+/+ P1 mouse pups. (B) 
Quantification of nerve density using a modified line incept method to compare sympathetic 
innervation of the heart between GITR+/+ and GITR-/- P1 mouse pups. (C) Branching, where the 
number of bifurcations was measured in three randomly placed boxes of set size over the heart 
micrographs, in GITR+/+ and GITR-/- P1 mouse pups. N = 3. Statistical comparisons: ** P<0.01 
compared with controls was found using an unpaired student t-test. Scale bar = 1mm.  
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Figure 7.5: Sympathetic innervation of the stomach is not affected in P1 GITR-/- mouse pups. 
(A) Representative images of P1 mouse stomach which was whole-mount DAB-TH immunostained 
showing the extent of innervation of the stomach in GITR-/- compared to control GITR+/+ P1 mouse 
pups. (B) Quantification of nerve density using a modified line incept method to compare sympathetic 
innervation of the stomach between GITR+/+ and GITR-/- P1 mouse pups. (C) Branching, where the 
number of bifurcations was measured in three randomly placed boxes of set size over the stomach 
micrographs of GITR+/+ and GITR-/- P1 mouse pups. N = 3. Statistical comparisons: No statistical 
significant difference compared with controls was found using an unpaired student t-test. Scale bar = 
1mm.  
 
 
 
 
 
 
 
150 
 
 
Figure 7.6: Sympathetic innervation of the small intestine is not affected in P1 GITR-/- mouse 
pups. (A) Representative images of P1 mouse small intestine which was whole-mount DAB-TH 
immunostained showing the extent of innervation of the small intestine in GITR-/- compared to 
control GITR+/+ P1 mouse pups. (B) Quantification of nerve density using a modified line incept 
method to compare sympathetic innervation of the small intestine between GITR+/+ and GITR-/- P1 
mouse pups. (C) Branching, where the number of bifurcations was measured in three randomly placed 
boxes of set size over the small intestine micrographs of GITR+/+ and GITR-/- P1 mouse pups. N = 
3. Statistical comparisons: No statistical significant difference compared with controls was found 
using an unpaired student t-test. Scale bar = 1mm. 
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Figure 7.7: Sympathetic innervation of the ureter is not affected in P1 GITR-/- mouse pups. (A) 
Representative images of P1 mouse ureter which was whole-mount DAB-TH immunostained 
showing the extent of innervation of the ureter in GITR-/- compared to control GITR+/+ P1 mouse 
pups. (B) Quantification of nerve density using a modified line incept method to compare sympathetic 
innervation of the small intestine between GITR+/+ and GITR-/- P1 mouse pups. (C) Branching, 
where the number of bifurcations was measured in three randomly placed boxes of set size over the 
ureter micrographs of GITR+/+ and GITR-/- P1 mouse pups. N = 3. Statistical comparisons: No 
statistical significant difference compared with controls was found using an unpaired student t-test. 
Scale bar = 1mm.  
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Figure 7.8: Sympathetic innervation density and branching within the bladder is reduced P1 
GITR-/- mouse pups. (A) Representative images of P1 mouse bladder which was whole-mount 
DAB-TH immunostained showing the extent of innervation of the bladder in GITR-/- compared to 
control GITR+/+ P1 mouse pups. (B) Quantification of nerve density using a modified line incept 
method to compare sympathetic innervation of the bladder between GITR+/+ and GITR-/- P1 mouse 
pups. (C) Branching, where the number of bifurcations was measured in three randomly placed boxes 
of set size over the bladder micrographs, in GITR+/+ and GITR-/- P1 mouse pups. N = 3. Statistical 
comparisons: ** P<0.01, * P<0.05, compared with controls was found by using an unpaired student t-
test. Scale bar = 1mm.  
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Figure 7.9: IGF-1R and TNF mRNAs are up-regulated in the absence of GITR in neonatal 
SCG neurons. (A, B, C) Expression of (A) IGF-1, IGF-1R, GAPDH (B) IL-1, TNFα, IL-1R1, 
IL1R2, TNFR1, TNFR2, GAPDH and (C) TrkA, GAPDH mRNAs in GITR+/+ and GITR-/- P1 
mouse SCG. Upregulation of IGF-1R (A) and TNFα (B) mRNA was evident following RT-PCR in 
GITR-/- P1 SCG neurons when compared to GITR+/+ P1 SCG neurons. PCR products of 210bp, 
345bp, 289bp, 367bp, 641bp, 530bp, 244bp, 264bp, 197bp, 388bp indicate IGF-1, IGF-R1, IL-1, 
TNF-α, IL-1R1, IL-1R2, TNFR1, TNFR2 and GAPDH expression, respectively.  
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Organs                              GITR-/-  
 Neurite density  Branching  
Trachea  -  -  
Heart  -       ** P<0.01  
Stomach  -  -  
Small Intestine  -  -  
Ureter  -  -  
Bladder       * P<0.05       ** P<0.01  
 
Table 7.1: Sympathetic neurite density and branching in GITR-/- organs. Table 7.1 summarises 
the extent of neurite density and branching in organs from P1 GITR-/- SV-129 neonates compared to 
GITR+/+ neonates. Organs include trachea, heart, stomach, small intestine, ureter and bladder. There 
was a significant reduction in branching in GITR-/- heart compared to GITR+/+ (** P<0.01), while 
neurite density and branching was significantly reduced in GITR-/- bladder compared to GITR+/+ (* 
P<0.05; ** P<0.01). (-) refers to no change compared to control or GITR+/+ neonates.  
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7.6 Discussion 
There is a heterogeneous in vivo requirement for NGF in peripheral target organ 
innervation of the PNS (Glebova and Ginty, 2004). GITR is required for NGF-
promoted growth and target innervation of developing sympathetic neurons 
(O'Keeffe, et al., 2008). However the requirement for GITR in regulating NGF-
dependent target innervation has only been established in target organs of the SCG, 
including the nasal mucosa and iris (O'Keeffe, et al., 2008). The requirement of 
GITR for NGF-promoted axonal growth and target innervation in target organs from 
other sympathetic ganglia has not been investigated.  
 
TH is expressed by sympathetic neurons and functions as a rate-limiting 
enzyme involved in catalyzing the biosynthesis of catecholamines such as dopamine, 
epinephrine and norepinephine (Levitt, et al., 1965). The growth promoting effects of 
NGF are accompanied by selective induction of TH, whereby NGF produces a 15-20 
fold increase in TH activity in SCG neurons from neonatal rats (Thoenen, et al., 
1971). In this chapter, TH has been selected as a marker of sympathetic neurite 
density and branching in neonatal sympathetic neurons. The expression of TH was 
confirmed in P1 mouse SCG and dissociated cultured SCG. As a confirmed marker 
of sympathetic neurons, TH staining was used in subsequent experiments examining 
the extent of sympathetic innervation in GITR-/- mice. Organs examined included 
the heart, in which target innervation is greatly reduced in the absence of NGF 
(Glebova and Ginty, 2004); the stomach, small intestine, ureter and bladder in which 
target innervation is diminished in the absence of NGF (Glebova and Ginty, 2004); 
and the trachea in which target innervation is unaffected in the absence of NGF 
(Glebova and Ginty, 2004). Here, we found that there was a significant decrease in 
innervation in terms of branching in the heart (Figure 7.3), in addition to a reduction 
in neurite density and branching in the bladder (Figure 7.8) of GITR-/- mice when 
compared to controls. These results suggest that sympathetic neurons requirements 
for GITRL-GITR signalling in target organ innervation corresponds to that of NGF 
in the trachea (Figure 7.3), heart and bladder (Figure 7.4 and 7.8). However this is 
not the case for the stomach, small intestine and ureters (Figure 7.5, 7.6 and 7.7). 
Glebova and Ginty report a pattern in which targets of paravertebral ganglia display 
156 
 
a greater reduction in sympathetic innervation than targets of prevertebral ganglia in 
the absence of NGF and suggest that targets of prevertebral ganglia may produce 
neurotrophic factors other than NGF, and as a result depend on these factors for full 
target innervation (Glebova and Ginty, 2004). This is supported by a study that 
found postganglionic neurons arising from prevertebral ganglia express TrkB to a 
greater extent than neurons from paravertebral ganglia (Dixon and McKinnon, 1994) 
implying that targets from prevertebral ganglia require neurotrophins BDNF and/or 
NT-4 for correct innervation. It could be argued that the reduction of innervation 
density in some targets and not others may be due to a down regulation of TH in 
innervating neurons. This was addressed by O’Keeffe et al in which levels of TH 
mRNA and TH immunofluorescence were quantified in the SCG of GITR+/+ and 
GITR-/- mice. There was no significant difference in the levels of TH mRNA or TH 
immunofluorescence in SCG of GITR-/- mice compared to controls indicating that 
the reduction in TH staining in the sympathetic targets of GITR-null mice is the 
result of a reduction in the number of sympathetic axons and not down regulation of 
TH in these targets (O'Keeffe, et al., 2008). On this basis, it was presumed that the 
reduction in target innervation in the heart and bladder of GITR-/- mice is due only 
to the decrease in number of axons innervating sympathetic targets. 
 
A number of additional factors have recently been implicated in sympathetic 
target innervation. Egr3 is a NGF-induced transcriptional regulator expressed by 
sympathetic neurons and is required for normal sympathetic target innervation as 
demonstrated by target tissue innervation abnormalities and physiologic sympathetic 
dysfunction, similar to humans with dysautonomia in mice lacking Egr3 (Eldredge, 
et al., 2008; Li, et al., 2011; Quach, et al., 2013). Like NGF and GITR, Egr3 affects 
target tissue innervation heterogeneously. In some tissues, such as salivary glands, 
heart, spleen, bowel, kidney, pineal gland and the eye, Egr3 is essential for normal 
innervation, whereas in other tissues such as lung, stomach, pancreas and liver, Egr3 
appears to have little role in innervation (Li, et al., 2011). NGF is expressed 
normally in the submandibular gland and the heart in the absence of Egr3 (Li, et al., 
2011) indicating that abnormal target tissue innervation is not due to dysregulation 
of NGF in these target tissues. Glebova and Ginty found that NGF is required for 
target innervation of these organs (Glebova and Ginty, 2004). Combined studies 
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suggest Egr3 is just one of a number of effectors of NGF signalling and therefore 
could have a relatively restricted function in a sub-population of NGF-dependent 
neurons. Previous studies show that Egr3 is regulated by NGF signalling in 
sympathetic neurons; therefore it is possible Egr3 modulates gene expression 
required for at least some aspects of NGF-mediated sympathetic terminal axon 
extension and target tissue innervation (Eldredge, et al., 2008). Similiarly, GITRL-
GITR signalling appears to modulate NGF-dependant sympathetic target innervation 
in a non uniform manner. This is demonstrated by a requirement for NGF for the 
innervation of salivary glands, iris, heart, stomach, small intestine, ureters and 
bladder (Glebova and Ginty, 2004), whereas GITR is required for NGF-promoted 
innervation of iris (O'Keeffe, et al., 2008), heart and bladder (shown in the present 
study). 
 
Using RT-PCR, we found that knocking out GITR resulted in an increase in 
TNF mRNA expression in SCG neurons. Treatment of neonatal SCG neurons with 
TNF also results in the inhibition of neurite growth in these neurons (Gutierrez, et 
al., 2008). Increased production of pro-inflammatory cytokines including TNF can 
be due to increased immune activation such as in maternal inflammation (Cai, et al., 
2000; Liverman, et al., 2006) and may contribute to the development of neurological 
diseases such as cerebral palsy (Nelson and Willoughby, 2000). Exposure to pro-
inflammatory cytokine IL-1 impairs neural progenitor cell proliferation and alters 
their differentiation. In addition, IL-1 inhibits developing sympathetic neuron 
axonal growth (Nolan, et al., 2011). TNF-α is considered a potent cytotoxic agent in 
neuronal tissue (Botchkina, et al., 1999) and its application results in a significant 
inhibition of sympathetic neuronal growth in the developing PNS (Gutierrez, et al., 
2008). Given that inhibition of GITR increased TNF levels as shown in the present 
study and both inhibition of GITR and increased levels of TNF result in the 
inhibition of neurite growth in addition to effects of maternal inflammation, it is 
possible that GITR knock null mutants could be a possible future model of 
inflammation in neonatal mice. However TNF is only one cytokine and to establish 
the possibility of GITR knock down as a model of maternal inflammation, the effect 
of GITR on other cytokines including IL-1 and receptors needs to be undertaken. 
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The specific target genes regulated by GITRL-GITR signalling during NGF-induced 
axonal growth and target tissue innervation in sympathetic tissue are currently 
unknown. To investigate specific target genes regulated by GITR we used an 
alternative approach. Inhibition of GITRL-GITR signalling results in the inhibition 
of neurite growth in P1 SCG neurons that mirrors the inhibition of neurite growth in 
P1 SCG neurons treated with TNF (Gutierrez, et al., 2008). It could be postulated 
that the inhibition of GITR results in an inhibition of neurite growth by and increase 
in TNF. This could be investigated by transfecting neurons with GITRW plasmid 
(where the GPD is deleted) and examining the effect on growth by sholl analysis and 
expression of TNFa by IHC and densitometric analysis.   
 
Using mRNA extracted from TNF treated SCG cells; a microarray analysis 
was performed to identify changes in gene expression in TNF-treated compared 
with control-treated tissue. Microarray analysis identified two genes that were 
upregulated in response to treatment, Insulin-like growth factor 1 (IGF-1) and 
receptor IGF-1R. RT-PCR, performed to examine the expression of these genes in 
GITR-/- SCG, demonstrated an increase in IGF-1R expression in GITR-/- SCG 
compared with control. IGF-1 and IGF-1R are members of the IGF family of 
proteins and play an important role in the regulation of systemic growth (Liu, et al., 
1993). Interestingly, disruption to IGF1-R gene has more severe consequences than 
that of IGF-1 gene, resulting in invariable death at birth due to respiratory failure, 
more severe growth deficiency, muscle hypoplasia, developmental delays in 
ossification and CNS abnormalities (Liu, et al., 1993). This is similar to disruption of 
NGF versus receptor TrkA, where consequences of TrkA gene disruption are of 
greater severity that those resulting from NGF gene disruption and is highlighted by 
symptoms of HSAN IV versus HSAN V neuropathies (Indo, et al., 1996). Both IGF-
1 and IGF-1R are expressed in SCG neurons of rat (Bitar, et al., 1997) and has IGF-
1 been shown to enhance neurite outgrowth in cultured sympathetic neuroblasts but 
not postnatal sympathetic neurons (DiCicco-Bloom and Black, 1988). In the present 
study, there is an increase in the expression of IGF-1R mRNA when GITR is 
inhibited. GITR inhibition results in a reduction in neurite growth, therefore the 
question stands, given the role of IGF-1R in the enhancement of growth why would 
its expression be increased in a model of growth inhibition (i.e. GITR-/-)? In a recent 
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model of maternal diabetes, there is a significant upregulation of IGF-1R, as seen by 
real time RT-PCR, in the cerebellum of rat pups born to diabetic mothers at P0 
compared to controls (Haghir, et al., 2013). If we imagine maternal diabetes and 
GITR inhibition as the insult and inhibition of growth as the effect, then perhaps 
IGF-1R is responding to the insult in an effort to control the negative growth 
inhibitory effect and therefore the consequences of changes in IGF-1R levels in 
GITR knock down SCG tissue may be compensatory for growth inhibition.  In the 
same study, there was a marked reduction in cerebellar expression of IGF-1R mRNA 
in the diabetic group of neonates by P7. Given that levels of GITR mRNA peak in 
the SCG between P1-3, it is plausible that there would be reduction in IGF-1R levels 
in SCG from P7 GITR-/- mice also. However, further work is required to investigate 
the relationship between GITR and IGF-1R further.  
 
In summary, this chapter reveals a heterogenous requirement for GITR in 
NGF-promoted sympathetic target innervation in the PNS. In addition, GITR 
inhibition results in an upregulation of TNF, providing food for thought regarding 
GITR as a novel model of inflammation while IGF-1R may act as a regulatory 
molecule in the control of neonatal neuronal growth.  
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8.0 Final Discussion 
The correct development of the SNS is crucial for optimal functioning of body 
organs. Abnormal development of the SNS and its manifestations is highlighted by 
HSAN IV (Indo, et al., 1996). An autosomal recessive disorder, HSAN IV is 
predominantly characterised by congenital insensitivity to pain with anhidrosis and 
results from mutations in the TrkA gene, which encodes for TrkA, the high affinity 
receptor for NGF (Indo, et al., 1996). NGF binds two receptors TrkA of the Trk 
family and p75NTR of the TNFRSF, of which p75NTR increases the sensitivity of 
sympathetic neurons to NGF (Lee, et al., 1994b) and can do so by modulating NGF-
TrkA binding (Matusica, et al., 2013). NGF-TrkA binding is essential for the 
survival, axonal growth and target innervation of developing sympathetic neurons 
(Glebova and Ginty, 2004; Kuruvilla, et al., 2004; Levi-Montalcini, 1987).   
GITR is a member of the TNFRSF and has an established role in the immune 
system where it regulates innate and acquired immune responses (Nocentini, et al., 
1997). However, it is now known that GITR plays an important role in SNS 
development in which it is required for NGF-induced ERK1/2 activation resulting in 
the promotion of growth and target innervation of developing sympathetic neurons 
(O'Keeffe, et al., 2008). This is a novel finding and little is known regarding the 
molecular mechanism behind GITR-promotion of growth in developing sympathetic 
neurons. Postganglionic sympathetic neurons of the SCG, are an extensively used, 
experimentally tractable model to study axonal growth and target innervation of 
sympathetic neurons (Gutierrez, et al., 2008; Nolan, et al., 2011; O'Keeffe, et al., 
2008; Vizard, et al., 2008). This project uses postganglionic sympathetic neurons of 
P1 mouse SCG to study the molecular basis of GITR in axonal growth and target 
innervation of sympathetic neurons.  
Prior to this project, it was not known how GITR promoted the growth and 
target innervation of NGF-dependant sympathetic neurons. One hypothesis was that 
it did so by increasing neurons sensitivity to NGF, similar to its TNFRSF member 
p75NTR (Lee, et al., 1994b). Chapter 5.0 results indicate that GITR signalling may 
affects the sensitivity of SCG neurons to NGF at concentrations of 1ng/ml NGF. 
Recently, a mechanism by which p75NTR increases sympathetic neuron’s sensitivity 
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was put forward. By interaction of the intracellular domain of p75NTR (p75ICD) 
with TrkA, the binding of NGF to TrkA was modulated, significantly increasing the 
amount of NGF bound to TrkA-expressing cells (Matusica, et al., 2013). Indeed it 
may be possible that GITR interacts with p75NTR directly where p75NTR 
subsequently increases sympathetic neurons sensitivity to TrkA. This study went on 
to examine the effect of GITR, and specifically the intracellular region of GITR, on 
TrkA expression in sympathetic neurons. In Chapter 6.0, the effect on TrkA 
expression in P1 SCG neurons transfected with a mutant plasmid in which almost the 
entire intracellular region was missing (GITRW) was examined. There was no 
significant reduction in TrkA expression in these neurons. A supporting result is 
found in chapter 7.0, in which there is no difference in mRNA expression for TrkA 
in GITR-/- compared to GITR+/+.  However, when TrkA expression was examined 
in neurons transfected with GITR5, in which sites of the juxtamembrane 
intracellular region, Tyr190 and Ser199 (amino acids 12 and 21), were constitutively 
phosphorylated, there was a significant reduction in TrkA expression. Indeed, in 
chapter 5.0, there was a reduction in neurite length and branching in cells transfected 
with GITR5. Given these results and previous findings mentioned, it may be 
possibly that constitutive phosphorylation at these sites in the GPD of GITR affects 
TrkA, possible by reducing cell-TrkA expression, resulting in fewer available 
binding sites for NGF and subsequently reducing NGF binding to TrkA, thereby 
decreasing the TrkA expressing cells’ sensitivity to NGF. It would be interesting to 
see the effect of inhibiting phosphorylation at these same sites, Tyr190 and Ser199, 
on TrkA expression using mutant plasmid GITR4. This was not indicated earlier as 
cells transfected with GITR4 showed no significant reduction in sympathetic 
neuronal growth. Given antagonist GITRL treatment was effective reducing 
sympathetic neuronal growth at concentration of 1ng/ml NGF as seen in chapter 5.0, 
it would be interesting to look the effects of these discussed plasmids on TrkA 
expression in media containing 1ng/ml NGF. In addition, it would be very 
interesting to investigate the interaction of GITR and p75NTR by first assessing for 
co-expression of both receptors and subsequently the effect of GITRW and GITR5 
on the expression of p75NTR by means of transfection, immunocytochemistry and 
densitometry. These experiments may provide answers to the question of why 
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constitutive phosphorylation of sites in the GPD of GITR reduces TrkA expression. 
Perhaps GITR regulates TrkA expression indirectly, via p75NTR.  
Although, it was previously known that GITR is crucial for NGF-promoted 
growth in SCG neurons, the region of GITR responsible for these effects was 
unknown. Chapter 5.0 results indicates that GITRL-GITR signalling may be via the 
GITR receptor and not the ligand. This direction of signalling is in contrast to that of 
‘reversed’ signalling reported in the immune system (Grohmann, et al., 2007). To 
confirm GITRL-GITR signalling is forward and not reversed as is the case in the 
immune system, one could examine the the effect of a Fc-chimera reversed 
signalling molecule, similar to that used by Kisiswa et al (Kisiswa, et al., 2013) on 
the growth of sympathetic neurons. Next it was found that the GITR receptor exerts 
growth promoting effects via the juxtamembrane intracellular region, the GPD, of 
GITR. These data were accomplished by transfection experiments using mutant 
plasmids containing deletions of the ligand and receptor’s intracellular domains. In 
further analysis of the intracellular region and subsequent intracellular signalling, it 
was demonstrated that the GPD of GITR activates ERK1/2 and inhibits NF-B 
signalling in an inverse fashion to allow for optimal growth of neurons. While GITR 
has previously been found to facilitate NGF-induced ERK1/2 activation in 
sympathetic neurons (O'Keeffe, et al., 2008), it was unknown as to the effects of 
GITR on NF-B in sympathetic neurons. In the immune system, GITR inhibition of 
NF-B has been previously shown to involve the engagement of TRAF 2 (Esparza 
and Arch, 2005b) and TRAF 3 (Hauer, et al., 2005). However, the location of the 
TRAF binding site in the GITR receptor is outside the GPD suggesting GITR 
inhibition of NF-B is TRAF independent. Given that it has been previously shown 
that members of the TNFRSF can activate intracellular signalling pathways, such as 
NF-kB and ERK (Leo, et al., 1999), via adapter proteins, perhaps it is possible that 
GITR similiarly inhibits and activates these pathways via adapter proteins. Further 
work to ascertain the precise mechanism for GITR-mediated inhibition of NF-B 
may involve screening for known adapter proteins that interact with members of the 
TNFRSF; investigate the expression of these proteins in P1 SCG neurons; examine 
the effect of transfecting plasmid GITRW on the expression of proteins in P1 SCG 
163 
 
neurons and if indicated the effect of transfecting mutant plasmids of adapter 
proteins (affected by GITRW) on NF-B and ERK signalling by IHC.  
It has been reported that TNF treatment of sympathetic neurons results in 
the inhibition of NF-B signalling (Gutierrez, et al., 2008) and subsequent reduction 
in sympathetic neurite growth (Gutierrez, et al., 2008). The reduction in neurite 
growth displayed in cells treated with TNF is comparable to the reduction in 
growth exhibited by cells where GITRL-GITR signalling is inhibited as shown in the 
present results. In chapter 7.0, TNF mRNA levels were higher in GITR-/- 
compared with GITR+/+ SCG tissue as shown by RT-PCR. Given, that increased 
production of pro-inflammatory cytokines including TNF can be due to increased 
immune activation such as in maternal inflammation (Cai, et al., 2000; Liverman, et 
al., 2006), there may be a role for GITR knock out as a model for maternal 
inflammation. In addition, there is an upregulation in IGF-1R mRNA in GITR-/- 
SCG tissue compared to controls in chapter 7.0. Levels of IGF-1R have recently 
been found to be upregulated in cerebellar tissue of neonatal rat pups born to diabetic 
mothers (Haghir, et al., 2013). As diabetes is an inflammatory disease (Xie and Du, 
2011), these studies provide support for the potential use of GITR knock out as a 
model of inflammation.  
Previously, GITR requirement for NGF-promotion of target innervation had only 
been established in target organs of the SCG, including the nasal mucosa and iris 
(O'Keeffe, et al., 2008). To address how extensively GITR is involved in the 
establishment of sympathetic innervation, target innervation in various organs of the 
GITR-/- P1 mice was examined. Organs included the trachea, heart, stomach, small 
intestine, ureters and bladder. NGF is heterogeneously required for sympathetic 
innervation, and specifically required for sympathetic innervation of the salivary 
glands, iris, heart, stomach, small intestine, ureters and bladder (Glebova and Ginty, 
2004). Here, we found GITR is required for NGF-target innervation of the heart and 
bladder but not the stomach, small intestines and ureters. This discrepancy in the 
requirement for NGF and GITR for sympathetic target innervation is similar to that 
of NGF and Egr3. Egr3 is regulated by NGF signaling in sympathetic neurons, 
however tissues that require NGF for target innervation do not homogeneously 
require Egr3 (Li, et al., 2011). It is possible Egr3 modulates gene expression required 
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for at least some aspects of NGF-mediated sympathetic terminal axon extension and 
target tissue innervation (Eldredge, et al., 2008) and similarly, GITR appears to play 
a role in NGF-sympathetic target innervation in a non uniform manner. 
 
In conclusion, the aim of this thesis was to answer basic biological questions 
pertaining to the role of GITR in the promotion of growth and target innervation of 
sympathetic neurons. These biological questions included (i) whether GITR 
increased the sensitivity of sympathetic neurons to NGF similar to that of p75NTR; 
(ii) what region of GITR is responsible for its growth promoting effects; (ii) the 
effect of GITR on downstream pathways including ERK1/2 and NF-B and (iv) how 
extensively is GITR involved in the target innervation of the developing sympathetic 
nervous system. This thesis has added to a large body of knowledge regarding 
factors involved in the development of the sympathetic nervous system. GITR and 
its specific ligand GITRL is expressed by neonatal sympathetic neurons of which 
binding occurs through the extracellular tail of GITRL which activates GITR and 
specifically the juxtamembrane region of GITR to promote the growth of 
sympathetic neurons. The GPD of GITR activates ERK1/2 and inhibits NF-B 
activity in an inverse fashion to induce the growth promoting effects of GITR while 
the phosphorylation sites Tyr190 and Ser199 of the same region regulate TrkA 
expression and possible TrkA – NGF binding in these neurons, in a manner that may 
increase sympathetic neuron’s sensitivity to NGF. GITR is required for NGF-target 
innervation of developing sympathetic neurons; however its requirement is 
heterogenous. Inhibition of GITR signalling results in the reduction of sympathetic 
neurite growth to the same extent as treatment with pro-inflammatory cytokine 
TNF. TNF is upregulated in GITR-/- SCG tissue along with IGF-1R. As IGF-1R 
is upregulated in neural tissue post maternal inflammation, it is therefore possible 
that GITR knock out could be considered as a model of inflammation in future 
studies.  
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